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INTRODUCTION
Despite the general tendency of decrease in the incidence of gastric cancer in 
the world, it still represents one of the leading causes of death from malignant 
diseases in many countries (Craanen, 1992). In Estonia the incidence of gastric 
cancer is higher and its decline has been less expressed than it is in most of the 
neighbouring North-European countries (Cancer Society of Finland, 1990; 
Cancer Society of Finland, 1992; Holleb, 1991; Lauren, 1993; Lindahl, 1988; 
Tekkel, 1992; Thomson, 1994). In addition, most cases of gastric cancer are 
detected in advanced stages and only very rare we can operate for tumors in 
early stages. The differences in the overall survival curves for gastric cancer 
patients after curative operations are large, with 5-year survival rates of more 
than 60% in Japanese and less than 40% in non-Japanese series (Akoh, 1992; 
Bozzetti, 1990; Breaux, 1990; Ovaska, 1989; Maruyama, 1987b; Murray, 1989; 
Noguchi, 1989).
The high survival rates obtained in Japan are attributed to a successful 
screening program for the detection of early gastric cancer, accurate staging and 
aggressive surgical treatment with combined organ resections and extended 
lymphadenectomy (Cuschieri, 1989). The improvement in early gastric cancer 
diagnosis is referred to various advances in diagnostic intervention including 
fiberoptic gastrointestinal endoscopy, double-contrast radiography, and mass 
screening in a high risk population. These advances have increased the early 
gastric cancer prevalence in Japan from approximately 2% in 1950 to over 30% 
in 1980 and over 50% in 1990 (Maruyama, 1987b; Maruyama, 1989; Naka­
mura, 1992; Noguchi, 1989; Soga, 1988). Extended lymph node dissection 
(R2-R3 lymphadenectomy) became standard treatment in Japan for all cases of 
gastric cancer during the middle of the 1970s and most of the Japanese authors 
have pointed out the relationship between extensive lymph node dissection and 
better cure results (deAretxabala, 1988; Maruyama, 1987b; Maruyama, 1989; 
Soga, 1988). Unfortunately, in the opinion of many authors, other treatment 
modalities, such as the adjuvant chemotherapy, offered modest benefit in the 
improvement of the results of curative gastric cancer (Bleiberg, 1992; Kore- 
naga, 1992; Schlag, 1987; Shiu, 1987b)
In the Western world only half of the patients have resectable tumor, and 
less than a half of these are suitable for curative resection (Bonenkamp, 1992). 
Besides, radical lymphadenectomy is performed in only 50% of all European 
patients, and the treatment of gastric carcinoma by general surgeons has shown 
results considerably poorer than those reported by special referral centres 
(15%) (Akoh, 1991; Jaehne, 1992; McCulloch, 1994). The generally held pe­
rception that gastric cancer is a disease that is diagnosed late, has high ope­
rative mortality rate and overall 5-year survival rate of less than 15% has led to
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a nihilistic attitude towards treatment of the disease outside Japan (Akoh, 1991; 
AHum, 1989; Guardagni, 1993; Inoue, 1993; Sano, 1992).
As extensive screening programs are not still feasible in Europe, the thera­
peutic results can be improved only by using extensive surgical techniques. 
Because of the good results shown in Japanese studies the practice of extended 
lymphadenectomy has found increased acceptance in many hospitals outside 
Japan in recent years (Bonenkamp, 1993; Jatzko, 1992a; Roukos, 1990; Sigal, 
1991). In our hospital the principles of extended lymphadenectomy were intro­
duced at the end of the 1970s and now we consider this procedure unavoidable 
in curative gastric cancer surgery.
The prognosis of cancer patients is determined by a series of patient-, tumor- 
and treatment-associated factors (Adam, 1989; Maruyama, 1987b; Maruyama, 
1989; Moriguchi, 1991a; Noguchi, 1989). In the ideal situation, as many 
prognostic factors as possible should be known before initiation of therapy to 
design a therapeutic concept for the individual patient. Therefore, the iden­
tification of prognostic factors and determination of their clinical relevance is 
an important aspect of oncological research.
Because surgery remains the only method of treatment that offers the 
potential for cure for gastric cancer patients, it is most important to examine the 
influence of the extent of gastric resection and regional lymphadenectomy on 
survival. The questions most often asked are as follows: How much of the 
stomach should be resected? How useful is lymphadenectomy? If gastric 
resection is to be performed, how wide the resection of neighbouring organs 
should be?
To seek answers to these questions and to evaluate the influence of 
different clinicopathological and treatment related factors on the prognosis of 
primary gastric cancer patients we conducted a retrospective study of 406 
patients, whose primary gastric carcinomas had been resected with curative 
intent in Hospital of Oncology, Tartu from 1978 to 1987.
The previous studies performed in Estonia concerned the precancerous 
conditions or the relationship between precancerouses and gastric cancer 




Marked variation in the incidence of gastric cancer as well as a general 
tendency of decrease is observed around the world. The incidence varies 
approximately tenfold internationally, the highest rates per 100,000 inhabitants 
are observed in Japan (males 82; females 36), parts of China (males 58; females 
25) and Costa Rica (males 59; females 25). Intermediate rates prevail in 
Europe, where the incidence is slightly higher in the south (Italy: males 44; 
females 20) and eastern Europe (Poland: males 44; females 17) compared to the 
northern and western parts (England: males 19; females 8). The lowest in­
cidence rates are seen in the United States (whites: males 8; females 3), Austra­
lia (males 15; females 6) and in Africa (Nigeria: males 7; females 4). A twofold 
variation in the incidence of gastric cancer has been found within the Nordic 
region, covering Denmark (men 14, women 8), Iceland (men 31, women 14), 
Norway (men 18, women 9) and Sweden (men 25, women 13) (Hansson, 1991; 
Hansson, 1993). In Finland it was the most common malignant neoplasm in 
both male and female patients up to the 1950s (65 per 100 000 in the male 
population and 38 per 100 000 in the female population), but in 1980s the 
incidence was 21 and 11 per 100 000 respectively (Lauren, 1993). In general, 
the risk of gastric cancer in the Northern hemisphere tends to increase with in­
creasing latitude (Cancer Society of Finland, 1992; Hansson, 1993). A sub­
stantial annual decline in stomach cancer incidence is of about 2% -7%  in most 
regions (Hoel, 1992). However, no significant decrease has been found in some 
of these regions in the recent decade and therefore the decline in the incidence 
could not be interpreted as evidence that the disease is disappearing (Correa, 
1991; Macintyre, 1991).
Up to 1980s stomach was the most common location of cancer in Estonia. 
Although this place has been conquered by the lung cancer in 1980s the 
incidence of gastric cancer is still frequent and the percentage of advanced 
cases is too high for the contentment with the situation. The morbidity rate in 
our country has changed from 53.1 in male and from 39.4 in female per 
100 000 in 1970s to 41.9 in male and to 32.0 in female per 100 000 in 1980s 
(Cancer Society of Finland, 1990; Tekkel, 1992). It is also one of the main 
causes of death due to cancer: according to the data of the Estonian Cancer 
Registry about 450 to 500 patients per year died from this malignance.
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2. Survival
Stomach cancer continues to carry a dismal prognosis in most W estern 
countries where the overall 5-year survival ranges from 5 to 20%, in Estonia 
this rate is 17% (Akoh, 1992; Bollschweiler, 1993; Bozzetti, 1989; Breaux, 
1990; Craanen, 1992; Cady, 1989; Cancer Society of Finland, 1990; Hoel, 
1992; Inoue, 1991; Ovaska, 1989). The differences in the overall survival 
curves for patients with carcinoma in the stomach after curative or radical 
operations are large, with 5-year survival rates of more than 60% in Japanese 
and less than 40% in non-Japanese series (Akoh, 1992; Bozzetti, 1990; Breaux, 
1990; Ovaska, 1989; Maruyama, 1987b; Murray, 1989; Noguchi, 1989).
The analysis of one hundred series published in English has shown an 
improvement in 5-year survival rates over the past 30 years (Akoh, 1992). The 
5-year survival rate after resection has increased significantly from 20.7% 
before 1970 to 28.4% before 1990, and following curative or radical resection 
from 37.6% before 1970 to 55.4% before 1990. When the Japanese series were 
excluded from the analysis the 5-year survival rate after all resections is 23.4%, 
and after curative or radical resection 39.4% before 1990. W anebo et al. (1993) 
compared the results of gastric cancer therapy as recorded by the American 
College of Surgeons study with the results of a number of selected Japanese 
hospitals (by Maruyama, 1987b) (Table 1.1):
T a b l e  1.1
Comparison of gastric cancer therapy between the American College of Surgeons 
and selected Japanese hospitals (by Wanebo, 1993)
Incidence Resected patients survival 
Japan United States________Japan United States
No.of patients 15,589 18,365 12,535 10,237
Stage I (%) 33.7 17.1 95.6 50.0
Stage II (%) 14.5 16.9 70.1 29.0
Stage III (%) 28.7 35.5 36.3 13.0
Stage IV (%) 23.1 30.5 23.1 3.0
Survival (%) 45.5 14.0 56.3 19.0
3. Prognostic factors
The prognosis of patients with malignancy depends upon biological aspects of 
the tumor, tum or-host relationship, and the therapy prescribed (Janssen, 1992; 
M origuchi, 1991a). Some authors describe high-risk populations for gastric 
cancer, such as the Japanese, as having different epidemiological (social, 
dietary, infectious) factors compared with low-risk populations in North-
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America and in Europe (Adam, 1989; Bollschweiler, 1993; Maehara, 1991a; 
M aehara, 1992d; Parsonnet, 1991; Wanebo, 1993). The inverse socio-economic 
gradient has been observed in most populations, and the rate in lower socio­
economic classes is two to three times that in more affluent classes (Adam, 
1989; Correa, 1992; Hansson, 1993; Kato, 1992). Dietary factors and improve­
ments in food storage and handling are thought to be major factors relevant to 
the decline of gastric cancer in high risk regions. Reduction in toxic methods of 
food preservation, such as smoking and pickling, declining salt consumption, 
widespread use of refrigeration, and increasing fruit and vegetable con­
sumption, may account for many of the changes in stomach cancer incidence 
(Hoel, 1992; Lauren, 1993; paper V).
Some authors have found the higher incidence of the intestinal type should 
be correlated with a high-risk population and a better prognosis of survival 
(Lauren, 1965; Lauren, 1993; Adam, 1989; Bollschweiler, 1993). Others have 
described, that the histologic tumor type is not an important independent 
prognostic factor and postulated differences in the relative frequency of intes­
tinal (differentiated) and diffuse (non-differentiated) cancers in different coun­
tries ought not to have a heavy impact on the survival rates (Maruyama, 1989).
The prognosis of patients with gastric carcinoma is determined by a series 
of prognostic factors. These factors can be grouped into three categories: 
patient related, tumor related, and treatment related. There may be a multitude 
of interactions of different strength among the different factors. The identi­
fication of these factors, their interactions and determination of their clinical 
relevance is extremely important.
3.1. Patients related prognostic factors
Age
That gastric cancer is a disease of ageing is demonstrated by the fact that about 
50% of the cases in male and 60% of the cases in females occurred in those 
who are older than 60 years (Wanebo, 1993). Young age is rare among the pa­
tients and this disease rarely occurs in children (Bollschweiler, 1993; Maehara, 
1991a; McGill, 1993; Tso, 1987).
It has become clear that age in itself is a prognosticator of cancers. Ob­
servations of cancers of the lung, colon, breast, prostate gland and kidney have 
shown that advancing age reduces growth of tumors (Ershler, 1986; Janssen, 
1991). In patients with gastric cancer, some authors noted a close relationship 
between the prognosis and age of the patients (Bollschweiler, 1993; Bozzetti, 
1986; Maehara, 1991a; Matley, 1988), while others found no such relationship 
(Mitsudomi, 1989; Moriguchi, 1991a; Moriguchi, 1993a). Moriguchi, 1993b 
found an increased mortality in the very young (<30 years) and the very old (>
80 years) age groups for patients with gastric cancer who had undergone 
gastrectomy. For young patients, a poor prognosis is attributed to a delay in the 
diagnosis or to a more aggressive course of the disease (Maehara, 1991a; 
Matley, 1988). The long-term life expectancy for elderly patients who had un­
dergone gastrectomy is reduced because of the exhausted immunological 
response or there may be a relatively prolonged life expectancy because of the 
slow progression of the tumor (Bozzetti, 1986; Tsukuma, 1983).
The shorter survival time in young patients is related to larger tumor size, 
extended serosal invasion, diffuse macroscopic type, poorer differentiation, 
peritoneal dissemination and lymph node metastasis, although some authors 
have found that gastric cancer in elderly may also be significantly large and 
may have métastasés when detected because of relatively mild symptoms 
(Bandoch, 1991; Esaki, 1990; Janssen, 1991; Lauren, 1965; Maehara, 1991b; 
Maehara, 1991c; Maruyama, 1987b; Mishima. 1987; Moriguchi, 1993b). In 
addition, many authors have reported that gastric cancers in the elderly are 
more frequently located in the distal part of the stomach, compared with those 
in young patients (Bandoch, 1991; deCalan, 1988; Husemann, 1989; Kawaura, 
1988; Moreaux, 1988; Rohde, 1991; Welvaart, 1980).
Some investigators argue that total gastrectomy for the elderly might lead to 
increased deaths without essentially improving the long-term prognosis (Shiu, 
1987a). It is well known that more than 50% of the elderly patients have 
pulmonary or cardiovascular complications before operation and some opera­
tive deaths could be attribute to such complications deteriorating after ope­
ration (Bandoch, 1991). Therefore, as total gastrectomy carries a risk of exces­
sive intraoperative blood loss, longer operative time, and pulmonary compli­
cations compared with cases of a distal partial gastrectomy, caution is needed 
when attempting extensive surgical resection in elderly patients (Korenaga,
1991). However, when tumors are located at the cardia or have spread in­
volving the entire stomach beyond the confines of subtotal gastrectomy, total 
gastrectomy is certainly indicated irrespective of the patient's age (Maruyama, 
1987b; Mishima, 1987; Shiu, 1987a)).
Sex
In general, gastric carcinoma affects men more often than women (Boll­
schweiler, 1993; Craanen, 1992; Hoel, 1992; Korenaga, 1992). The male: 
female ratio usually falls between 1.5 and 3.0 and tends to be higher in areas 
with a high than with a low incidence (Hansson, 1993; Nakamura, 1993). The 
higher percentage of women may reflect the ageing of most countries with 
women living longer, thereby allowing for a greater occurrence of gastric 
cancer (Wanebo, 1993).
In most studies the sex of patients seems not to be a significant factor 
influencing the prognosis; however, clinicopathological factors of gastric 
cancer between the sexes do differ (Arveaux, 1992; Haugstvedt, 1993; Jatzko,
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1992a; Maehara, 1992b; Msika, 1989; Roder, 1993; Shiu, 1987). The age, 
tumor size and location, Borrmann type, and especially histology were consi­
dered as the sex-related associations. The non-differentiated types, which show 
a diffusely infiltrative growth pattern and results in a shorter survival time than 
seen with differentiated type, are prominent in women (Armstrong, 1986; Tso, 
1987). In particular, advanced cases were dominant in women and most often a 
non-curative resection was done (Maehara, 1992b). Some authors found more 
men with proximal cancers than with distal cancers (deCalan, 1988; Husemann, 
1989; Janssen, 1991; Kawaura, 1988; Moreaux, 1988; Rohde, 1991; Welvaart, 
1980).
3.2. Tumor related prognostic factors
According to the General Rules for the Gastric Cancer Study in Japan, four 
pathologic factors —  gastric wall invasion, lymph node metastasis, peritoneal 
dissemination and liver metastasis —  have proved to be the significant 
prognostic factors and are useful as criteria for classification according stage 
(Kaijtani, 1981). After curative gastrectomy, in patients without peritoneal 
dissemination or liver metastasis, mainly gastric wall invasion and lymph node 
metastasis were thought to determine the stage of tumor progression (Kaibara, 
1987a; Maehara, 1991c; Maruyama, 1987a; Maruyama, 1987b; Maruyama, 
1989; Moriguchi, 1990; Moriguchi, 1992; Msika, 1989). In addition, tumor 
gross appearance, tumor location, size and histologic type are also reported to 
be the independent prognostic factors in patients without distant metastasis 
(Bozzetti, 1986; Jatzko, 1992a; Kaibara, 1987a; Maehara, 1991c; Maruyama, 
1987a; Moriguchi, 1990; Noguchi, 1989). All these factors may be closely 
linked to the others and dispose the prognosis after curative surgery.
Depth of invasion
Most studies agree on the fact that depth of invasion within the gastric wall is 
one of the most important prognostic factors (Allum, 1989; Arveux, 1992; Boz­
zetti, 1986; Maruyama, 1987a; Msika, 1989). The prognosis of early gastric 
cancer is remarkably good, compared with advanced tumors: the 5-year survival 
after gastrectomy for early gastric cancer is over 90%, as compared with 30 - 
40% for patients with T2-T4 cancer (Boku, 1989; Guadagni, 1993; Inoue, 
1991 ; Lawrence, 1991 ; Moreaux, 1993; Noguchi, 1989; Sowa, 1989).
In Japan, where the developments in diagnosis and the introduction of mass 
screening programs have been in use, the proportion of early gastric cancers has 
risen from 9.4% for the period 1963-1966 to 43.8% during 1979-1987. At the 
same time in the USA the overall proportion of gastric cancers diagnosed early
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is only 3-4%  constantly and European series report a value <10% (Boll­
schweiler, 1992; Guardagni, 1993; Inoue, 1993; Sano, 1992).
Although the overall 5-year survival rate for patients with early gastric 
cancer has improved, the problem of cancer recurrence remains. As a rule, 
lymphatic métastasés and vascular métastasés are rare when cancer cells are 
limited to the mucosa, but they begin to appear when the cells have penetrated 
into the submucosal layer. In general, recurrence after gastrectomy because of 
early gastric cancer is mainly related to the following factors:
1) Depth of invasion —  mucosal or submucosal (Inoue, 1993).
2) Histologic type —  differentiated or non-differentiated (Adachi, 1993; Law­
rence, 1991; Mishima, 1987; Moreaux, 1993).
3) Presence or absence of lymph node metastasis (Endo, 1990; Hioki, 1990; 
Ichiyoshi, 1990; Inoue, 1991; Itoh, 1989; Lawrence, 1991; Maehara, 1992d; 
Moreaux, 1993).
4) Vascular invasion and hematogenous métastasés —  the mucosal hyper­
vascularity is more common for the protruded differentiated carcinomas 
(Adachi, 1993; Eriguchi, 1991; Sano, 1993).
5) Macroscopic type. Lymph node metastasis are significantly more frequent in 
the protruded or combined type of early gastric cancer such as Ila+IIc, and 
from large tumors (>2.0 cm in diameter) which are poorly differentiated and 
invade the submucosa (Boku, 1989; Habu, 1990; Hioki, 1990).
6) Peritoneal dissemination is extremely rare in patients with early gastric 
cancer (Endo, 1990; Hioki, 1990; Inoue, 1991; Itoh, 1989; Lawrence, 1991; 
Maehara, 1992d; Moreaux, 1993).
In contrast to the current experiences in Japan, most of the gastric carcinomas 
are diagnosed at advanced stages in Western part of the world, so that the 
survival rates are generally poor. After curative gastrectomy in patients with 
advanced carcinoma of the stomach, a close relationship was noted between the 
extent and the area of serosal invasion of carcinoma and the prognosis (Baba, 
1989b; Boku, 1990; Haraguchi, 1991; Kaibara, 1987a; Korenaga, 1994; 
Moriguchi, 1990; Maehara, 1991b; Maehara, 1992c). A factor also relating to 
intraperitoneal dissemination is the possibility of cancer infiltration from 
metastatic lymph nodes. Serosal invasion cases have many lymph nodes in 
which cancer cells invade perinodal fatty tissues, and that these cases have the 
peritoneal dissemination (Boku, 1990).
Lymph node métastasés
The localised forms of malignant disease are clinically most significant since 
small tumor loads can be treated more effectively than disseminated ones 
(Debruyne, 1991). If growth of tumor cells at secondary sites —  lymph node 
metastasis —  has occurred, the prognosis becomes worse. Nodal involvement 
has been reported to have the same prognostic significance as the depth of
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invasion (Okusa, 1990). One of the important causes of recurrence for gastric 
cancer patients is found to be the incompletely dissected lymph node 
micrometastasis and the best survival rates after curative surgery appeared to be 
in patients with no or limited nodal disease (N0 and N1) (Boku, 1989; Maehara, 
1992d; Noguchi, 1989).
A number of studies have paid meticulous attention both to the site and 
extent of nodal involvement. Histological analysis of all the lymph nodes 
removed at the operation make nodal staging more accurate and increase the 
incidence of higher stages when compared to series with less rigorous node 
dissection. After extended curative resection about half of the patients with 
gastric carcinoma have been found to have lymph node métastasés (Boll­
schweiler, 1993; Wang, 1993). Independent risk factors for the occurrence of 
lymph node metastasis are found to be submucosal or deeper invasion, large 
tumor size, and lymphatic involvement by tumor cells (Maehara, 1992d; Oka- 
mura, 1988). The depth of invasion correlates strongly with the incidence of 
lymph node métastasés. The incidence of métastasés to lymph nodes in patients 
with early gastric cancer has been reported as varying from 0% to 7% in cases 
of intramucosal cancer, and from 2.3% to 50% in cases of submucosal cancer 
(Hioki, 1990; Iriyama, 1989; Lauren, 1965; Moreaux, 1993). Incidence of 
lymph node métastasés increases markedly if the muscular layer (>40% of 
cases) or serosa (>80% of cases) is penetrated (Boku, 1990; Roukos, 1990; 
Wang, 1993). These associations are explained by the findings that lymph ca­
pillaries are found only in the deep lamina propria adjacent to and within the 
muscularis mucosae; the upper and middle levels of the lamina propria of the 
gastric mucosa contain no lymph capillaries. The entire mucosa show a rich 
supply of blood capillaries, many of which are adjacent to the basal lamina of 
gastric glands and the surface epithelium (Lehnert, 1985; Ming, 1992; Sano,
1992).
The expected extent of lymph node metastasis can be predicted approxi­
mately by the location of the tumor. Studies show an orderly spread to the 
nodes clearly related to the position of the tumor, which occurred with de­
creasing frequency along identifiable lymphatic chains along the arteries, and 
converged to a wide area around the upper abdominal aorta (Maruyama, 1989; 
Sigal, 1976; Soga, 1988). If the tumor is located at the upper third of the 
stomach, cardiac and lesser curvature nodes are the most common sites fol­
lowed by left gastric, celiac axis and splenic vessels nodes; cardiac carcinoma 
also may often involve the inferior oesophageal and diaphragmatic lymph 
nodes. With the tumor at the middle third, lesser and greater curvature nodes 
and infrapyloric and left gastric nodes are involved frequently; the nodes 
around the oesophagogastric junction also may be frequently involved. In this 
group of tumors it is important to point out that nodes along the splenic vessels 
and in the hilus of the spleen are involved in approximately 10% of instances. 
With the tumor at the lower third, infrapyloric nodes are the most frequent,
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followed by lesser and greater curvature nodes. Involvement of left gastric, 
common hepatic, and celiac nodes are frequent regardless of tumor location 
(Boku, 1989; deAretxabala, 1987; Maruyama, 1989; Mishima, 1987; Noguchi, 
1989; Roukos, 1990; Wang, 1993). Limited spread to perigastric nodes cor­
relates to better survival rates than deposits around the celiac artery, the poorest 
prognosis being associated with métastasés in the hepatoduodenal ligament, 
behind the pancreas head, at the root of mesentery, and along the aorta (station 
numbers 12 to 16) (Maruyama, 1989). In advanced cases the pattern of 
lymphatic spread is reported to be unpredictable from the location of the tumor 
(Maruyama, 1989; Ponsioen, 1989).
Analysis of the histologic types of gastric cancer reveals no differences in 
frequency of node métastasés (Maehara, 1992c; Roukos, 1990). In some studies 
the relationship between tumor size or Borrmann type and incidence of lymph 
node métastasés is also reported (Maehara, 1992c; Maruyama, 1989). Ne­
vertheless, these factors are closely related to the depth of invasion and the 
lymph node involvement is more significantly caused by it.
It seems likely that, regardless of possible geographic differences in aggres- 
sivity of stomach cancer, the lymphogenous métastasés follow the same paths 
of dissemination. Most of patients demonstrated very similar incidence of 
lymph node metastasis in the various node stations in curatively resected cases 
(Bollschweiler, 1993; Maruyama, 1989).
Borrmann type
Macroscopic classification of the tumor would be the most useful clinically, 
because the macroscopic types are closely related to tumor histologic type, 
pattern of spread, and ultimately, prognosis. For example, polypoid and 
ulcerating circumscribed tumors mostly evinced a well or moderately dif­
ferentiated histologic type and a rather fair prognosis, when ulcerating 
infiltrative and diffusely infiltrative tumors often revealed a poorly diffe­
rentiated histologic type and poor prognosis (Abe, 1991; Maehara, 1992a; 
Nakamura, 1992). Gross appearance is also reported to be the independent 
prognostic factor for curative gastric cancer by soma authors (Arveaux, 1992; 
Haugstvedt, 1993).
Histologic type
Most of the other pathological features of gastric carcinoma have been shown 
to be closely related to histologic subtypes. The histologic composition of 
gastric carcinoma varies from case to case and from area to area. As a result, 
several histologic classifications have been proposed. Lauren divided gastric 
carcinomas into two types: intestinal and diffuse, with relative frequency of 
53% and 33% respectively; the remaining 14% of carcinomas did not fit into 
these patterns and were unclassified (Lauren, 1965). Based on the pattern of
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tumor growth and invasiveness, the gastric carcinomas are divided into 
expanding and infiltrative types (Ming, 1992). In the M ing's classification the 
microscopic patterns of tumor growth are reflected in the gross appearance of 
the tumor. Nakamura (Nakamura, 1992) simply divided the gastric cancers into 
differentiated and non-differentiated types, using gland formation as the 
indicator for differential diagnosis. In this study histology was classified 
according to the WHO classification as papillary and well or moderately 
differentiated tubular adenocarcinoma, interpreted as the differentiated types, 
and poorly differentiated adenocarcinoma, signet-ring cell, mucinous, or 
undifferentiated carcinomas, interpreted as the non-differentiated types (Oota, 
1977). There are similarities between these classification: carcinomas of the 
differentiated type are mostly intestinal and expanding carcinomas, and 
carcinomas of the non-differentiated type are diffuse and infiltrative carcinomas 
(Ming, 1992). The non-differentiated types are found more often in the 
advanced stages than in the early stage, and these results may be explained by 
difficulties in detecting and more rapid growth of this type of cancer (Ikeda, 
1994; Janssen, 1991; Lauren, 1965; Moriguchi, 1991b). In addition, the 
differentiated adenocarcinomas tend to give rise to vascular métastasés, and 
non-differentiated to lymphatic ones or show peritoneal dissemination, also 
some authors have found out no significant differences in the survival rate 
based on histopathologic type of gastric cancer (Adachi, 1993; Lawrence, 1991; 
Mishima, 1987; Moreaux, 1993).
Beside being morphologically different, the two types appear to differ with 
respect to their epidemiological characteristics (Lauren, 1991; paper V). The 
differentiated (intestinal) types seem to be particularly age dependent whereas 
the non-differentiated (diffuse) types strike all age groups uniformly (Bandoch, 
1991; Lauren, 1991; Lundegardh, 1991; Ming, 1992). Accordingly, the 
predominance of intestinal types of cancer increases with increasing age. More 
men are also marked among patients with the intestinal type of gastric car­
cinoma (Lauren, 1991; Lundegardh, 1991; Ming, 1992). It has been suggested 
that the remarkable decline in gastric cancer, which has been witnessed during 
the past few decades, is due mainly to a decrease in the incidence of the 
intestinal types; but no significant difference between high- and low-risk areas 
has been found in the age-adjusted rates for the diffuse types of gastric cancer 
(Amorosi, 1988; Correa, 1988; Correa, 1991; Correa, 1992; Lauren, 1993; 
paper  V).
However, despite the differences in the epidemiological and pathologic 
features, according to most of the authors the histologic type of gastric cancer 
itself has no significant influence on the prognosis in multivariate analysis 




Gastric carcinomas may occur anywhere in the stomach. About one half of 
them involve the pyloric mucosa; one quarter, the cardial mucosa, and another 
quarter, middle part of the stomach. In reports from the recent years, the cardia 
is involved in more than 25% of cases, and there is a decrease of antral 
carcinomas (Bollschweiler, 1993; Craanen, 1992; Hermann, 1993; Ming, 1992; 
Meyers, 1987; Wanebo, 1993).
Although a relatively less common neoplasm, adenocarcinoma of the cardia 
is drawing more attention whereas carcinomas of the proximal third of the 
stomach have increased in relative frequency, and have significantly worse 
prognosis and higher hospital mortality than those of other locations (Antonioli, 
1982; Cady, 1977; Husemann, 1989; Maruyama, 1987b; Meyers, 1987; Powell, 
1990). Carcinoma of the cardia is characterised by younger patients and a high 
percentage of advanced tumor stages (between 50 and 75%) (deCalan, 1988; 
Husemann, 1989; Kawaura, 1988; Moreaux, 1988; Rohde, 1991). Carcinomas 
of the upper third of the stomach have lymph node métastasés more often than 
those of the distal stomach (Bollschweiler, 1993). 5-year survival rates for 
patients with cardial cancer ranging from 10% to 15% in most series; better 5- 
year survival rates are reported occasionally, but it is less than 1/3 in all 
collected series (Adam, 1989; Blomjous, 1992; Bollschweiler, 1993; Stipa, 
1992; Rohde, 1991).
Size
The mean diameter of advanced tumors is much larger than that of early 
carcinomas (6 to 7 cm versus < 4 cm), and directly correlates with a lower sur­
vival rate in advanced cases (Nakamura, 1992). In general, the tumors docu­
mented in Japan have smaller diameter than those documented in Europe 
(Bollschweiler, 1993; Haugstvedt, 1993; Maruyama, 1987b; Roder, 1993). 
Tumor size seems to be closely associated with other pathologic factors of 
gastric cancer and is not independent prognosticator itself.
3.3. Treatment related prognostic factors
Radical surgery
Despite the new developments in the treatment of gastric cancer, such as 
neoadjuvant and intraperitoneal chemotherapy, surgical resection is still the 
therapy of choice. Statistical analyses show that, even though there are 
predetermined clinicopathologic factors that govern survival, the surgeon's 
choice and manner of execution of surgery can have a significant effect on 
prognosis (Akoh, 1992; Maruyama, 1987b; Pacelli, 1993; Shiu, 1987a; Stipa, 
1994). Although the first successful resection of a carcinoma of the stomach
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was accomplished more than 100 years ago, the optimal surgical management 
of this disease is still the subject of debate (Adam, 1989; Holleb, 1991). Some 
surgeons perform only simple gastrectomy, while others advocate extensive 
gastrectomy with en bloc lymphadenectomy.
In general, the basic tenets of oncologic resection for epithelial cancers 
require wide excision of the primary tumor and en bloc removal of the 
lymphatic drainage network, including the regional lymph nodes and 
intervening lymphatic vessels (deAretxabala, 1987; Shiu, 1987a; Smith, 1991). 
Long established and practised, the concept has been undergoing revaluation 
for carcinomas of the breast, colon, and head and neck region. For these 
tumors, radiation therapy, chemotherapy and hormonal therapy have shown 
increasing effectiveness, to the extent that they may indeed permit lesser 
resectional surgery without jeopardising tumor control. For gastric cancer, 
however, these modalities have only limited therapeutic value at the present 
time (Bleiberg, 1992; Korenaga, 1992; Schlag, 1987; Shiu, 1987a; Shiu, 
1987b). For successful control of this disease, the absence of distant métastasés 
and the peritoneal dissemination is essential, but sufficient gastrectomy with 
extended lymph node dissection and combined organ resection is also important 
(Adachi, 1992; Adam, 1989). Even when surgery is palliative due to the 
presence of various incurable factors, gastrectomy still seems preferable to 
gastrojejunostomy, because symptoms are alleviated and the survival time is 
prolonged (Korenaga, 1988a).
There are two modalities of surgery for gastric cancer: limited and 
extended. Limited surgery includes endoscopic polypectomy for a mucosal 
polypoid cancer, endoscopic laser therapy, and local excision of the stomach 
wall for a small mucosal cancer in experimental studies (Eriguchi, 1991; 
Guadagni, 1991; Hioki, 1990; Inoue, 1991; Lawrence, 1991; Sue-Ling, 1992; 
Yasuda, 1993). Extensive surgery is indicated in all cases of advanced gastric 
cancer and in cases of early gastric cancer with submucosal invasion. The goals 
of extended radical surgery are to excise direct contiguous invasion from the 
primary to the surrounding organ, to achieve complete lymph node dissection, 
and to excise localised peritoneal implantation (Boku, 1989; Korenaga, 1988a; 
Maruyama, 1987b; Noguchi, 1989). The techniques of radical operation have 
been well standardised by the Japanese Research Society for Gastric Cancer 
(Kaijtani, 1981).
Extent of gastrectomy
The resection, either distal or total, is determined by the proximal distance from 
the cardia. The distal division line is always placed at the duodenal bulb 
because the pylorus is usually a barrier to the distal extension of gastric cancer 
(Kakeji, 1991). There is general agreement that a distance of 6 cm from the 
cranial edge of a gastric cancer, as measured by the pathologist on the fresh 
specimen, can guarantee a safe margin of proximal transection in the vast
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majority of operable cases (Bozzetti, 1988; Bozzetti, 1992a; Maruyama, 
1987b). According to some authors this distance can be reduced somewhat 
when dealing with tumors confirmed to the muscularis propria, in early and 
non-early well-circumscribed types and the intestinal variety according to the 
Lauren's classification (Adam, 1989; Bozzetti, 1992b; Gennari, 1986; Gouzi, 
1989; Launois, 1991; Stipa, 1994).
Total gastrectomy de principle  is open to question in the management of 
cancer of the antrum and of the cardia. A number of investigators contend that 
total gastrectomy is the treatment of choice for infiltrative tumors and there is 
also a tendency to perform total gastrectomy for the diffuse type according to 
Lauren's classification (Adam, 1989; Bandoch, 1992; Bozzetti, 1990; Bozzetti, 
1992a; Cuschieri, 1986; Gennari, 1986; Gouzi, 1989; Iida, 1993; Sigal, 1991; 
Stipa, 1994). On the other hand, only a minority of recurrences is confirmed to 
the gastric stump and would have consequently been prevented by a total 
gastrectomy —  fact that points against the better radicality of total versus 
subtotal gastrectomy (Bozzetti, 1990; Dent, 1988; Moriguchi, 1992). The 
second justification is therefore better lymph node dissection, mainly by 
associated splenectomy and juxtapancreatic node dissection, although in fact 
splenic system nodes can be dissected without associated pancreatectosple- 
nectomy (Maruyama, 1987b). The other lymph node groups, the dissection of 
which could be theoretically dependent on the extent of gastric resection are the 
paragastric nodes, but technically the lymphadenectomy in this region can also 
be performed with subtotal resection to the same radical degree obtained in 
total gastrectomy (Bozzetti, 1990; Hiischer, 1992). Nevertheless, because 
advanced lesions tend to metastasise to all the regional nodes, the only 
procedure that is theoretically capable of encompassing the primary tumor with 
its lymphatic drainage is total gastrectomy combined with splenectomy and 
distal pancreatic resection (Adam, 1989; Launois, 1991). Poorer prognosis is 
reported in patients who had undergone total gastrectomy, which likely is 
reflective of the extent of disease, proximal tumor location, and surgical 
perspective (radical or potentially radical). Nevertheless, gastrectomy does not 
have to be total to be curative, and many total gastrectomies without extensive 
lymphadenectomy performed in the West are non-curative procedures 
(Monson, 1991; Nakamura, 1992).
Because of its technical simplicity and lower postoperative mortality, some 
surgeons favour high, distal subtotal gastrectomy in the treatment of middle and 
lower third tumors (Adam, 1989; Gennari, 1986; Gouzi, 1989; Launois, 1991; 
Stipa, 1994). This procedure should include a high transection of the stomach 
proximally and at least 1 centimetre of duodenum with excision of at least 80% 
of the stomach, ligation of the left gastric artery at its origin, resection of both 
omenta and dissection and removal lymph nodes located in the hepatoduodenal 
ligament, hepatic, celiac and left gastric arteries, and in the left paracardial 
region; preservation of the spleen seems to be preferable (Adam, 1989;
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Launois, 1991). However, complete R2 or R3 lymph node dissection with 
subtotal gastrectomy may be dangerous: lymph node dissection along the 
splenic artery and at the splenic hiius (N groups 10 and 11) requires the 
interruption of both the posterior gastric artery and the short gastric vessels, 
with a risk of ischaemia for the gastric remnant (Guadagni, 1993).
The type of surgery for proximal cancer of the stomach remains a subject of 
controversy. Cardial cancer's site at the border between the thorax and abdomen 
can make the intraoperative staging and the choice of the optimal surgical 
procedure (type of incision, type and extent of lymphadenectomy, type of 
reconstruction of the digestive tract) extremely difficult, the operation 
dangerous and too often unsuitable for extended surgery (deCalan, 1988; 
Kaibara, 1987b; Kawaura, 1988; Rohde, 1991; Moreaux, 1988; Welvaart,
1980). Carcinoma of the gastric cardia has been found to have such dismal 
prognosis by some authors that any surgical treatment is thought to be 
essentially palliative —  hence, the recommendation that the less extensive 
proximal subtotal resection should be performed (Adam, 1989). Nevertheless, 
proximal resection of the stomach is not generally recommended by the 
majority of surgeons because of the high percentage of post-operative 
complications and reduced radicality associated with it (deCalan, 1988; 
Kaibara, 1987b; Kawaura, 1988; Maruyama, 1987b; Moreaux, 1988; Rohde, 
1991; Santoro, 1991; Stipa, 1992; Welvaart, 1980). In addition, carcinoma of 
the cardia commonly spreads into the oesophageal wall and thus a wide 
oesophageal resection is also required to control the disease in this area (Iida, 
1993; Stipa, 1992).
Lymphadenectomy
In Japan there is wide consensus on the desirability of a standardised extensive 
node dissection as proposed by the Japanese Research Society for Gastric 
Cancer (Kaijtani, 1981). The extensive lymph node dissection is found to give 
better survival rates compared with limited dissection, and decreases the 
incidence of local recurrence without added morbidity and mortality (deAretxa- 
bala, 1987; Korenaga, 1988a; Maehara, 1993; Maruyama, 1987b; Maruyama, 
1989; Noguchi, 1989; Soga, 1988). Although several retrospective Japanese 
studies have showed the importance of extensive lymph node dissection, a 
radical lymphadenectomy in Europe is performed in less than 50% of all 
curatively operated patients (Heberer, 1988; Valen, 1988). In the United States 
only a small percentage of cases had operations similar to the Japanese R2 
dissection; only in 13% of gastrectomies the celiac node are dissected, which is 
minimal for the R2 lymphadenectomy (Wanebo, 1993). This may, in part, 
explain the disappointing 5- and 10-year survival rates even after potentially 
curative resections in the Western hemisphere compared with the Japanese 
results (Akoh, 1991; Akoh, 1992; Allum, 1989; Bunt, 1994; Dent, 1988; 
Ovaska, 1989; Wanebo, 1993).
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Thus, the extent of lymph node metastasis and whether or not these meta- 
statically involved lymph nodes are dissected are important factors which 
influence the prognosis of patients with gastric cancer (Maehara, 1991c; Msika,
1989). In general, according to the Japanese surgeons, at least the R2 dissection 
of the lymph nodes seems to be certainly needed in all these cases where 
primary gastric cancer reaches an advanced stage (Maehara, 1991b; Maehara, 
1992c; Maruyama, 1989; Mishima, 1987; Moriguchi, 1990a). Some non- 
Japanese authors find no differences in the probability of survival for patients 
with gastric cancer between R1 and R2-R3 lymph node dissection or report 
about the increased postoperative mortality after extensive lymphadenectomy 
(Dent, 1988; Irvin, 1988; Roukos, 1990). However, the reported high morbidity 
after R2 resection in Western countries seems to result from a lack of properly 
trained surgeons and quality control (Bonenkamp, 1992). Several Western 
studies have also shown the survival advantage of extensive over limited 
lymphadenectomy without increasing the postoperative morbidity and mortality 
(Bonenkamp, 1992; Gunven, 1991; Jatzko, 1992b; Keller, 1994; Pacelli, 1993; 
Siewert, 1993).
When focusing on the problems of lymphadenectomy one has to consider, 
however, that the extent of lymphadenectomy is difficult to quantify by the 
surgeon alone. Due to this fact, the intraoperative assessment of the TNM stage 
is unprecise with up to 40% overstaged or understaged cases (Jaehne, 1992). 
Therefore, an accurate histopathologic examination of the resected specimen, 
including the dissected lymph nodes, seems to be absolutely necessary for 
quantifying the extent of lymphadenectomy and for exact staging (Maruyama, 
1989; Takahashi, 1994).
Resection of adjacent organs
Adjacent organ resection in gastric cancer surgery was started in Japan in the 
1960s with the goal of increasing the rate of survival (Maruyama, 1987b). The 
spleen, distal pancreas, transverse colon and mesocolon, gallbladder, abdominal 
oesophagus, left adrenal gland, and the left lobe of the liver can be removed to 
eradicate direct contiguous invasion from the stomach to these surrounding 
organs or to enable more complete lymph node dissection without technical 
difficulty as well as without any trouble occurring postoperatively (Iida, 1993; 
Iriyama, 1994; Launois, 1991; Maruyama, 1987b; Noguchi, 1989). Resection of 
invaded organs proved to be worthwhile even in patients with multiple organ 
involvement. Some authors have employed extremely extensive methods of 
surgery in the treatment of Borrmann type 4 gastric carcinoma (specially the so- 
called linitis plastica type) —  left upper abdominal evisceration. With this 
operative technique, the stomach and transverse colon, pancreas body and tail, 
spleen and left adrenal gland are resected en bloc (Furukawa, 1988). However, 
patients with tumors extending to adjacent organs frequently have factors 
apparent at laparotomy (peritoneal dissemination, liver metastasis and wide­
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spread nodal involvement) which indicate incurability (Bines, 1993; Korenaga, 
1988b; Mishima, 1987; Maruyama, 1989).
Distal pancreaticosplenectomy for lymph node dissection is used because of 
the intimate relation of nodes to these organs. Sequential section examination 
of the distal pancreas, with surrounding nodes dissected during surgery, is 
shown remnant nodes in 75% along splenic artery suggesting that organ re­
section in the absence of true invasion is necessary to improve the node 
dissection (Furukawa, 1988; Noguchi, 1989).
Local invasion of surrounding structures and organs is a frequent occur­
rence in patients with gastric cancer, the reported incidence ranged from 10 to 
23 per cent (Bozzetti, 1990). Combined resection is performed in 37-85%  of 
patients undergoing gastrectomies for cancer (Habu, 1990; Korenaga, 1988b). 
In the opinion of Japanese authors surgeons should be aggressive in performing 
gastrectomy with en bloc removal of invaded organs when cancer appears to be 
in a potentially curable cases, because more than 20% of the patients under­
going curative resections survived more than five years (Bozzetti, 1990; Habu, 
1990; Korenaga, 1988b; Maruyama, 1987b). 5-year survival rates were reported 
to be 33% to 48% for patients with liver resection; 29% to 31% for those with 
colon resection, and 24% to 43% for those with pancreas and spleen resections 
(Noguchi, 1989; Korenaga, 1988b).
Diagnosis of contiguous invasion is not easy. Direct invasion is proven 
histologically in 45% to 57% of cases with combined organ resection for intra­
operative macroscopic diagnosis of direct invasion (Noguchi, 1989). For 
example, the tumors arising at the greater curvature of the gastric body and 
antrum invade the mesocolon occasionally, but the direct invasion of the 
transverse colon is uncommon (Adachi, 1992). Parenchymal invasion is proven 
histologically in 33% of macroscopically diagnosed direct invasion into liver, 
another 1/3 have invasion limited to the capsule, and the final 1/3 have fibrous 
adhesions only (Noguchi, 1989). False-positive cases might, in part, be a factor 
in the high figures of 5-year survival reported for combined resections.
Splenectomy
There is no consensus of opinion regarding the therapeutic value of sple­
nectomy. A number of investigators reported that patients who have undergone 
combined gastrectomy and splenectomy had a longer survival time than did 
those who had been treated by gastrectomy alone (Bozzetti, 1990; Koga, 1981; 
M aruyama, 1987b; Noguchi, 1989). Others, however, observed that the pro­
gnosis after gastrectomy was improved in patients with intact spleen and that a 
combined splenectomy may adversely affect the prognosis (Clark, 1991; 
Maehara, 1991b; Noguchi, 1989). There are also some reports that splenectomy 
has no affect on the prognosis of patients with gastric cancer, but may increase 
the morbidity after curative gastrectomy and should be avoided unless the 
spleen is close to or invaded by the tumor (Brady, 1991; Korenaga, 1992).
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Fulminating infectious disease is one common and fatal complication after 
splenectomy, not only in young but also in adults (Maehara, 1991b; Viste,
1990). However, other workers have found that the spleen has negative effect 
on tumor immunity or that splenectomy did not adversely affect cellular 
immunity (Clark, 1991; Fuyuhiro, 1984; Kanayama, 1985; Noguchi, 1989).
Splenectomy has commonly been performed simultaneously with total 
gastrectomy to treat patients with gastric cancer, especially when the primary 
tumor is located in the upper or middle third of the stomach (Clark, 1991; 
Korenaga, 1992). Regional lymphatic drainage from this site is to the splenic 
hilar lymph nodes and radical lymphadenectomy of these first order lymph 
nodes usually include splenectomy.
Postoperative complications and mortality
Many clinicians continue to view the results of gastric cancer surgery with 
pessimism. Although radical surgical resection offers the only prospect of cure, 
the postoperative complication and mortality rates are regarded as unacceptably 
high by many non-Japanese practitioners (McCulloch, 1994). Complication 
rates of 20-40%  are commonly reported in the Western series (Adam, 1989; 
Allum, 1989; Bonenkamp, 1993; Gennari, 1986; Launois, 1991; Macintyre, 
1991; Pacelli, 1991; Viste, 1988). Review of 49 series over the world with 
patients operated on approximately at the same period show that 33 had an 
operative mortality rate of <10%; 14 had an operative mortality rate of between 
10% and 20% and two of >20%; the median was 4.6% and the mean was 7.8%, 
ranged from 0% to 28.0% (Macintyre, 1991). Especially in elderly patients 
results seem to be controversial: some reports have shown increasing compli­
cation and mortality rates with age, whereas others have challenged these fin­
dings (Bandoh, 1991; Pacelli, 1991; Viste, 1988). In recent years, preoperative 
preparation, anaesthesia, surgical technique, and postoperative care have 
significantly improved, to the extent that postoperative morbidity and mortality 
have decreased to a much more acceptable level for gastric resections 
(deAretxabala, 1987; Pacelli, 1991; Smith, 1991).
The difference between the survival rates from Japan and from the rest of 
the world has been so great that it has led to the suggestion that the biology and 
natural history of the disease in Japan is somehow different (Maruyama, 1989). 
Similarly, the lower Japanese operative mortality rates have been variously 
attributed to a higher proportion of patients with early disease, younger mean 
age, lower incidence of coexisting pathology, and a body habitus in Japanese 
patients which makes surgery technically easier (Korenaga, 1988b; Macintyre, 
1991; Maruyama, 1987b; Maruyama, 1989). However, some authors have 
concluded that in Europe extensive lymphadenectomy can be also done safely if 
carried out by properly trained surgical oncologists (Bonenkamp, 1992).
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Other treatment possibilities
Although there has been recent progress in gastric cancer surgery and improve­
ment of treatment results, we had to accept limits of radicality, especially in 
patients with peritoneal metastasis, liver metastasis, distant lymph node 
metastasis, and Borrmann type 4 cancer (Aranha, 1989; Maruyama, 1987b). In 
order to improve the treatment results in such cases, other treatment modalities 
such as adjuvant and neoadjuvant chemotherapy, intraperitoneal chemotherapy, 
intra-arterial infusion into hepatic artery for liver métastasés, hormonal therapy 
(tamoxifen), immunotherapy, and hyperthermia have been introduced, but these 
methods have little effectiveness for advanced gastric cancer at the present time 
(Ajani, 1993; Bleiberg, 1992; Harrison, 1989; Hermann, 1993; Highley, 1993; 
Kim, 1992; Shiu, 1987b; Takahashi, 1994).
AIM OF THE STUDY
The general objective of the study was to analyse the results of curative 
(radical) gastric cancer surgery in Tartu Hospital of Oncology and to define the 
prognostic factors for patients with curative gastric cancer in Estonia.
The specific aims were:
1) to write up the clinicopathological features and to evaluate the independent 
patients related, tumor related and treatment related prognostic factors for 
curative gastric cancer;
2) to determine the indications and the suitable extension of dissection of 
organs and lymph nodes in radical gastric cancer surgery;
3) to compare the treatment policy and long-term results of gastric cancer 




This thesis is based mainly on three studies where the different aspects of 
gastric cancer surgery were analysed. Among 690 patients with primary gastric 
cancer (with the exception of stomach stump cancer) treated surgically at the 
Department of Surgery, Tartu Hospital of Oncology, Estonia during the 10-year 
period from 1978 to 1987, there were 406 (58.8%) patients who had undergone 
curative resection of tumors with extended (R2 or R3) lymphadenectomy 
(Kajitani, 1981). Adjuvant chemotherapy (5-FU alone or FAM-combination) 
was administered in 122 more advanced cases without significant influence on 
the survival. The medical reports of all these patients were analysed in the first 
study {paper I). For the second study {paper IP) we used data on 361 patients 
who had undergone curative surgery for primary gastric cancer from 1978 
through 1986; i.e. all data of the patients analysed in the first study expected 
the patients operated on in 1987.
From these studies the following cases were excluded:
1. Patients who had undergone bypass procedures or palliative resections 
because of distant métastasés or technical inoperability (n=240);
2. Patients who had undergone total (n=13) or subtotal (n=22) gastrectomies 
with only group 1 lymph node dissection (R1 lymphadenectomy). We 
classified these cases as non-curative, because the perigastric lymph nodes 
as the first barrier for cancer cells are involved at least in 10% of T1 cases, 
more deeper invasion is frequently associated with N2 métastasés (Hioki, 
1990; Inoue, 1991; Inoue, 1993; Iriyama, 1989; Lauren, 1965; Lawrence, 
1991; Lehnert, 1985; Maehara, 1992d; Moreaux, 1993; Sakita, 1989). 
Therefore the risk of locoregional recurrence after R1 lymphadenectomy is 
extremely high. These operations were performed in limited number of 
elderly patients with concomitant diseases and with high operative risk. 
Moreover, lymph node métastasés and the postoperative prognosis must be 
evaluated only in the series of curative gastric resections because there is 
insufficient information regarding lymph node involvement after incomplete 
lymphadenectomy in patients treated with noncurative resection.
3. Some patients (n=9) with N4 métastasés, who had undergone R4 lympha­
denectomy (i.e. dissection of N4, mainly the para-aortal lymph nodes) with 
very high postoperative mortality or early recurrence (Inada, 1994; Kaijtani,
1981). We have desisted from this procedure at the present.
All patients were followed after surgery, and relative 5-year survival rates 
were calculated. Only patients who had clearly died of gastric cancer were
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considered as tumor-related deaths. All the data concerning the death of 
patients were collected from the database of the Estonian Cancer Registry.
Third study {paper III) is based on 203 patients with histologically proved 
primary gastric cancer treated at the Department of Surgery of Oulu University 
Hospital, Finland during the 5-year period from 1983 to 1987. For this study 
the medical reports of the Oulu University Hospital and the database of the 
Finnish Cancer Registry were used. The co-operation traditions between gastro­
enterologists of Oulu and Tartu Universities have had about twenty years 
history. The previous joint-studies concerned the relationship between pre- 
cancerous conditions and gastric cancer but not the gastric cancer itself 
(Lehtola, 1989). Although the incidence of gastric cancer has markedly de­
creased during recent decades in Finland as well as in most industrialised 
countries, the decline is less marked in some regions where the data are closer 
to those of in Estonia, for example in North-Finland. In addition, the treatment 
policy of gastric cancer is quite different in these two countries. There is the 
network of specialised oncological aid for cancer patients in Estonia and the 
more extensive surgery has been in use. The gastric cancer patients in Finland 
are treated by the general surgeons with conventional methods of surgery (see 
“Operative methods”). Because of these differences it is extremely interesting 
to compare the data of gastric cancer patients in Oulu and Tartu regions. We 
tried to evaluate the influence of clinicopathological factors and operative 
procedures on the prognosis of patients with primary gastric cancer treated at 
the Department of Surgery of Oulu University Hospital, Finland {paper III, see 
“Results”). In the “Discussion” the comparison of prognostic factors and 
treatment aspects of gastric cancer between Tartu and Oulu materials {paper 
VI) will be presented.
2. Methods
The medical reports of all patients were analysed to ascertain the characteristics 
and duration of symptoms, the physical findings and laboratory data on 
admission. Operative records were investigated with regard to operative 
findings, adjacent organ invasion, lymph node métastasés, and operative pro­
cedure including gastrectomy with different extension, lymph node dissection, 
and combined organ resection. Pathological findings were reviewed with re­
spect to the depth of invasion, size, location, gross appearance, histologic type 
of tumor, and lymph node involvement. These operative and pathologic fin­
dings were principally based on the UICC TNM classification and on the 
General Rules for Gastric Cancer Study outlined by the Japanese Research 
Society for Gastric Cancer (Hermanek, 1987; Kajitani, 1981). All specimen re­
moved were examined pathologically.
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The number and the anatomical name of regional lymph nodes and N categories 
(N1, N2, N3, N4) for each primary gastric cancer locating in the upper (C), middle 
(M) or lower (A) third, and whole stomach
T a b l e  2.1
\Location of the tumor Lower Middle Upper Whole
Lymph nodes
No.l right cardial 3  N2 I N1 N1 N1
No.2 left cardial N3 N2 N1 N1
No.3 along the lesser curvature N1 N1 N1 N1
No.4 along the greater curvature N1 N1 N1 N1
No.5 suprapyloric N1 N1 N2 N1
No.6 subpyloric N1 N1 N2 N1
No.7 along the left gastric artery N2 N2 N2 N2
No.8 along the comm. hep. artery N2 N2 N2 . N2
No.9 around the celiac artery N2 N2 N2 N2
No. 10 at the splenic hilus N3 N2 N2 N2
No. 11 along the splenic artery N3 N2 N2 N2
No. 12 in the lig. hepatoduodenal N3 N3 N3 N3
No. 13 behind the pancreatic head N3 N3 N3 N3
No. 14 at the mesenteric root N3 N3 N3 N3
No. 15 at the middle colic artery i t N4 N4 N4
No. 16 para-aortic N4 N4 N4 N4
Depth o f  invasion was divided into T1 (tumor confined to mucosa and sub­
mucosa), T2 (invasion of proper muscle layer and subserosa), T3 (invasion into 
serosa) and T4 (invasion of contiguous structures) according to the UICC rules 
(Hermanek, 1987).
Tumor location was divided into the upper (cardia, cardia+corpus), the 
middle (corpus, corpus+cardia, corpus+antrum) and the lower (antrum, 
antrum+corpus) third or the total (more than two thirds) involvement of the 
stomach.
Histology was classified according to the WHO classification as papillary 
and well or moderately differentiated tubular adenocarcinoma, interpreted as 
the differentiated types, and poorly differentiated adenocarcinoma, signet-ring 
cell, mucinous, or undifferentiated carcinomas, interpreted as the non-differen- 
tiated types (Nakamura, 1992; Oota, 1977).
M acroscopic types of tumor were classified according to Borrmann's clas­
sification as type 1 —  polypoid, type 2 —  ulcerated evaluated, type 3 — 
ulcerated with partially diffuse infiltrating border and type 4 —  diffusely 
invading tumor (Kaijtani, 1981).
Lymph nodes from different anatomical positions (lymph node stations 1 to 
16, Table 2.1) were divided into four N-groups (N1, N2, N3 and N4) according 
to the General Rules for Gastric Cancer Study outlined by the Japanese
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Research Society for Gastric Cancer (Kaijtani, 1981). In each case only the 
most distant lymph node station affected is mentioned.
3. Operative procedures
There are three components in the standard curative gastrectomy performed at 
the Departmant of Surgery, Tartu Hospital of Oncology: (1) the total or subtotal 
gastrectomy, (2) the extensive lymphadenectomy (3), and the en bloc resection 
of adjacent organs. All lymph nodes and neighbouring organs are always re­
moved en bloc with the stomach and surrounding fatty tissue (Berjozov, 1976; 
Bozzetti, 1990; Iida, 1993; Maruyama, 1987b; Sigal, 1976).
The required cancer-free distance at the proximal margin is at least 5 cm in 
circumscribed tumors and at least 8 cm in infiltrative tumors. Total gastrectomy 
is defined as the removal of the whole stomach and is indicated when the 
proximal distance from the cardia is less than required or in Borrmann types 3 
and 4 (Maruyama, 1987b). In case of subtotal gastrectomy all the lesser cur­
vature up to oesophagus and most of the greater curvature higher than the level 
of splenic hilus have been dissected. This type of gastrectomy is performed 
mainly in cases of circumscribed tumors. The lesser omentum and the greater 
omentum with the anterior leaf of the mesocolon is always removed together 
with the stomach.
Lymph node dissection , called R2 lymphadenectomy, always includes the 
perigastric nodes (excluding the left cardial nodes in distal gastrectomy), and 
nodes located along the left gastric, common hepatic, splenic and coeliac ar­
teries (Table 2.1). In cases of non-antral location the nodes in the splenic hilum 
and left cardial nodes were also removed. To achieve better lymph node re­
moval in this region the splenectomy is performed in most of these cases.
The nodes of group 3 (R3 lymphadenectomy) from the hepatoduodenal 
ligament, behind the pancreatic head and body, and the root of mesenterium 
were also dissected in cases of palpable changes in the perigastric lymph nodes 
(Table 2.1). The anterior leaf of both the hepatogastric and hepatoduodenal 
ligaments with lymph nodes and fatty tissue is removed, preserving only the 
common and hepatic arteries, as well as the portal vein and common bile duct. 
The removing of the pancreatic capsule and the nodes behind pancreatic head 
and body is also important (Kajitani, 1981; Inoue, 1991; Maruyama, 1987b; 
Mishima, 1987).
If needed, frozen sections are examined before making decisions about the 
extent of lymphadenectomy. In cases of métastasés, the aim of the dissection is 
to have a margin at least of one uninvolved group of lymph nodes distal to the 
most peripheral involved group of node stations.
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The removal o f  the neighbouring structures or organs (spleen, oesophagus, 
pancreas, mesocolon, transverse colon, diaphragm, liver, gallbladder) was 
performed in cases of direct invasion or to achieve better lymphadenectomy.
The reconstruction of the gastrointestinal tract is performed by gastro­
jejunostomy with Brown's anastomosis or by the Roux-en-Y method after sub­
total gastrectomy, and by end-to-side or end-to-end Roux-en-Y oesophago- 
jejunostomy after total gastrectomy.
Conventional gastrectomy used in radical gastric cancer surgery at Oulu 
University Hospital is either the total or distal subtotal removal of the stomach 
and perigastric regional lymph nodes, i.e. R1-lymphadenectomy according to 
the Japanese General Rules for the Gastric Cancer Study (Kaijtani, 1981). In 
this study the gastric resection is classified as radical if the lymph node involve­
ment was restricted to the perigastric (N1) nodes, no tumor was left following 
the surgery, and no microscopical invasion in the resection margins was found 
on the postsurgical histological examination. The minimal distance of the upper 
resection margin in radical cases was 5 cm, however in infiltrative cases total 
gastrectomy was always performed. No patients with T4 tumors were operated 
on with curative intention. Roux-en-Y method is applied to reconstruct the 
alimentary tract.
4. Definitions
Advanced gastric cancer was defined as “invasion or deeper invasion of the 
tumor into muscularis propria layer by histopathological examination” (Kaij­
tani, 1981).
Early gastric cancer is defined as a disease in which the depth of invasion 
is limited to the gastric mucosa or submucosa, regardless of the presence or 
absence of lymph node metastasis (Sleisenger, 1993, p.765).
Since the UICC TNM classification gives no any definition of radicality or 
curability, we decided to use the terms of the General Rules for Gastric Cancer 
Study outlined by the Japanese Research Society for Gastric Cancer (Cuschieri, 
1986; Kajitani, 1981; Rohde, 1989):
1. Absolute curative resection. There are no peritoneal and hepatic deposits. 
All macroscopic cancer i.e., primary tumor with margins histologically free 
of cancer and all involved lymph nodes are removed. At least one echelon of 
non-involved lymph nodes must have been removed beyond those contain­
ing secondary deposits (resection level R must be higher than level of nodal 
involvement N);
2. Relative curative resection — the only difference between this and “absolute 
curative” is that R equals N;
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I3. Relative non-curative resection — although there is complete removal of the 
tumor, the criteria described above are not met.
4. Absolute non-curative resection — there is evidence of residual cancer. 
Absolute or relative curative resections are defined as the operation with cura­
tive (radical) intention, and relative or absolute non-curative resections are 
defined as palliative operation in this study.
Extensive lymph node dissection (extensive lymphadenectomy) is defined as 
the removal of more than perigastric lymph nodes, etc. N2, N3 (or N4) nodes.
Postoperative mortality was defined as the number of deaths within the 30 
days after surgery. All postoperative deaths were included in the survival ana­
lyses as it is recommended by Akoh, 1992.
5. Statistical methods
The statistical data analysis was made in the SPSS-for-Windows 6.0 system, 
using uni- and multivariate analyses of variance. For the univariate analysis the 
cross-tabulation and two-sample analysis of variance was used. For the multi­
variate data analysis the multiple stepwise regression analysis. All factors 
affected the relative 5-year survival rates were analysed by the Cox regression 
model of survival analysis in a forward stepwise regression method.
The significance's were calculated by the chi-squared statistics using 
Likelihood ratio, Pearson's and Mantel-Haenszel's tests for linear association.
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RESULTS
The results are divided into two main parts: the results of the radical gastric 
cancer surgery in Tartu Hospital of Oncology, Estonia, and the results of the 
gastric cancer surgery in Oulu University Hospital, Finland. The main part of 
this retrospective study presents a review of prognostic factors influencing the 
survival of 406 gastric cancer patients radically operated on in the Tartu 
Hospital of Oncology in 1978-1987 {paper I and II). To compare the different 
policies for gastric cancer surgery the analysis of prognostic factors for 203 
patients with gastric cancer treated in the non-specialized, general surgical 
institution (Department of Surgery of the Oulu University Hospital) during the 
5-year period from 1983 to 1987 was also performed {paper III).
1. Patient related prognostic factors
Age
To analyse the influence of the age patients were classified into 6 groups by the 
age at the time of operation. The mean age was 62.4 years and median 63 years 
(range 31-85 years). 7 (1.7%) of patients were at the age of below 40 years, 49 
(12.1%) at the age of 40-49 years, 106 (26.1%) at the age of 50-59 years, 119 
(29.3%) at the age of 60-69 years, 115 (28.3%) at the age of 70-79 years and 
10 (2.5%) at the age of over 80 years (Figure 1). Although all the operated 
patients showed the peak of incidence between 60 and 70 years and patients 
with early gastric cancer between 50 and 60 years, the age distribution of early 
gastric cancer patients did not differ significantly from the overall distribution 
of age groups observed in this study.
In general the elderly patients had shorter duration of symptoms (Table 
3.2). We observed epigastric pain and anorexia more frequently in younger pa­
tients, general symptoms were more typical for the elderly patients (Table 3.4).
T a b l e  3.1
Multiple regression analysis of variables influenced by the age of patients
Variable Location (p<0.05) Nodal status (p<0.05)
Age group Antrum Non-antral N0 N+
Younger group 69 (42.6) 93 (57.4) 102 (63.0) 60 (37.0)
(n=162)
Elderly group 131 (53.7) 113 (46.3) 123 (50.4) 121 (49.6)
(n=244)
* — in all tables the relative frequences in percentages are presented in parentheses
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According to the results of univariate and multiple regression analysis only 
the antral location of primary tumor and the presence of lymph node métastasés 
was more frequent in patients over 60 years of age (Table 3.1). There were no 
significant differences in the distribution of tumor size, Borrmann types, T 
values or morphological types of cancer by the age groups.
In patients over 60 years of age the incidence of general postoperative 
complication and mortality rates were significantly higher (Table 3.15). In 
contrast no significant difference was found in the incidence of surgical 
complication.
Figure 1. Age distribution of gastric cancer patients 
Sex
In the 10-year period from 1978 to 1987 the sex distribution showed a male 
predominance 1.35:1 for all gastric cancer cases in Estonia but not for 
curatively operated patients (0.95:1) and moreover not for the patients with 
early gastric cancer (0.48:1) in the material of Tartu Hospital of Oncology 
(Figure 2).
No differences was found in the sex-distribution of any prognostic factors 
or symptoms at the time of admission (Table 3.4). There was also no significant 
independent factors for male or female patients according to the results of 







A —  all gastric cancer 
patients in Estonia
В —  all patients radically 
operated on in Tartu 
Hospital of Oncology
С —  patients with early 
gastric cancer
0% 50% 100%
Figure 2. Sex distribution of gastric cancer patients (%)
Symptoms
The period from the onset of symptoms to the date of admission ranged from 1 
month to 5 years with mean of 11.1 month. In 27.8% of the patients the disease 
was diagnosed within 3 month from the onset of symptoms, 26.8% of patients 
had had symptoms for 4 to 6 month, 26.8% for 7 to 12 month, and 18.5% of 
patients had had symptoms for longer than one year. The duration of symptoms 
had no significant differences when observed in various sex, Borrmann type, 
tumor size, nodal status and histologic type groups, but had differences with 
respect to the age of patients and the depth of gastric wall invasion. According 
to our results the elderly patients had shorter duration of symptoms (p=0.04) — 
for 32.4% of them it was less than 4 month compared with 21.0% for the 
younger patients; 23.4% for the patients at the age below 60 years and 15.2% at 
the age over 60 years group had had complaints for more than the 12 month 
before the admission (Table 3.2).
T a b l e  3.2
Duration of symptoms in different age groups
Duration of 
symptoms
< 60 year of age > 60 years of age all cases
< 4 month 34 (21.0) 79 (32.4) 113 (27.8)
4 -6  month 45 (27.8) 64 (26.2) 109 (26.8)
7-12 month 45 (27.8) 64 (26.2) 109 (26.8)
> 12 month 38 (23.4) 37 (15.2) 75 (18.5)
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The patients with early gastric cancer had relatively longer duration of 
symptoms when compared with other patients (p=0.008, Table 3.3): the mean 
duration of symptoms for patients with early gastric cancer was 17.8 month 
compared with 11.1 month for all patients (12.3 month for T2, 10.8 month for 
T3 and 9.0 month for T4 tumors).
T a b l e  3.3
Duration of symptoms and depth of gastric wall invasion
Duration of symptoms T1 all T
< 6 month 12(38.7) 222 (54.7)
7-12 month 10(32.3) 109 (26.8)
> 12 month 9 (29.0) 75 (18.5)
T a b l e  3.4
Symptoms at admission
Symptom 1 2 3 4 5 6 7
Variable
All cases 285 123 91 28 159 33 135
(n=406) (70.2) (30.3) (22.4) (6.9) (39.2) (8.1) (33.3)
Male 139 57 49 16 75 19 72
(n=198) (72.7) (28.8) (24.7) (8.1) (37.9) (9.6) (36.4)
Female 141 66 42 12 84 14 63
(n=208) (67.8) (31.7) (20.2) (5.8) (40.4) (6.7) (30.3)
p-value NS NS NS NS NS NS NS
Age < 60 129 42 25 7 58 14 38
(n=162) (79.6) (25.9) (15.4) (4.3) (35.8) (8.6) (23.5)
Age > 60 156 81 66 21 101 19 97
(n=244) (63.9) (33.2) (27.0) (8.6) (41.4) (7.8) (39.8)
p-value .001 NS .008 NS NS NS .001
T1 24 4 7 1 6 0 8
(n=31) (77.4) (12.9) (22.6) (3.2) (19.4) (0.0) (25.8)
T2-T4 261 119 84 27 153 124 127
(n=375) (69.6) (31.7) (22.4) (7.2) (40.8) (33.0) (33.9)
p-value NS 0.04 NS NS 0.04 0.03 NS
N0 169 58 53 15 91 12 65
(n=225) (75.1) (25.8) (23.6) (6.7) (40.4) (5.3) (28.9)
N1-N3 116 65 38 13 68 21 70
(n= 181) (64.1) (35.9) (21.0) (7.2) (37.6) (11.6) (38.7)





1 2 3 4 5 6 7
Antrum 127 79 55 14 88 5 75
(n=200) (63.5) (39.5) (27.5) (7.0) (44.0) (2.5) (37.5)
Corpus 110 31 24 13 50 4 41
(n=140) (78.6) (22.1) (17.1) (9.3) (35.7) (2.9) (29.3)
Cardia 29 8 7 1 12 20 11
(n=42) (69.0) (19.0) (16.7) (2.4) (28.6) (47.6) (26.2)
Total 19 5 5 0 9 4 8
(П=24) (79.2) (20.8) (20.8) (0.0) (37.5) (16.7) (33.3)
p-value 0.02 .007 NS NS NS .000 NS
Borrmann 137 60 48 21 68 9 53
I-II (n=193) (71.0) (31.1) (24.9) (10.9) (35.2) (4.7) (27.5)
Borrmann 147 63 43 7 91 24 82
III-IV(n=213) (69.0) (29.6) (20.2) (3.3) (42.7) (11.3) (38.5)
p-value NS NS NS 0.01 NS 0.04 NS
Differentiated 117 53 49 14 59 12 61
(n=171) (68.4) (31.0) (28.7) (8.2) (34.5) (7.0) (35.7)
Non-differ. 168 70 42 14 100 21 74
(n=235) (71.5) (29.8) (17.9) (6.0) (42.6) (8.9) (31.5)
p-value NS NS 0.01 NS NS NS NS
0  < 4 cm 46 17 14 1 19 1 11
(n=57) (80.7) (29.8) (24.6) (1.8) (33.3) (1.8) (19.3)
0  4-7 cm 131 64 41 17 75 11 64
(n=192) (68.2) (33.3) (21.4) (8.9) (39.1) (5.7) (33.3)
0  > 7 cm 108 42 36 10 65 21 60
(n=157) (68.8) (26.7) (22.9) (6.4) (41.4) (13.4) (38.2)
p-value NS NS NS NS NS 0.02 0.04
1 — epigastric pain; 2 — nausea and/or vomiting; 3 — anorexia; 4 — gastrointestinal
bleeding; 5 — dyspepsia; 6 —  dysphagia; 7 — general complains (fatigue, weakness).
Incidence of complaints and their association with different clinicopathologic 
variables at the time of the first admission of the patients is presented in Table
3.4. Epigastric pain (77.4% in early and 70.2% in advanced cases), weight loss 
(45.2% and 61.8%), dyspepsia (19.4% and 39.2%) and general dyscomfort 
(25.8% and 33.3%) were more frequent symptoms for both the patients with the 
early as well as with the advanced gastric cancer (Table 3.4). Nausea/ vomiting, 
dyspeptic complains and dysphagia were associated with deeper (T2-T4) 
gastric wall invasion. There were significant differences in the frequencies of 
existing symptoms between the patients with different location of cancer: 
nausea/vomiting, anorexia, dyspepsia and general dyscomfort were more 
frequent in cases of antral tumors; epigastric pain in cases of corporal tumors 
and in patients with total involvement of the stomach. Cardial tumors were 
more likely to cause dysphagia. In patients with total stomach cancers more 
frequently the palpable epigastric pain (in 33.3% of all these cases) and
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palpable tumor (in 54.1% of all these cases) was found on the objective 
investigation. Bleeding was observed more frequently in patients with Borr­
mann type I—II cancers, when the Borrmann type III—IV tumors were more often 
the cause of dysphagia.
251 (61.8%) patients had weight loss at the time of admission (Table 3.5), 
which was the evidence of advanced stage of disease in these patients: its 
incidence and quantity changed significantly with T stages (p=0.005). The 
weight loss was also more noticeable in patients with infiltrative types of 
cancer (p=0.016).
T a b l e  3.5
Weight loss at admission














Main laboratory data are listed in Table 3.6. In general we observed only few 
patients with abnormal laboratory findings: hypoproteinaemia (serum protein 
level less than 50.0 g/1) was found in 4 cases, uraemia (serum urea level more 
than 10.0 mmol/1) in 30 cases and hyperbilirubiaemia (serum bilirubin level 
more than 21.5 mmol/1) in 39 cases. Although in 6.9% of patients one of the 
symptoms was gastrointestinal bleeding, anaemia (serum haemoglobin level 
less than 100 g/1) was found in 21.4% of cases. The abnormal renal or liver 
function was not significantly associated with higher postoperative compli­
cations or mortality.
T a b l e  3.6
Laboratory findings at the admission
Laboratory data Mean Range Abnormality Abnormal findings
Protein (g/1) 75.11 42.0 to 118.0 <50.0 in 4 (0.9%) cases
Urea (mmol/1) 6.04 1.7 to 15.8 >10.0 in 30 (7.4%) cases
Bilirubin (mmol/1) 13.9 1.7 to 49.2 >21.5 in 39 (9.6%) cases
Hgb (g/1) 122.4 40.0 to 176.0 <100.0 in 87 (21.4%) cases
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2. Tumor related prognostic factors
Depth of invasion
Thirty one (7.6%) of our patients had T l, 63 (15.5%) had T2, 218 (53.7%) had 
T3 and 94 (23.2%) had T4 tumors (Figure 3). The distribution of the other 
pathologic variable by T stages by the results of univariate analysis are 
presented in Table 3.7.
T l (7.6%) T2 (15.5%) 
T4 (23.3%)
T3 (53.7%)
Figure 3. Distribution of T stages.
We found significant differences in the distribution of Borrmann type, nodal 
involvement, location of tumor, histologic type, and tumor size by the T stages. 
The deeper the gastric wall invasion the more infiltrative the Borrmann type. 
The characteristic feature for the early gastric cancer was the absence of nodal 
involvement (in 90.3% of these cases). Early gastric cancer was more 
frequently located in the middle part of the stomach when T2-T3 tumors were 
found in the distal part in most cases; T4 tumor was typical for the total 
involvement of the stomach more than other T stages. Differentiated histologic 
types dominated in T1-T2 cases, T 3-T 4 tumors had more frequently un­
differentiated morphological pattern. Tumor size had also strong correlation 
with tumor invasion: the deeper the invasion extended the larger the tumor size 
was. According to the results of multivariate analysis the distribution of the 
Borrmann type (p=0.0008), tumor size (p=0.00001) and histologic pattern of 
the cancer (p=0.019) were significantly associated with the depth of the gastric 
wall invasion.
There were only 31 patients (7.6% of all curative cases) with early (T l) 
cancers operated on with radical intention in Tartu Hospital of Oncology in the 
observed period. Early tumors were more frequently located in the middle part 
of the stomach (58.1%), had non-infiltrative forms of growth (93.6%) and well 
or moderately differentiated histologic features (64.5%); in 35.5% of cases the 
size of tumor was more than 3 cm (Table 3.7). In early cases the lymph node 
métastasés were recognised in 9.7% of cases, all up to N2 nodes.
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Distribution of pathologie variables by T stages
T a b l e  3.7
Variable Tl T2 T3 T4 all T
Borrmann (p<0.0001)
I 7 (22.6) 3 (4.8) 6 (2.8) 1 (1.1) 17 (4.2)
II 22 (70.9) 36 (57.1) 91 (41.7) 27 (28.7) 176 (43.3)
III 2 (6.5) 11 (17.5) 67 (30.7) 25 (26.6) 105 (25.9)
IV 0 (0.0) 13 (20.6) 54 (24.8) 41 (43.6) 108 (26.6)
N stage (pcO.OOOl)
N0 28 (90.3) 37 (58.7) 106 (48.6) 54 (57.4) 225 (55.4)
N1 0 (0.0) 7(11.1) 45 (20.6) 5 (5.3) 57 (14.0)
N2 3 (9.7) 10(15.9) 57 (26.1) 29 (30.9) 99 (24.4)
N3 0 (0.0) 9(14.3) 10 (4.6) 6 (6.4) 25 (6.2)
Location (pcO.OOOl)
Antrum 12(38.7) 34 (54.0) 120 (55.0) 34 (36.2) 200 (49.3)
Corpus 18(58.1) 23 (36.5) 72 (33.0) 27 (28.7) 140 (34.5)
Cardia 1 (3.2) 6 (9.5) 18 (8.3) 17 (18.1) 42(10.3)
Total 0 (0.0) 0 (0.0) 8 (3.7) 16(17.0) 24 (5.9)
Histology (p<0.0001)
Differ. 20 (64.5) 42 (66.7) 79 (36.2) 30 (31.9) 171 (42.1)
Non-differ. 11 (35.5) 21 (33.39 139 (63.8) 64 (68.1) 235 (57.9)
Tumor size (pcO.OOOl)
< 4 cm 20 (64.5) 13 (20.6) 19 (8.7) 5 (5.3) 57(14.0)
4-12 cm 11 (35.5) 40 (63.5) 112(51.4) 29 (30.9) 192 (47.3)
>12 cm 0 (0.0) 10(15.9) 87 (39.9) 60 (63.8) 147 (38.7)
Lymph node métastasés
One hundred and eighty one (44.6%) patients had the lymph node involvement, 
in 57 (14.0%) cases it extended to N1-nodes, in 99 (24.4%) cases to N2-nodes 
and in 25 (6.2%) cases to N3-nodes (Figure 4).
To assess the influence of other clinocopathological variables on the extent 
of nodal involvement we used data on 361 patients who had undergone curative 
surgery for primary gastric cancer at the Tartu Hospital of Oncology, Tartu, 
Estonia from 1978 through 1986 {paper //). It is 45 patients less than analysed 
in other papers (i.e. the patients operated on in 1987). There were 174 men and 
187 women in this study. The mean age was 62.3, ranged from 31 to 85. 134 
(37.1%) total and 227 (62.9%) subtotal gastrectomies were performed. In all 
cases the extensive lymph node dissection was used: R2 lymphadenectomy in 




Figure 4. Distribution of N stages.
The nodal involvement was found in 167 (46.3%) patients. Métastasés 
limited with perigastric (N1) nodes presented in 51 (14.1%) patients, the 
involvement up to N2 nodes was found in 89 (24.7%) and up to N3 nodes in 27 
(7.5%) cases. Lymph node involvement was diagnosed in 65.4% of patients 
who survived less than one year, in 57.8% of patients who survived less than 
three years and in 26.9% of cases with five year survival time (p<0.00001).
Table 3.8 shows the incidence of node negative and node positive cases for 
other clinical and pathological variables according to the univariate analysis. 
Lymph node métastasés occurred more frequently in cases of muscularis 
propria or deeper invasion, tumor size more than 4 cm and infiltrative 
macroscopic type. In this study the node positive cases were found more 
frequently in elderly people than in younger ones.
M ultiple regression analysis indicated that the age of patients (p=0.034) and 
Borrmann type (p=0.0023) were statistically the independent prognostic factors 
for lymph node involvement. Although the Borrmann type is closely related to 
the degree of gastric wall invasion and tumor size, it was the only independent 
pathologic prognostic factor associated with lymph node status. In our study the 
univariate analysis shows the significantly different distribution of node 
negative and node positive cases only when the early cases (T l) and advanced 
tumors were compared. The distribution of lymph node negative and positive 
cases differed significantly in two groups of lymphadenectomy (p<0.0001) but 
not in patients who underwent gastrectomy with different extension.
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T a b l e  3.8
The distribution of cases without lymph node métastasés and with lymph node for 
different clinicopathological variables
Variable No. of cases Without lymph 
node métastasés
With lymph node 
métastasés
Age (p<0.001)
<50 50 29 (58.0) 21 (42.0)
50-59 94 60 (63.4) 34 (36.6)
60-69 104 59 (57.0) 45 (43.0)
70-79 103 43 (41.7) 60 (58.3)
>79 10 4 (40.0) 6 (60.0)
Sex (NS)
Men 174 93 (53.4) 81 (46.6)
Women 187 103 (55.1) 84 (44.9)
T stage (p<0.001)
Tl 29 26 (89.7) 3 (10.3)
T2 54 29 (53.7) 25 (46.3)
T3 190 90 (47.4) 100 (52.6)
T4 88 51 (58.0) 37 (42.0)
Borrmann type (p<0.005)
I-II 177 108 (61.1) 69 (38.9)
III-IV 184 86 (46.5) 98 (53.5)
Location (NS)
Antrum 187 101 (54.0) 86 (46.0)
Corpus 116 70 (60.3) 46 (39.7)
Cardia 15 6 (40.5) 9(59.5)
Total 10 5 (47.6) 5 (52.4)
Histologic type (NS)
Differentiated 152 88 (57.9) 64 (42.1)
Non-differentiated 209 108 (51.7) 101 (48.3)
Size (p<0.005)
< 4 cm 54 46 (85.2) 8 (14.8)
> 4 cm 307 150 (48.9) 157 (51.1)
Gastrectomy (NS) 
Total 134 66 (49.3) 68 (50.7)
Subtotal 227 130 (57.3) 97 (42.7)
Lymphadenectomy (p<0.()0001) 
R2 239 148 (61.9) 91 (38.1)
R3 122 50(41.3) 72 (58.7)
Histologic types
The most common histologic types were moderately differentiated tubular 
adenocarcinoma (25.6%) and poorly differentiated adenocarcinoma (25.4%), 
followed by undifferentiated carcinomas (18.2%), well differentiated carcino­
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mas (12.8%) and signet ring cell carcinomas (10.6%) (Table 3.16). M ucinous 
adenocarcinomas (5.7%) and papillary adenocarcinomas (1.7%) were found 
only in single cases.
The non-differentiated gastric carcinomas (poorly differentiated adeno­
carcinoma, signet ring cell, mucinous and undifferentiated carcinomas) tend to 
spread more extensively in the gastric wall — we found the non-differentiated 
types of gastric cancer more often in T3-T4 stages than in the early cases 
(p=0.000001). Most of the non-differentiated cancers had infiltrative macro­
scopic type of grow (p=0.0007). Our findings also indicate that the ratio of non- 
differentiated tumors increased strongly with the increasing tumor size 
(p=0.00002), but the nodal status had no differences associated with histologic 
type of cancer (p=0.162). We also did not observed differences in the distri­
bution of the histological types by the sex or age of patients in our material.
Location
49.3% (n=200) of our patients had cancer with antral location, 34.5% (n=140) 
with corporal location and only 10.3% (n=42) with cardial location (Figure 5). 
In 5.9% (n=24) of cases more than two parts of the stomach were involved and 
these cases are classified as cancers with total tumors. During the observed 10- 




Figure 5. Location of gastric cancer.
Most minute (less than 4 cm in diameter) gastric cancers were found in the 
antrum or corpus of the stomach (p=0.000001). The cardial and total tumors 
proceed more silently and are larger at the moment of diagnosing. We also 
found significantly lower incidence of early tumors and higher incidence of 
cancers with deeper (T3-T4) invasion in cardia compared with other locations 
(p=0.000003). The infiltrative Borrmann types were located more often in the 
upper part or had total involvement of the stomach (p=0.000001). Cardial 
tumors were also more common in younger patients (p=0.013). There were no 
significant differences in the distribution of the histologic types (p=0.056), N 
stages (p=0.081), and sex of patients (p=0.919) by the location of the tumor.
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Borrmann type
The ratio of the circumscribed and the infiltrative macroscopic types of tumors 
according to the Borrmann classification was 0.9:1.0 (193:213). In 17 (4.2%) 
cases the macroscopic type of tumor was classified as Borrmann I, in 176 
(43.3%) cases as Borrmann II, in 105 (25.9%) cases as Borrmann III and in 108 
(26.6%) cases as Borrmann IV (Table 3.16). Univariate analysis showed the 
significantly different distribution of depth of invasion (p=0.000001), location 
(p=0.000001), size (p=0.000001), morphology (p=0.00074), nodal involvement 
(p=0.027) by Borrmann types of the primary tumor. Infiltrative types of gastric 
cancer were more frequently associated with deeper gastric wall invasion, 
cardial location or total involvement of the stomach, larger tumor size, non- 
differentiated histologic types and lymph node involvement.
Size
The mean diameter of the removed tumors was 6.2 cm, ranged from 1 to 23 cm. 
Fifty seven (14.0%) patients had cancers with diameter less than 4 cm, in 192 
(47.3%) cases the tumor size was 4 to 7 cm, in 123 (30.3%) cases it was 8 to 12 
cm, and in 34 (8.4%) cases more than 12 cm (Table 3.16). The distribution of 
tumors by size was greatly different for Borrmann types (p<0.00001), T stages 
(pcO.OOOOl), histologic type (p=0.00002), and also for tumors with different 
location (pcO.OOOOl) —  tumor size was larger in infiltrative types of tumor, in 
cases with deeper invasion, non-differentiated histological pattern, and cardial 
or total involvement. The size of tumor was not influenced by the age or sex of 
patients.
3. Treatment related prognostic factors
Gastrectomy
226 (55.7%) distal subtotal, 170 (41.8%) total and 10 (2.5%) proximal subtotal 
gastrectomies were performed (Table 3.9). Distal subtotal gastrectomy was the 
most common operation performed in our study. Total gastrectomy was more 
often used in cases of deeper invasion, in cases of cardial or total involvement 
of the stomach and large tumor size. Proximal subtotal gastrectomy was per­
formed only in single cases of cardial tumors (n=10), and was avoided in most 
cases because of limited radicality and high postoperative complications rate.
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Extent of gastrectomy










All cases 33 (8.1) 137 (33.7) 199 (49.0) 27 (6.7) 10(2.5)
T stage p<0.05
Tl 4(12.9) 4(12.9) 23 (74.2)
T2 5 (7.9) 13 (20.6) 37 (58.7) 5 (7.9) 3 (4.3)
T3 17 (7.8) 66 (30.3) 120 (55.0) 9(4.1) 6(2.8)
T4 7 (7.4) 54 (57.4) 19(20.2) 13 (13.8) 1 (LI)
N stage NS
N0 17 (7.6) 70 (31.1) 122 (54.2) 12 (5.3) 4(1.8)
N1 10(17.5) 16(28.1) 26 (45.6) 5 (8.8)
N2 5(5.1) 42 (42.4) 43 (43.4) 4 (4.0) 5(5.1)
N3 1 (4.0) 9 (36.0) 8 (32.0) 6 (24.0) 1 (4.0)
Location p<0.0001
antrum 7 (3.5) 19 (9.5) 152 (76.0) 22 (11.0)
corpus 19(13.6) 70 (50.0) 47 (33.6) 5 (2.9)
cardia 3(7.1) 28 (68.7) 10(24.2)
total 4 (16.7) 20(83.3)
Borrmann p<0.01
I-II 19 (9.8) 36(18.7) 118 (61.1) 15 (7.8) 5 (2.6)
III-IV 14 (6.6) 101 (47.4) 81 (38.0) 12 (5.6) 5 (2.3)
Size p<0.001
< 4 cm 4 (7.0) 10(17.5) 41 (71.9) 1 (1.8) 1 (1.8)
4-7 cm 18 (9.4) 34(17.7) 119(62.0) 15 (7.8) 6(3.1)
8-12 cm 9 (7.3) 67 (54.5) 35 (28.5) 9 (7.3) 3 (2.4)
> 12 cm 2 (5.9) 26 (76.5) 4 (11.8) 2(5.9)
Histology NS
Differentiated 15 (8.8) 40 (23.4) 101 (59.1) 10(5.8) 5 (2.9)
Non-differ. 18 (7.7) 97 (41.3) 98 (41.7) 17 (7.2) 5(2.1)
Univariate analysis of variance showed that the combined gastrectomies were 
more frequently performed for the treatment of T3-T4 tumors, but also in cases 
of infiltrative Borrmann types and larger tumor size. According to our treatment 
policy of gastric cancer the invasion of neighbouring organs by the primary 
tumor or the lymph node métastasés is not hindrance to radical surgery, 
excluding the invasion of large blood vessels. Neighbouring organs were 
resected in 176 cases (42.9%), most frequently the spleen (n= 141), oesophagus 
(n=32), the distal part of the pancreas (n=28), transverse colon (n=12), and 
transverse mesocolon (n=12). Resections of the liver (n=5), diaphragm (n=5) or 
duodenum with the proximal part of the pancreas (n=3) were also performed. 
More than one neighbouring organ was resected in 60 cases and more than two
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in 21 cases: mostly the splenectomy was combined with resection of the oeso­
phagus (n=32), distal pancreatectomy (n=27) or resection of the transverse 
colon (n=10).
One hundred forty one (34.7%) patients did undergo splenectomy. In all these 
cases the splenectomy was performed to obtain the better lymph node 
dissection and not because of the direct invasion of the primary tumor into the 
spleen. Nevertheless there was no significant correlation with the extent of the 
lymph node involvement and splenectomy although we had decided about the 
need of splenectomy mostly by the accidental biopsies of the lymph nodes 
before gastrectomy. In patients subjected to splenectomy the non-antral location 
(85.1%), deeper (T3-T4) invasion (85.8%) and infiltrative type of growth 
(72.3%) of primary cancer were more frequent.
T a b l e  3.10
Univariate analysis of postoperative complications associated with splenectomy




General-all cases 0.003 34 (24.1) 36(13.6)
cardiovascular 10(7.1) 5(1.9)
pulmonal 10(7.1) 22 (8.3)
other organs 4(2.8) 7 (2.6)
thrombembolic 8 (5.7) 1 (0.4)
septic* 2(1.4) 1 (0.4)
Surgical-all cases 0.0001 35 (24.8) 25 (9.4)
infectious 22(15.6) 18 (6.7)
others 13 (9.2) 7 (2.7)
Mortality 0.0001 16(11.3) 8 (3.0)
* — all general septic conditions without simultaneous local surgical complications
Unfortunately the patients who underwent gastrectomy combined with sple­
nectomy had higher frequency of both the general and surgical postoperative 
complications as well the higher mortality rate (Table 3.10). Also splenectomy 
was mainly associated with total gastrectomy (92.9%) and R3 lymph­
adenectomy (70.9%) it was the only independent prognostic factor (p=0.0033) 
associated with higher postoperative complication rate according to the multi­
variate analysis.
Extensive lymphadenectomy
In 64.0% (n=260) of the cases the patients underwent the dissection of N1 and 
N2 nodes (R2-resection) and 36.0% (n=146) were the so-called R3-resections. 
The former was more frequently (p<0.05) associated with subtotal gastrecto­
mies and the latter with total or combined total gastrectomy (Table 3.11).
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T a b l e  3.11
Distribution of lymphadénectomies with different extension by the gastrectomies
Gastrectomy R2-lymphadenectomy R3-lymphadenectomy
All cases 260 (64.0) 146 (36.0)
Total 10(30.3) 23 (69.7)
Combined total 33 (24.1) 104 (75.9)
Distal subtotal 188 (94.5) 11 (5.5)
Combined distal subtotal 20 (74.1) 7 (25.9)
Combined proximal subtotal 9 (90.0) 1 (10.0)
These differences were caused by the stage of primary tumor. As a rule the 
more extensive lymph node dissection as well as the more extensive gastrecto­
mies were performed in cases of more advanced primary tumor —  T2-T4 
stage; Borrmann type III-IV; tumor size more than 8 cm (Table 3.9 and Table 
3.12). Moreover, the extent of lymph node métastasés which became evident at 
the postoperative histologic examination had different distribution in R-groups: 
we found that R2-dissection was more frequently performed in cases of limited 
nodal (N0-N1) involvement and R3-dissection in cases with more distal (N 2- 
N3) lymph node métastasés (Table 3.12). The extent of lymphadenectomy was 
similar in different age and sex groups, and for cancers with different morpho­
logic pattern.
The Japanese definition of radical resection of gastric cancer is divided into 
absolute curative and relative curative resection relative to the distance of node 
dissection from the level of nodal involvement — “R minus N” factor 
(Cuschieri, 1986; Kajitani, 1981; Rohde, 1989; Shiu, 1987). Using these de­
finitions, all our operations may be classified as follows: 325 (80.1%) were 
absolute curative, and 81 (19.9%) were relative curative (N2 cases in R2-group 
and N3 cases in R3-group; Table 3.12). In addition, in 77 (19.0%) cases the “R 
minus N” was equal to 1, in 193 (47.5%) cases it was equal to 2, and in 55 
(13.6%) cases equal to 3.
Postoperative complications and mortality
We documented the postoperative complications as general and surgery-related, 
as it is also made by others (Gouzi, 1988; Launois, 1991; Mäkelä, 1992). The 
incidence of the complications and the mortality caused by these complications 
is presented in Table 3.13.
Postoperative complications and mortality according to operative procedure 
are given in Table 3.14. The surgical complications rate was highest for 
combined total gastrectomy followed by combined subtotal gastrectomy; the 
general complications rate was highest for proximal gastrectomy followed by 
combined and simple total gastrectomy. Both the surgical and general
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complications rate was significantly higher after R3 resections (21.2% and 
24.0% respectively) compared with R2 resections (10.8% and 13.8% 
respectively) (p=0.0064 and p=0.0146).
The incidence of general postoperative complications resulted to be signi­
ficantly higher in older patients (p=0.002). In contrast no significant difference 
was found in the incidence of surgical complications (Table 3.15). No signi­
ficant differences were also found in the incidence of surgical complications in 
different sex groups.
T a b l e  3.12 
Extent of lymphadenectomy by the pathologic variables
Variable R2-lyimphadenectomy R3-lymphadenectomy
All cases 260 (64.0) 146 (36.0)
T stage (pcO.OOl)
Tl 27 (87.1) 4(12.9)
T2 40 (63.5) 23 (36.5)
T3 149 (68.3) 69 (31.7)
T4 44 (46.8) 50 (53.2)
N stage (p<0.000001)
N0 170 (75.6) 55 (24.4)
N1 34 (59.6) 23 (40.4)
N2 56 (56.6) 43 (43.4)
N3 - 25 (100.0)
Borrmann type (p=0.00001)
I-II 145 (75.1) 48 (24.9)
III-IV 115 (54.0) 98 (46.0)
Location (pcO.OOOOOl)
Antrum 167 (83.5) 33 (16.5)
Corpus 72 (51.4) 68 (48.6)
Cardia 17 (40.5) 25 (59.5)




117 (68.4) 54 (31.6)
Non-differentiated 143 (60.9) 92 (39.1)
Size (pcO.OOOOOl)
< 4 cm 47 (82.5) 10(17.5)
4-7 cm 140 (72.9) 52 (27.1)
8-12 cm 60 (48.8) 63 (51.2)
> 12 cm 13 (38.2) 21 (61.8)
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T a b l e  3.13
Postoperative complications and mortality caused by these complications
Incidence Mortality
General-all cases 70(100.0)
pulmonal 31 (44.3) 6(19.4)
cardiovascular 15 (21.4) 7 (46.7)
thrombophlebitis 6 (8.6) 0 (0.0)
thrombembolia a. pulmonalis 4 (5.7) 2 (50.0)
renal 4 (5.7) 2 (50.0)
CNS 4 (5.7) 1 (25.0)
liver 3 (4.3) 1 (33.3)
sepsis 3 (4.3) 2 (66.7)
Surgical-all cases 60(100.0)
intra-abdominal infection 19(31.6) 2(10.5)
acute pancreatitis 18 (30.0) 2(11.1)
anastomotic leakage 11 (18.3) 4 (36.4)
wound infection 10(16.7) 0 (0.0)
haemorrhage 1 (1.7) 0 (0.0)
ileus 1 (1.7) 0 (0.0)
T a b l e  3.14
Complications and mortality rates
after surgery
Gastrectomy Surgical General Postoper.
complications complications mortality
(p=0.018) (P=NS) (p=0.008)
Total (n= 33) 3(9.1) 5(15.2) 2(6.1)
Combined total (n= 137) 35 (24.8) 32(24.1) 16(11.7)
Subtotal (n=199) 18(9.0) 26(13.1) 4 (2.0)
Combined subtotal (n= 27) 4(14.8) 2(7.4) 1 (3.7)
Proximal (n= 10) 0 (0.0) 5 (50.0) 1 (10.0)
All cases (n=406) 60(14.5) 70(17.5) 24 (5.9)
In the uni- and multivariate model extent of surgery (gastrectomy, lymph­
adenectomy, splenectomy) and preoperative objective findings (haemoglobin, 
bilirubin, urea, protein, weight loss) were analysed. According to the results of 
this analyses the splenectomy performed with gastrectomy was independently 
associated with both the surgical and general complications (p=0.0001). We 
found the anaemia (p=0.027) for higher general complications rate and weight 
loss (p=0.029) for higher surgical complications rate in addition to splenectomy 
to be the independent prognostic factors.
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Distribution of complications by age groups
T a b l e  3.15




30-39 (n=7) 1 (14.3) 0 (0.0)
40-49 (n=49) 3(6.1) 4 (8.2)
50-59 (n=106) 21 (19.8) 11 (10.4)
6 0 -6 9 (n=119) 18(15.1) 25 (21.0)
7 0 -7 9 (n=115) 16(13.9) 29 (25.2)
>79 (n=10) 0 (0.0) 2 (20.0)
Mortality
In our study the 30-day postoperative mortality for all radically operated 
patients was 5.9% (24 of 406). This rate 11.7% following combined total 
gastrectomy was higher than that following gastrectomy alone (6.1%), but the 
mortality rate 3.7% following combined subtotal gastrectomy was close to that 
following subtotal gastrectomy alone (2.0%) (Table 3.14). The mortality rate 
was also high for proximal subtotal gastrectomy (10.0%), but the number of 
cases in this group was too small (n=10) for conclusion making. Further, it 
should be noted that the mortality rate after R3 lymphadenectomy ( 11.0%) was 
higher than the mortality rates after R2 lymphadenectomy (3.1%).
In patients over 60 years of age the postoperative mortality rate was also 
significantly higher (7.3% versus 3.7%) compared with young patients, but it 
was similar for male and female patients.
Univariate analysis revealed both the general (p=0.000001) and surgical 
(p=0.044) complications, extent of lymphadenectomy (R3 versus R2) 
(p=0.00259) and splenectomy (p=0.0015) as the significant prognostic factors 
for postoperative mortality. Acute cardial insufficiency (n=7), pulmonal 
complications (n=6), and anastomotic leakage (n=4) were the complications 
which more frequently led to mortality in postoperative period.
Results of multivariate regression analysis showed that the presence of 
preoperative weight loss (p=0.043), incidence of general complications 
(p=0.00001) and more extensive (R3) lymph node dissection (p=0.013) were 
the independent factors which led to higher postoperative mortality.
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4. Univariate analysis of prognostic factors
All the prognostic factors for the patients with curative gastric cancer analysed 
in this study may be connected to the survival of these patient, but the intensity 
of influence is various. In the multivariate analysis, where all interactions 
between variables are considered, some of these factors may not become 
evident as prognosticators. Table 3.16 shows the distribution of the prognostic 
factors and the 5-year survival rates for the patients who underwent curative 
surgery calculated by the univariate analysis. Relative survival rates after 
surgery for cure for gastric cancer including postoperative mortality were 
80.3% at one year, 66.8% at two year, 55.7% at three year, 50.5% at four year 
and 46.1% at five year.
The total 5-year survival rate after surgery for early gastric cancer was 
80.7%, for T2 tumors 54.0%, for T3 tumors 44.0% and for T4 tumors 34.0% 
compared with 46.1% in all radically operated cases. The 5-year survival rates 
differed much depending on the presence of métastasés in the lymph nodes and 
were strongly correlated with the extent of the nodal involvement. It was 60.0% 
for patients without nodal involvement, 42.1% for N1-cases, 25.3% for N2- 
cases and 12.0% for N3-cases.
Two macroscopic characteristics of gastric cancer —  Borrmann type and 
tumor size —  had close relation to the survival rates. Borrmann type I cancer 
had 5-year survival rate of 76.5%, type II —  57.4%, type III —  38.1%, and type
IV —  30.6%. From the patients who had the cancers with diameter less than 
4 cm 71.9% were alive after 5 year of surgery, for cancers with size 4 to 7 cm 
this rate was 44.3%, for cancers with size 8 to 12 cm —  43.1%, and for cancers 
with diameter more than 12 cm it was 23.5%. The survival rates were nearly 
two times higher in the cases of the antral (51.5%) or the middle (47.9%) 
location than in the cardial (28.6%) location or in the total involvement (20.8%) 
of the stomach.
Non-differentiated types cancer resulted in a shorter survival than was seen 
in cases of the differentiated types. Survival rates were noticeably higher in 
cases of papillary (57.1%) and well (63.5%) or moderately (50.9%) differen­
tiated adenocarcinoma. The 5-year survival rate in our study was also relatively 
high in cases of poorly differentiated adenocarcinomas (47.2%) and signet ring 
cell carcinomas (36.7%), that might be associated with poor prognosis. The 5- 
year survival rate was lower for patients with the cancer of mucinous (30.4%) 
or undifferentiated (32.4%) structure.
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IT a b l e  3.16








Sex: male 198 (48.8) 46.9
female 208 (51.2) 45.2
Age: 30-39 years 7(1.7) 71.4
40-49 years 49(12.2) 44.9
50-59 years 106 (26.1) 55.7
60-69 years 119(29.3) 47.9
70-79 years 115 (28.3) 36.5
>79 years 10 (2.5) 20.0
T stage: T1 31 (7.6) 80.7
T2 63 (15.5) 54.0
T3 218 (53.7) 44.0
T4 94 (23.2) 34.0
N stage: N0 225 (55.4) 60.0
N1 57(14.0) 42.1
N2 99 (24.4) 25.3
N3 25 (6.2) 12.0
Location: Antrum 200 (49.3) 51.5
Corpus 140 (34.5) 47.9
Cardia 42(10.3) 28.6
Total 24 (5.9) 20.8
Borrmann type: I 17 (4.2) 76.5
II 176 (43.3) 57.4
III 105 (25.9) 38.1
IV 108 (26.6) 30.6
Histologic type: Papillary adenocarcinoma 7(1.7) 57.1
Well differentiated tubular adenoca. 52(12.8) 63.5
Moderately different tubular adenoca. 112(27.6) 50.9
Poorly differentiated adenocarcinoma 108 (26.6) 47.2
Mucinous adenocarcinoma 23 (5.7) 30.4
Signet ring cell carcinoma 30 (7.4) 36.7
Undifferentiated carcinoma 74 (18.2) 32.4
Tumor diameter: < 4 cm 57 (14.0) 71.9
4-7 cm 192 (47.3) 44.3
8-12 cm 123 (30.3) 43.1
> 12 cm 34 (8.4) 23.5
Gastrectomy: Distal subtotal 226 (55.7) 56.2
Proximal subtotal 10(2.5) 50.0
Total 170 (41.8) 32.4
(continued)
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Prognostic factor No. of patients 5-year sur­
vival rate (%)
Lymphadenectomy: R2 260 (64.0) 52.7
R3 146 (36.0) 34.3
Extent of lymphadenectomy relative to nodal
stage (R minus N):0 81 (20.0) 23.5
1 77 (19.0) 31.2
2 195 (48.0) 59.0
3 53 (13.0) 54.7
In addition to the patient- and tumor-related prognostic factors the extent of 
surgical intervention also influence the survival rates of gastric cancer patients. 
The 5-year survival rate after distal subtotal gastrectomy was 57.3%, after 
combined distal subtotal gastrectomy 48.1%, after proximal gastrectomy 
50.0%, after total gastrectomy 42.4%, and after combined total gastrectomy 
29.9%.
The overall 5-year survival rate was 52.7% for R2-resections and 34.3% for 
R3-resections. Comparing the lymphadenectomies with different extension as 
to the extent of lymph node involvement (R minus N), extensive lymph- 
adenectomy had a favourable effect only provided it encompassed more than 
one uninvolved group of lymph nodes. The 5-year survival was 27.2%, when R 
minus N was equal to 0 or 1 and 58.1%, when it was equal to 2 or 3. For the 
patients who had underwent splenectomy the 5-year survival rate was 30.5% 
compared with 54.3% in patients without splenectomy.
To find the influence of the subgroups of these factors on the survival the two 
sample analysis of variance was performed (Table 3.17). This analysis brought 
forth as favourable factors the age below 70, tumor location in the lower or 
middle part of the stomach, Borrmann I—II type, tumor size less than 4 cm, 
differentiated histological type, T 1-2 stage, limited (N0-N1) lymph node 
involvement, subtotal gastrectomy, R2 versus R3 lymphadenectomy and the 
extent of lymphadenectomy more than one N-group from the involved lymph 
nodes. The influence of the age of the patient at the moment of the operation, 
tumor sites and different histological types was statistically less marked than 
other factors. The year of the operation and the sex of patients did not have a 
significant influence on the survival.
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T a b l e  3.17
Univariate analysis of prognostic factors influencing the 5-year survival 
of gastric cancer patients




Age <0.01 < 70 years 51.9 > 70 years 35.2
T stage <0.0001 1-2 67.8 3-4 41.0
N stage <0.00001 0-1 56.4 2-3 22.6
Histologic type <0.01 differentiated 55.0 non-differ. 39.6
Borrmann type <0.0001 I-II 59.1 III-IV 34.3
Size of tumor <0.0001 < 4 cm 71.9 > 4 cm 41.8
Location <0.0001 antrum/corpus cardia/
50.0 total 25.8
Gastrectomy <0.00001 subtotal 55.0 total 32.4
Lymphadenec­
tomy <0.00001 R2 52.7 R3 34.3
R minus N2 <0.00001 2-3 58.1 0-1 27.2
1 — not significant,2 — extent of lymphadenectomy relative to nodal stage
Table 3.18 and Figure 6 show the relationship between the 5-year survival rate 
and the presence of lymph node métastasés at the different levels of intramural 
cancer invasion. In general, the 5-year survival rate correlated well with both 
the extent of lymph node métastasés and the depth of tumor penetration. There 
was a significant difference of the 5-year survival rates between the node­
positive and the node-negative groups, 28.7% and 60.0% respectively, and also 
between the early and the advanced cases of cancer, 80.7% and 43.2% 
respectively.
T a b l e  3.18
Incidence and the 5-year survival rates in relation to T and N stages
T Tl T2 T3 T4 all T
N n1 5-y2 n 5-y n 5-y n 5-y n 5-y
N0 28 82.1 37 64.9 106 56.6 54 51.9 225 60.0
N1 0 - 7 71.4 45 42.2 5 0.0 57 42.1
N2 3 66.7 10 30.0 57 28.1 29 13.8 99 25.3
N3 0 - 9 22.2 10 10.0 6 0.0 25 12.0
all N 31 80.7 63 54.0 218 44.0 94 34.0 406 46.1
1 — number of cases,2 — 5-year survival rate (%)
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Figure 6. 5-year survival rates in different TN stages after curative gastric 
cancer surgery in Tartu Hospital of Oncology
The 5-year survival rate for early gastric cancer showed unexpectedly lower 
survival values (66.7%), when lymph node métastasés are present, in com­
parison with the survival rate of patients without lymph node métastasés 
(82.1%). The lowest 5-year survival rate was for the patients with T3-T4 
tumors with N3-positive nodes (6.3%). The extent of lymph node involvement 
showed the dependence on the T stage.
5. Multivariate analysis of prognostic factors
All the prognostic factors are closely interrelated. For example larger tumor 
size may be associated with higher degree of gastric wall invasion and presence 
of lymph node métastasés, it may need more extended gastrectomy and so on 
(Moriguchi, 1992). Therefore the analysis of these factors by multivariate 
models provides more information pertinent to decision-making processes than 
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IIn the multivariate analysis using the Cox regression model (Table 3.19), all 
factors tested by the univariate analysis were used. This analysis identified five 
prognostic variables —  nodal involvement, extent of gastrectomy, depth of 
gastric wall invasion, histologic type of cancer, and age of patients at the time 
of operation —  that significantly influenced the prognosis of our patients.
T a b l e  3.19
Results of the Cox regression multivariate analysis of prognostic factors after 
curative surgery for gastric cancer





N1 1.57 (1 .04-2 .37)
N2 2.48 (1 .81-3 .41)
N3 3.98 (2 .45-6 .48)
Extent o f gastrectomy 0.0003
Subtotal 1.0
Total 1.68 (1 .27-2 .23)
Depth o f invasion 0.0098
T1 1.0
T2 2.04 (0 .84-4 .96)
T3 2.27 (0 .99-5 .23)
T4 3.24 (1 .38-7 .62)
Histologic type 0.0168
Papillary or tubular 1.0
Poorly differentiated 1.01 (0 .70 -1 .43 )
Others2 1.51 (1 .09-2 .09)
Age 0.0172
< 70 years 1.0
> 70 years 1 .42 (1 .0 7 -1 .8 8 )




Extent o f lymphadenectomy 0.0588
R minus N factor 0.4656
Sex 0.4634
1 —  95% confidence interval for relative risk o f death, 2 —  mucinous, signet ring cell 
and undifferentiated carcinomas
Among these, lymph node involvement was the most important independent 
prognostic factor followed by the depth of invasion and the histological type of 
cancer. The risk of death was 1.57 times higher in N1 cases, 2.48 times higher
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in N2 cases, and 3.98 times higher in N3 cases compared with patients without 
lymph node métastasés. According to the results of this analysis the extent of 
gastrectomy was the only independent treatment related prognostic factor. The 
age of patients also influenced the risk of death in the multivariate model if the 
patients below and over 70 years of age were compared. Other tumor related 
factors —  Borrmann type, location and size of the tumor, as well as the extent 
of lymphadenectomy, and sex of patients did not significantly improve the 
model where all the interactions between variables were taken into account.
6. Results of gastric cancer surgery 
in Oulu University Hospital
We studied the data of 203 patients with primary gastric cancer treated at the 
Department of Surgery of Oulu University Hospital, Finland during the 5-year 
period from 1983 to 1987 {paper III)- The lower third of the stomach appeared 
to be the most common location, invaded in 44.3% of the cases, followed by the 
upper third (22.7%), the middle third (21.1%) and the total involvement 
(11.8%). The distribution of macroscopic types of tumors showed the pre­
valence of infiltrative cases (Borrmann type I—II —  45.3%, type III—IV — 
54.7%). The pathological examination found Lauren's intestinal type in 50.2%, 
diffuse type in 35.0% and mixed type in 14.8%% of the cases. The ratio of the 
intestinal type to the diffuse type was 1.43. T1 was found in 9.9%, T2 in 
16.8%, T3 in 32.5% and T4 in 39.4% of the cases. The lymph nodes were 
involved in 49.3% of the cases (N1 in 15.8% and N2 in 33.5 according to the 
TNM classification). In 12.3% of the cases the extent of nodal involvement 
could not be retrospectively established. Distant métastasés were diagnosed in 
23.7% of the patients.
Palliative gastric resections in Oulu was performed in 47 (23.2%) and 
symptomatic bypass-procedures in 27 (13.3%) cases. Although only 3.4% of 
the patient did not undergo surgery, in more than half of those who did. 
potentially curative resection was not feasible. Although palliative resection for 
gastric cancer is mainly indicated to improve the quality of the patients 
remaining life by reducing the danger of complications (Mäkelä, 1992), it also 
offers a possibility of longer survival for patients who cannot undergo radical 
surgery. In Oulu study 6.4% of the patients were alive five years after palliative 
resection. We agree with authors, who think that if the resection is palliative 
due to the presence of various incurable factors, it still seems preferable to 
laparotomy alone or gastrojejunostomy (Korenaga, 1988b; Maehara, 1992a).
Radical gastrectomy was performed in 88 (43.3%) with overall 5-year survival 
of 45.5%. Conventional gastrectomy used in radical gastric cancer surgery at
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Oulu University Hospital was either the total or distal subtotal removal of the 
stomach and perigastric regional lymph nodes, i.e. R1 -lymphadenectomy ac­
cording to the Japanese General Rules for the Gastric Cancer Study (Kaijtani, 
1981). The gastric resection was classified as radical if the lymph node 
involvement was restricted to the perigastric (N1) nodes, no tumor was left 
following the surgery, and no microscopical invasion in the resection margins 
was found on the postsurgical histological examination. No patients with T4 
tumors were operated on with curative intention in Oulu.
The cure results in Oulu are easily comparable to those in contemporary 
Western hospitals where gastrectomy is performed without extended lymph­
adenectomy, but they are inferior to those in centres where extensive lymph 
node dissection is routinely practised (Akoh, 1991; Bollschweiler, 1993; 
Brems-Dalgaard, 1993; Haugstvedt, 1993; Lindahl, 1988; McCulloch, 1994; 
Noguchi, 1989; Siewert, 1993).
T a b l e  3.20
Results of the Cox regression multivariate analysis for prognostic factors after 
curative surgery in Oulu University Hospital





T2 4.99 (1 .45-17 .15)
T3 9.56 (2 .89-31 .64)







type o f gastrectomy 0.5730
N stage 0.8080
1 —  95% confidence interval for relative risk o f death
Univariate analysis indicated that tumor size, location, gross appearance, 
degree of gastric wall invasion, presence of lymph node and distant métastasés, 
and radicality of operative procedures were the significant prognostic factors of 
survival. No significant relationship was found between the survival rates and 
the age or sex of patients, Lauren histopathological type or splenectomy per­
formed with gastrectomy. In a Cox multivariate analysis of the eleven clinico- 
pathological and treatment variables, analysed by univariate analysis, the T 
stage and the presence of distant métastasés independently affected survival.
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When curative cases were analysed by the Cox regression model, only the 
gastric wall invasion appeared as an independent prognosticator (Table 3.20).
In addition to the patients curatively operated on, we found 108 (53.2%) 
patients with tumors T2-4N 0-N 2(N 3) (Table 3.21) in Oulu material who could 
have been possibly operated on with curative intention, if the combined 
resections of neighbouring organs and the extensive lymph node dissection had 
been used. In 19 cases the carcinomas were classified as M l tumors only be­
cause of the métastasés in non-perigastric lymph nodes. These cases might 
have been classified as T3-T4N3 tumors according to the General Rules of 
Japanese Research Society for Gastric Cancer (Kaijtani, 1981). We believe that 
in these cases of approach to the nodal staging the more extensive lymph­
adenectomy ought to be favoured. Moreover, the number of patient with lymph 
node métastasés may be larger if great number of nodes are dissected and more 
patients with occult metastasis may be detected (Gunven, 1991). There was a 
considerable number of N2 nodes involved (9.6%) in patients with early gastric 
cancer operated on in Tartu. No lymph node métastasés was found in T1 cases 
in Oulu, but the N2-N3 nodes were not normally dissected with the standard 
gastrectomy.
T a b l e  3.21
Patients in the Oulu University Hospital who might have been operated on with 
curative intention by extensive methods of gastric cancer surgery
Type of T l-2 T2 T3 T3 T4 T4 T3 T4 all
operation N0 N2 N0-1 N2 N0-1 N2 M l1 M l1 TNM
Palliative l 2 2 62 192 5 14 47
Sympto­
matic 2 4 14 2 5 27
Explora­
tive 6 16 3 9 34
total 1 2 6 21 15 44 5 14 108
1 —  these cases were classified according to the UICC TNM  classification as T 3 -  
T4M1 cases only because of the lymph node métastasés in “non-perigastric” nodes, 
but could be classified as N3 nodes according to the JRSGC classification;




The prognosis of patients with malignancy depends upon three groups of 
factors: biological and epidemiological aspects of the tumor, tumor-host re­
lationship, and the therapy prescribed (Akoh, 1992; Bollschweiler, 1992; Jans­
sen, 1992; Lauren, 1993; Moriguchi, 1991a). In our study we focused on pa­
tients with primary gastric cancer who had undergone curative resection and 
obtained evidence of prognostic significance of different clinical, pathologic 
and therapeutic factors of curative gastric cancer. Identification of prognostic 
factors in resected gastric carcinoma is necessary for the prediction of the 
outcome of patients. The analysis of prognostic factors influences also the 
choice of therapy. In the ideal situation, as many prognostic factors as possible 
should be analysed before the initiation of therapy to design a multimodal 
therapeutic concept for the individual patient.
The differences in the overall survival curves for patients with gastric 
carcinoma after curative or radical operations are large, with 5-year survival 
rates of 60% or more in Japanese and 40% or less in non-Japanese series 
(Akoh, 1992; Breaux, 1990; Bozzetti, 1990; Maruyama, 1987b; Murray, 1989; 
Noguchi, 1989; Ovaska, 1989). Relative survival rates after surgery for cure for 
our patient including postoperative mortality were 80.3% at one year, 66.8% at 
two year, 55.7% at three year, 50.5% at four year and the 5-year survival rate 
was 46.1%. In this study univariate analysis brought forth as favourable factors 
the age below 70, tumor location in the lower or middle part of the stomach, 
Borrmann I—II type, tumor size less than 4 cm, differentiated histological type, 
T 1-2 stage, limited (N0-N1) lymph node involvement, subtotal gastrectomy, 
R2 versus R3 lymphadenectomy and the extent of lymphadenectomy more than 
one N-group from the involved lymph nodes. The year of operation and the sex 
of patients did not have a significant influence on the survival.
Variables which influence survival time after curative gastrectomy for 
gastric cancer are inter-related. Multivariate analysis helps to determinate the 
importance of each variable, and useful prognostic factors can be identified. 
While independent prognostic factors for survival time have been defined based 
on multivariate analysis, there is a discrepancy in the data in different reports, 
probably, because some studies had less statistical power owing to smaller 
numbers of patients or because patients were stratified differently with respect 
to certain clinicopathological characteristics (Moriguchi, 1992). We consider 
our material large enough for this analysis. Multivariate analysis identified five 
prognostic variables for our patients that significantly influenced the risk of 
death. Among these, lymph node involvement was the most important 
independent prognostic factor, followed by the extent of gastrectomy, the depth 
of invasion, histological type of cancer and the age of patients.
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1. Patients related prognostic factors
Age
Gastric cancer is most frequently observed during the seventh decade of life 
within European series and only the patients in Japan are almost 6 -10  years 
younger. The mean age is reported to be 64-68 years (Bollschweiler, 1993; 
Jatzko, 1992a; McCulloch, 1994), in our study it was 62.4 years and median 63 
years (range 31-85 years). Therefore we consider the age of our patients to be 
comparable with patients from the other European countries.
We found the age to be a significant prognostic factor. The results show 
that it is the younger patient that benefit most from extensive surgery. Un­
fortunately the high 5-year survival rate for patients in the 30-39 year group 
(71.4%) after extensive radical surgery does not reflect the complete real 
situation. Because of the more aggressive course of the disease in young people 
the number of curatively operated patients in this group is relatively low (1.7%) 
and the overall prognosis is worse than it is in other age groups. By this fact 
also the similar distribution of histologic types of gastric cancer in different age 
groups of our radically operated patients could be explained.
30.8% of our patients were over 70 years old. We found a decreased 5-year 
survival in the old (over 70 —  35.2%) and the very old (over 80 —  20.0%) age 
groups. Hereby it must be noted that recurrent gastric cancer is the dominating 
cause of death among elderly patients operated on for gastric cancer. However, 
too few autopsies are made in this group of patients and the real cause of death 
may be other than gastric cancer.
In lights of our findings, age is not a contraindication to radical resection 
for gastric cancer. When considering the indications for total gastrectomy, 
elderly patients should not be regarded as a contraindication solely because 
they are aged. Nevertheless aggressive surgery with extensive lymph­
adenectomy does not always seem to contribute to a favourable prognosis in 
elderly patients, who usually have concomitant systemic cardiovascular and 
respiratory disorders and who are therefore at high risk for general 
postoperative complications and death. In our patients over 60 years of age the 
incidence of these complications as well as the mortality rate resulted to be 
significantly higher than in younger patients (Table 3.15). In contrast no 
significant difference was found in the incidence of surgical complication. 
Lower survival rates of the elderly patients in our study may be also caused by 
the more frequent lymph node involvement.
Sex
The male:female rate of gastric cancer patients in Estonia is 1.35:1, while in 
most reports the incidence of gastric cancer in male is said to be 1.5 times or 
more higher than it is in female (Bollschweiler, 1993; Holleb, 1991; Jatzko, 
1992a; Maruyama, 1987b; Maruyama, 1989; Soga, 1988). The difference can
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be attributed to a difference in the mean span of life which is about ten years 
lower for men in Estonia, in other words there is a high incidence of gastric 
cancer in the females who have outlived their male counterparts. Sex distri­
bution showed a female predominance for curatively operated patients 
(male.female ratio 0.95:1) and moreover for the patients with early gastric 
cancer (male:female ratio 0.48:1) on the material of Tartu Hospital of On­
cology. These differences can not be explained by the more aggressive course 
of the disease in men as the distribution of other pathological variables was 
statistically similar in the two sex groups. Uni- and multivariate analysis also 
showed no significant differences in the postoperative mortality and survival 
rates between male and female patients. That means that there are relatively 
fewer male patients capable of undergoing radical surgery and have early 
cancers only in single cases as men tend to care less for their health and turn 
later to doctors than women.
Symptoms
The exact date of onset of the first symptom is frequently not easy to establish 
and the subjective symptoms are differently described by the patients. There­
fore these data are difficult to compare. The average duration of symptoms is 
reported to be 4 to 6 month for patients with curative gastric cancer (Akoh, 
1991). In some studies the patients with early gastric cancer had symptoms 
more than one year before diagnosing in 45.5% of cases (Moreaux, 1993). For 
our patients the mean duration of symptoms was 11.1 month. Patients with 
early gastric cancer had relatively longer duration of symptoms when compared 
with total of all patients. The latter fact might be explained by the result that 
early gastric cancer have differentiated morphologic pattern more frequently 
than advanced ones, as it is reported in some other studies (Ikeda, 1994; 
Nakamura, 1992). Differentiated types of gastric cancer are thought to be the 
result of a long-term process associated with a range of sequential precancerous 
conditions having their own symptomatology, which is difficult to separate 
from gastric cancer symptoms (Correa, 1991; Lauren, 1993; Sue-Ling, 1993).
Previously it has been suggested that a history of symptoms of longer than 6 
month is associated with more favourable prognosis, when short history (less 
than 3 month) and the absence of epigastric pain or dyspeptic symptoms are 
associated with rapid growth of the tumor and poor prognosis (Armstrong, 
1986; Msika, 1989; Tso, 1987). In the present study we found no significant 
differences in survival rates associated with duration of preoperative symptoms.
In our study the elderly patients had shorter duration of symptoms than 
young patients. It is difficult to explain because there were no significant 
differences in the distribution of main pathologic variables as well as the 
subjective symptoms by age groups. It may be possible that the elderly stand at 
attention for their health more accurately than the younger ones. If we add the 
low rate of men among the patients with early gastric cancer we may conclude
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that the young men with dyspeptic disorders need special attention. The 
diagnosis is reported to have been made late in young patients also by others 
(Maehara, 1991a).
The present study is in agreement with other reports about the high 
predominance of epigastric pain and weight loss among the presenting 
symptoms (Craanen, 1992; Crean, 1994; Maehara, 1991a; Moreaux, 1993; Sue- 
Ling, 1992; Wanebo, 1993). Epigastric pain (77.4% in early and 70.2% in 
advanced cases), weight loss (45.2% and 61.8%), dyspepsia (19.4% and 39.2%) 
and general dyscomfort (25.8% and 33.3%) were more frequent symptoms for 
both the patients with the early as well as with the advanced gastric cancer 
(Table 3.4).
The expressive clinical symptomatology and the long duration of pre­
operative symptoms in a high percentage of cases is true in this study. Although 
the symptoms of gastric cancer are reported to be very similar to the symptoms 
of benign conditions such as peptic oesophagitis, gastritis and peptic ulcer, such 
nonspecific symptoms, particularly during the sixth or seventh decade of life, 
should not be regarded routinely as benign, non-neoplastic disease, and should 
not be treated with antacids or anti-ulcer drugs before a diagnosis has been 
established by examination (Lawrence, 1991; Moreaux, 1993). Such treatment 
may mask the symptoms of gastric cancer and lead to a delay in diagnosis 
(Allum, 1989; Craen, 1994; Sue-Ling, 1992). It is reported that in half of 
patients the reason for delayed diagnosis was poor interpretation of symptoms 
or incorrect diagnosis at the first evaluation (Arvanitakis, 1992). Pain and 
dyspepsia, specially if persistent, should make one consider the possibility of 
the cancer and the need of more profound investigation (Correa, 1988; Correa, 
1992; Sobala, 1993; Stalnikowicz, 1990; paper V).
2. Tumor related prognostic factors
After curative gastrectomy in patients without peritoneal dissemination or 
hematogenous distant metastasis, gastric wall invasion and lymph node involve­
ment have proved to be the most important pathological predictors of tumor 
recurrence (Baba, 1989a; Kaijtani, 1981; Maruyama, 1989). Our study showed 
that the prognosis of gastric cancer patients depends on three features of the 
tumor: depth of invasion, lymph node status and histologic type. In addition, the 
relatively high 5-year survival rates may be also caused by the high frequency 
of the differentiated histological types and lower or middle location of the 
tumor observed in this study.
Depth of invasion
Depth of tu ^ o r  infiltration through the stomach wall is not only one of the most 
important prognostic factors in gastric cancer but also of major weight in the
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decision process of the surgeon once he has opened the abdomen (Rohde,
1987). In general, because the disease tends to present at an advanced stage in 
most cases, the pessimism and surgical conservatism is prevailing among 
W estern surgeons (Macintyre, 1991; McCulloch, 1994).
This study has demonstrate a significant association between depth of 
gastric wall invasion and survival rates. The total 5-year survival rate after 
surgery for early gastric cancer was 80.7%, for T2 tumors 54.0%, for T3 tumors 
44.0% and for T4 tumors 34.0% (Table 3.16). Based on our data the muscularis 
propria or deeper invasion is really a predictor of relatively poor prognosis for 
gastric cancer patients and only the early cases are associated with satisfactory 
survival rate. The risk of death was 2.04 times higher in T2 cases, 2.27 times 
higher in T3 cases, and 3.24 times higher in T4 cases compared with early 
gastric cancer (Table 3.19). A further analysis of our data show that although 
the probability of the peritoneal dissemination of cancer cells and nodal 
involvement is reported to be high in T3-T4 cases, our patients with these 
tumors had a relatively favourable 5-year survival rates, especially when there 
were no lymph node métastasés (56.6% and 51.9% respectively).
Concerning the early cases of gastric cancer, the question remains whether it is 
an entity different from invasive gastric carcinoma or an early stage of the same 
disease. There are many arguments in favour of both propositions. The long 
duration of expressive preoperative clinical symptoms just as it has been 
noticed also in other series and the different pathologic features of early and 
advanced gastric cancer (Table 3.3, Table 3.4., Table 3.7) make it impossible to 
exclude absolutely the possibility that early gastric cancer might be an 
independent form of malignance. On the other hand transitions between early 
and invasive carcinomas are often met (Lawrence, 1991 ; Moreaux, 1993).
The overall incidence of early gastric cancer in our series was 7.6% 
compared with 3 to 21% in other European studies (Akoh, 1992; Arveaux, 
1992; Bollschweiler, 1992). In Japan the developments in diagnosis and the 
introduction of mass screening programmes have allowed increased detection 
of early gastric cancer, leading to an excellent survival prospect.
Lymph node métastasés
Lymph node involvement is often stated to be one of the prognostic factors for 
patients with gastric cancer (Baba, 1989a; Jatzko, 1992a; Mishima, 1987; 
Msika, 1989). In our study it was the most important independent prognosti- 
cator followed by the depth of invasion and the histological type of cancer. The 
risk of death was 1.57 times higher in N1 cases, 2.48 times higher in N2 cases, 
and 3.98 times higher in N3 cases compared with patients without lymph node 
métastasés (Table 3.19). Lymph node involvement was found in one hundred 
and eighty one patients (44.6%).
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The extent of lymph node involvement among our patients showed the 
dependence on the T-stage. Univariate analysis shows the significantly diffe­
rent distribution of node negative and node positive cases only when the T1 and 
advanced tumors were compared —  a high incidence of lymph node métastasés 
is accompanied with the proper muscular layer or deeper involvement (paper 
II). The survival rates in T2 cases come also closer to the rates for T3 than for 
T1 cases and therefore it is reasonable to consider the T2-tumors to be 
advanced ones, as it is prescribed by the Japanese surgeons (Kaijtani, 1981; 
Maruyama, 1987b; Maruyama, 1989).
We found the survival rate of early gastric cancer with lymph node 
métastasés to be significantly lower compared to the rate of early cancer 
without nodal involvement {paper I). Therefore we agree with Inoue, 1991 that 
the definition of early gastric cancer may need some revision —  it might be 
modified to “carcinoma with invasion confined to the mucosa or submucosa but 
without evidence of lymph node métastasés” (Inoue, 1991).
It is relevant here that in addition to the depth of tumor invasion the extent 
of lymph node involvement also correlated significantly with the Borrmann 
type and tumor size, but not with the histologic type or the location of the 
cancer.
The discrepancy among the Japanese Joint Committee (JJC) and International 
Union Against Cancer (UICC) classifications of the staging of gastric cancer 
has caused confusion (Noguchi, 1989). The UICC TNM classification defines 
the perigastric lymph nodes and nodes along the left gastric, common hepatic, 
splenic, and celiac arteries as regional lymph nodes; involvement of hepatoduo­
denal, retropancreatic, mesenteric, or para-aortic nodes is regarded as distant 
metastasis. According to the recommendations of the Japanese surgeons 
(Kaijtani, 1981; Maruyama, 1987b; Maruyama, 1989) the latter nodes are 
classified as regional (N3-N4) and in addition to the cancer-free resection 
margin only the R2, or more extensive lymphadenectomy is the pre-requisite of 
the curative gastric cancer surgery. In our patients the muscularis propria layer 
or deeper invasion was associated with the high incidence of lymph node 
métastasés and with lower survival rates. Those it is extremely important in our 
opinion to interpret the hepatoduodenal, retropancreatic and mesenteric nodes, 
or the nodes at the splenic hilus as regional (N3) and all cases with involvement 
of these nodes as curative.
A Cox model, including all prognostic variables, indicated that the depth of 
gastric wall invasion and presence of lymph node métastasés were the more 
important independent predictors of death. According to the results of 5-year 
survival analysis in different T and N categories all cases were divided into 
three prognostic groups. We can define the T1N 0-2 and T2N0-1 tumors as 
cases with good prognosis, T3N0-1 and T4N0 tumors as cases with inter­
64
mediate prognosis, and T2N 2-3, T3N2-3 and T4N 1-3 tumors as cases with 
poor prognosis (see Table 3.18. and Figure 6.).
Histology
M ultivariate analysis showed that the histological type of cancer is an 
independent and important prognostic factor. The high frequency of the 
intestinal types (differentiated types) is connected with a high-risk population 
and also a better prognosis of survival (Bollschweiler, 1993; Mishima, 1987). 
In our series the differentiated types: non-differentiated types ratio was 1.06 
(171:161) which is comparable to that in most of the reports on the high risk 
areas (Jatzko, 1992a; Lauren, 1993; Maruyama, 1993; Roukos, 1990). When 
the incidence of different histologic types was also comparable, the frequency 
of cases with signet cell carcinoma was relatively lower (7.4%) than it was 
reported in other series (Bollschweiler, 1993; Jatzko, 1992a; Maruyama, 
1987b). In 68.7% of all cases the tumors had histological patterns with higher 
5-year survival rates than the overall 5-year survival rate was. Beside the 
relatively well-differentiated types (papillary and tubular carcinomas) the 
poorly differentiated adenocarcinoma with the 5-year survival rate of 47.2% 
also complete this group.
The non-differentiated gastric carcinomas (poorly differentiated adeno­
carcinoma, signet ring cell, mucinous and undifferentiated carcinomas) tend to 
spread more extensively in the gastric wall (Heberer, 1988; Ikeda, 1994; 
Janssen, 1991). We found these types of gastric cancer more often in T3-T4 
stages than in the early cases. In addition, most of the non-differentiated 
cancers had infiltrative macroscopic type of grow and larger tumor size. These 
findings clearly show that the non-differentiated gastric carcinomas are 
clinically silent for a longer time than the differentiated-types and the early 
detection of the former is more difficult. It might be also possible that the non- 
differentiated types tend to grow more rapidly and that the alteration of the 
predominant histologic type alter with growth of tumor. On the other hand we 
did not observed differences in the lymph node involvement by the histological 
types. Accordingly, especially the resections of primary tumors should be re­
commended to be more extensive in patients with the non-differentiated 
cancers.
Some studies point out the fact that differentiated tumor is more frequent in 
men and older patients, whereas the diffuse type is more common in women 
and in the younger age groups (Lauren, 1965; Haugstvedt, 1992; Mecklin,
1988). We did not observed those associations in our material. It can be 
explained by the supposition that most of the young patients with non- 




We found carcinomas in the upper third of the stomach only in 10.3% of the 
cases. There was no increased incidence of cancer of this location in radically 
operated on patients, also it has been pointed out in many other reports 
(Cuschieri, 1989; Maruyama, 1987b; Bollschweiler, 1993; Meyers, 1987). So­
me authors have showed that proximal tumors tend to penetrate into the serosa 
and have lymph node métastasés more often than those of the distal stomach 
(Bollschweiler, 1993; Meyers, 1987). Because of the high percentage of cardial 
tumor in advanced stages (between 50 and 75%) the need for adequate 
screening programs is especially felt in the diagnosis of this location of gastric 
cancer (deCalan, 1988; Husemann, 1989; Kawaura, 1988; Moreaux, 1988; 
Rohde, 1991). There was 38.1% of N0 cases in cardial tumors in our study 
compared with 56.5% and 60.7% in antral and corporal tumors respectively, 
although these differences were not significant (p=0.081). A possible expla­
nation for this finding is the unique anatomic situation in the proximal third 
having lymph drainage directly into left paraaortic (N3) nodes.
Some authors have reported that carcinoma of the cardia is characteristic 
for older patients (deCalan, 1988; Husemann, 1989; Kawaura, 1988; Moreaux, 
1988; Rohde, 1991), when others have found more young with proximal 
cancers than those with distal cancers (deCalan, 1988; Husemann, 1989; Ka­
waura, 1988; Moreaux, 1988; Rohde, 1991; W elvaart, 1980). In our patients the 
incidence of cardial tumors was higher in less than 60 years of age (p=0.013), 
but no significant differences in the sex of patients was found (p=0.919).
The traumatic thoracoabdominal approach with combined gastrectomies in the 
treatment of cardial tumors also contributes to the high frequency of inoperable 
cases in particular with elderly patients who frequently suffer from concomitant 
diseases. This also accounts for the number of operable cases of cardial cancer 
being low. On the other hand the overwhelming majority of tumors were 
located in the lower (49.3%) and middle (34.5%) part of the stomach, where the 
radicality of resection should be better guaranteed. In our study, in cases of 
non-cardial carcinomas the survival rates are really about two times higher than 
in the cases with cardial location or total involvement of the stomach. 5-year 
survival rate for our patients with gastric cardia cancers was 28.6% compared 
with 51.5% for patients with antral cancers and 47.9% for patients with tumors 
located in the middle part of the stomach (p=0.005). This can partly be 
explained by the low rate of early cancers in this area and T l tumors of the 
proximal gastric third also have a worse prognosis than T l tumors of the distal 
stomach. Although the tumor location was not a significant prognostic para­
meter in the multivariate analysis because of the close connection with others, 
mainly with the extent of gastrectomy, we still think that distribution of both 
the tumor locations and histological types may be linked to the relatively good 
cure results in our study.
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Borrmann type
By the results of the univariate analysis the infiltrative types of gastric cancer 
were more frequently associated with deeper gastric wall invasion, cardial 
location or total involvement of the stomach, larger tumor size, non-differen- 
tiated histologic types and lymph node involvement. Although the Borrmann 
type was not a prognostic factor in the multivariate model, it is closely related 
to the other pathologic variables. The 5-year survival rates also differed sig­
nificantly between circumscribed and infiltrative types of tumor —  61.0% 
versus 39.0%. Considering these associations in clinical situation, as preope- 
ratively as at the time of operation, the macroscopic appearance of a tumor may 
be a simple and easy method to indicate the prognosis in patients with gastric 
cancer.
3. Treatment related prognostic factors
In addition to the predetermined prognostic factors, surgical strategy also has a 
marked impact on the prognosis for gastric cancer patients. A planned, properly 
executed gastric resection offers the only hope for cure in patients whose 
disease is confined to the stomach and regional lymph nodes. There are three 
considerations in planning the extent of a resection for gastric carcinoma: 1) the 
extent of stomach resection; 2) the scope of lymphadenectomy, and 3) the need 
for en bloc resection of adjacent organs. In contrast to surgery for peptic ulcer 
disease, the perigastric tissues need to be widely dissected and removed, and 
resection margins at the duodenum, stomach, oesophagus, and other 
neighbouring organs need to be widely cleared of tumor to avoid recurrence in 
the tumor bed (Maruyama, 1987a; Shiu, 1987b).
Curative surgery was possible for 58.8% (n 406) of the 690 patients with 
primary gastric cancer treated at the Tartu Hospital of Oncology, Estonia 
during the 10-year period from 1978 to 1987.
Gastrectomy
According to the data from this study of the three surgical treatment factors 
found to be prognostically significant by univariate analysis, the Cox model 
confirmed that only the type of gastrectomy was the important prognostic 
indicator. The total as opposed to subtotal gastrectomy was associated with 
higher postoperative mortality higher risk of death (Table 3.14 and 3.19). The 
big differences in the 5-year survival rates after total and subtotal gastrectomies 
(34.4% versus 55.9%) were not only determined by the extent of surgical 
invasion but they also depended on various tumor parameters, mainly the 
Borrmann type of growth, the maximal diameter and the depth of invasion of 
the primary tumor. We performed total gastrectomy mainly in case of
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infiltrative types and deep invasion and subtotal gastrectomies in case of 
limited tumors. The high percentage of differentiated carcinomas located in the 
gastric antrum and corpus also enabled us to carry out a high rate of subtotal 
gastrectomy. Considering the favourable oncological situation necessary to 
perform a subtotal gastrectomy, it follows logically that total gastrectomies 
have a much worse prognosis.
In conclusion, the extent of the primary tumor and the technical require­
ments must dictate the need for total gastrectomy in individual patients and the 
policy of applying total gastrectomy in case of any gastric cancer even when it 
can be widely resected with a subtotal gastrectomy is not justified. Dissection 
of the left and right paracardial nodes as well the retropancreatic nodes is 
technically possible without earring out a total gastrectomy, and only the 
question about jeopardising of the vascularisation by the skeletonizating of the 
upper part of the stomach and distal oesophagus remains (Hüscher, 1992). No 
ischeamic complications in the gastric stump was documented in our study. 
Furthermore, our data show that the choice between total and subtotal 
gastrectomy was made not only on the site and extent of the primary lesion in 
the stomach, but also on the desired extent of nodal dissection. If the extensive 
nodal involvement or extranodal spread existed, the total gastrectomy was 
preferred.
The small number of proximal subtotal gastrectomies —  10 (2.5% of the 
cases) —  can be accounted for by the operation on principle being performed 
only in cases of small circumscribed tumors, the incidence of which in cardial 
region, partly due to diagnostic problems, is very low.
Splenectomy
The effect of splenectomy on survival after resection for gastric cancer is not 
generally agreed upon. Removal of the spleen en bloc with the gastric specimen 
has traditionally been part of a standard radical gastric resection for cancer in 
many centres, although is reported to be associated with higher postoperative 
complications and mortality in others (Furukawa, 1988; Maehara, 1991b; 
Noguchi, 1989). In our study most of the splenectomies were performed with 
resections associated with a higher postoperative complications and a lower 
survival rates of itself —  total gastrectomy and R3-lymphadenectomy — 
because these procedures were used in cases of more advanced carcinomas. 
Significant differences between the cases with and without splenectomy existed 
in our study with respect to tumor size, location and gross appearance, serosal 
invasion, and lymph node metastasis. For patients subjected to splenectomy the 
non-antral location of primary cancer (85.1%), deeper (T3-T4) invasion 
(85.8%) and infiltrative type of growth (72.3%) were more frequent. There was 
no significant correlation with the extent of the lymph node involvement 
although we have decided about the need of splenectomy mostly by the 
accidental biopsies of the lymph nodes before gastrectomy.
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The postoperative mortality in our patients was 11.3% and the 5-year 
survival rate was 30.5% compared with 3.0% and 54.3% respectively in 
patients without splenectomy. Despite the differences in the survival rates the 
splenectomy was not the independent prognostic factor in the Cox model. 
Higher complications and mortality after splenectomy was mainly due to 
infectious complications. We concluded that the splenectomy was the cause of 
higher postoperative mortality induced by the infectious complications, but not 
the cause of lower 5-year survival rates more strongly conditioned by the 
prognostic factors associated with primary tumor. In our opinion splenectomy 
should not be performed routinely and should be reserved for tumors with non- 
antral location of the stomach or for antral tumors with N2 node involvement. 
In addition the adequate technique of the lymph node dissection in the splenic 
artery and splenic hilus regions without splenectomy is described by the 
Japanese authors (Maruyama, 1993).
Resection of adjacent organs
During the operation in many cases the surgeons are faced with the necessity of 
extending the resection to adjacent organs. This should prompt careful intra­
abdominal exploration and sampling of suspected areas of invasion for micro­
scopic frozen section analysis, especially when suspicion rests on parechymal 
organs where clinical assessment is less precise and biopsy less dangerous than 
in case of hollow viscera. Nevertheless, the clinical suspicion of infiltration of 
these organs was confirmed by the postoperative histological examination only 
in 39.1 % in our study.
We are of the opinion that direct invasion to adjacent organs is not an 
indicator of incurability when compared with factors such as peritoneal disse­
mination or liver metastasis. In cases of quaternary nodal involvement the 
postoperative mortality rate and incidence of early recurrence is extremely high 
and we consider these cases also as non-curative.
Tumors with invasion of contiguous structures (T4) had also good cure 
results (34.0% at 5-year) in our study, particularly in cases without nodal 
involvement. Therefore we think that combined resection of neighbouring 
organs directly invaded by gastric cancer is a very effective method of therapy. 
The importance of combined resections of neighbouring organs has been also 
reported by many others (Bozzetti, 1990; Jatzko, 1992a; Korenaga, 1988a; 
Maruyama, 1987b). They emphasise that surgeons should be aggressive in 
performing gastrectomy with en bloc removal of invaded organs in all cases 
when cancer appears to be in a potentially curable cases.
We consider that the current operative mortality rate of 10.0% and 11.7% 
after combined operations is acceptable and compares favourably with figures 
of 0% to 28.0% reported in other Western countries, even if it is still far from 




The extent of lymphadenectomy remains a controversial issue in the mana­
gement of gastric cancer. In Japan the standard treatment policy for all poten­
tially curable patients with gastric carcinoma is radical resection, including 
extensive lymphadenectomy. This policy is applied to early as well as advanced 
gastric cancer and substantial increases in survival time have always been 
reported (Korenaga, 1988a; Maruyama, 1987b; Noguchi, 1989).
Jaehne, 1992 reported that according to a European questionnaire a radical 
lymphadenectomy is performed in only 50% of all cases and concluded that this 
may, in part, explain the disappointingly low survival rates after potentially 
curative resections in the Western hemisphere. Candela, 1990 found that the 
surgical therapy in the form of extended R2 or R3 lymphadenectomy in Japan 
may be more effective than the generally applied standard R1 lymph­
adenectomy in the United States. The heterogeneity of techniques in gastric 
cancer surgery and a small percentage of dissections similar to the Japanese R2 
dissection in the United States is reported (Wanebo, 1993). In our hospital the 
dissection of at least N2 nodes was routinely performed in all cases.
Although it is widely recognised that lymph node métastasés affect survival of 
early gastric cancer as well as that of advanced cancer, the incidence and extent 
of nodal involvement in early cases is always lower. In cases of early gastric 
cancer the lymph node involvement rate always correlate with the depth of 
invasion: in patients with intramucosal carcinoma the lymph node métastasés 
are observed in single cases, when in patients with extensive submucosal in­
volvement the incidence if nodal deposits may be up to 50% (Sue-Ling, 1992; 
Hioki, 1990; Inoue, 1991; Iriyama, 1989; Lauren, 1965; Maehara, 1992d; 
Moreaux, 1993; Sakita, 1989). If the patients had not been divided by nodal 
status, early gastric cancer treated by subtotal gastrectomy with R0-R1 lymph­
adenectomy showed only a slightly lower survival rate than those undergoing 
total gastrectomy with R2 lympadenectomy (Guardagni, 1993; Hioki, 1990; 
Iriyama, 1989; Moreaux, 1993; Sakita, 1989). Therefore it would seem logical 
to carry out a more conservative (R l) resection with complete excision of only 
perigastric (N1) nodes in cases of early gastric cancer where it is confined to 
the mucosa, reserving the more radical (R2) resection for the cases where the 
tumor has penetrated to the submucosa and the incidence of lymphogenic 
métastasés is higher. Nevertheless, preoperative assessment of the depth of 
invasion of early gastric cancer would require the use of endoscopic endolu- 
minal ultrasound, which is not yet routinely available in most European centres 
(Sue-Ling, 1992). Even if it is available, accurate distinction between mucosal 
and submucosal tumors is not always achieved. The surgeons do not know the 
exact TNM stage of the tumor before the operation and the diagnosis of early 
gastric cancer is usually made in retrospect. Secondly, data from Japan 
(Kaijtani, 1981; Maruyama, 1987a; Maruyama, 1989; Shiu, 1987b) have
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consistently supported the view that the “R” number (0-3) of resection should 
exceed the “N” number (0-3) of nodal métastasés if absolute curative resection 
is to be achieved. As the métastasés to N1 nodes are not rare for early gastric 
cancer, it follows that R2 resection should be the treatment of choice. Thus, we 
think an aggressive surgical approach including extended (at least R2) lymph­
adenectomy should be used for all early gastric cancers as Japanese authors 
continue to advocate (Boku, 1989; Eriguchi, 1991; Guardagni, 1991; Hioki, 
1990; Inoue, 1991; Korenaga, 1988a; Maruyama, 1987b; Noguchi, 1989).
Significant differences existed in survival rates relative to the nodal status. 
Despite the extensive lymphadenectomy used in all cases, the cure results in N3 
positive cases were quite modest (12.0%). However, the frequency of 
métastasés in N2 (24.4%) and N3 (6.2%) nodes determined the necessity of N3 
node dissection. Univariate survival analysis showed the better 5-year survival 
rate after R2-lymphadenectomy (52.7%) than after R3-dissection (34.3%). 
These results are likely to reflect the extent of the disease: the R2-lymph- 
adenectomies were more frequently associated with subtotal gastrectomies and 
limited (N0-N1) lymph node involvement, while most of the R3-lymph- 
adenectomies were performed in cases of extended nodal disease and were 
associated with simultaneous total gastrectomy. The scope of lymphade­
nectomy in multivariate analysis showed no significant difference in survival 
because the extensive lymph node dissection was used in all patients.
The concept of lymphadenectomy being beneficial only when it widely 
encompasses the disease is not new (Shiu, 1987). This study showed that 
extensive lymph node dissection (R2 or R3) offers more benefit to the patients 
with either no or limited (N0-N1) nodal disease, that is in these cases where the 
dissected area was at least one nodal level wider than the actual lymphatic 
spread of the tumor. The second lymph node group (N2) should be removed 
with the extensive lymphadenectomy if no lymph node involvement is found. If 
there are clear macroscopic changes in the perigastric nodes, R3-lymphadenec- 
tomy is indicated. In the absence of palpable abnormalities in lymph nodes, the 
cure results of gastric cancer can be improved by a wide prophylactic node dis­
section, particularly in the patients with elevated risk to lymph node métastasés.
We have attempted to determine the extent of nodal disease before 
gastrectomy by the frozen-section examination of the macroscopically suspi­
cious nodes around the stomach. Unfortunately, the postoperative histological 
examination of the removed lymph nodes proves that accidental biopsies and 
evaluation of nodes by palpation during operation is not always reliable be­
cause of the large number of false-negative and false-positive results. The histo­
logical examination of lymph nodes in the observed period implied only the 
investigation of one-step sectioning of enlarged nodes and therefore some mic- 
rometastases might remain undetected. At present all removed nodes undergo 
microscopical examination and the three-step-sectioning method is being intro­
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duced to make data processing concerning the lymphogenic spread of cancer 
more precise.
Postoperative complications and mortality
A decline in operative mortality rates after radical gastric cancer surgery over 
the past 30 years has been demonstrated over the world, but it is still regarded 
as unacceptably high by many practitioners (Akoh, 1992). The overall 30-day 
postoperative mortality for our patients —  5.9% —  is higher than the one 
reported after comparable surgery in Japan, but it is equal to or lower than the 
rates published in non-Japanese series (Gouzi, 1988; Jatzko, 1992a; Kaibara, 
1990; Lindahl, 1988; Roukos, 1990; Shiu, 1987a; Viste, 1988). It is also lower 
than in a number of hospitals where the extensive lymph node dissection was 
not used (Akoh, 1992; Allum, 1989; Wanebo, 1993). The postoperative mor­
tality was higher after R3 lymphadenectomy and total gastrectomy (11.0% and 
10.6% respectively). Although we have achieved the higher radicality partly at 
the cost of higher mortality, we can not consider these mortality rates exten­
sively high to make us refrain from extensive surgery in gastric cancer therapy 
as there are no effective alternative methods at our disposal. Aggressive surgery 
with extensive lymphadenectomy can safely be performed on young patients, 
on elderly patients with concomitant systemic disorders this approach must 
have a selective use.
We also may conclude that the use of prophylactic measures against in­
fection, and the standardisation of surgical techniques in specialised hospitals 
should reduce the operative complications and mortality following extensive 
gastric resections.
4. Extended versus conventional surgery for gastric cancer
Adequate surgical resection offers the only chance for long-term survival for a 
patient who has potentially curable gastric carcinoma and the surgeon's choice 
and manner of execution of surgery can have a significant effect on prognosis 
(Akoh, 1992; Jatzko, 1992; Maruyama, 1987b; Pacelli, 1993; Shiu, 1987a, 
Stipa, 1994). In Finland and in Estonia the treatment policy of gastric cancer is 
quite different. The patients in Finland are treated by the general surgeons with 
conventional methods of surgery. In contrast there is the network of specialised 
oncological aid for cancer patients In Estonia and the more extensive surgery 
has been in use. In this part of discussion the two operative procedures with 
different radicality will be compared {papers I, 111 and VI).
The mean age for patients who underwent curative treatment was 63.0 years 
in Oulu (range 27 to 81) and 62.4 years in Tartu (range 31 to 85 years). Rela­
tively more male patients were found among curable gastric cancer patients in 
Oulu study (59.1% versus 48.8% in Tartu study).
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The 5-year survival rates following surgery for cure was 45.5% in the Oulu 
study. It was approximately the same as in our study (46.1 %) and it seemed that 
the extensive methods of surgery were not essential in the reduction of the 
mortality after gastric cancer surgery. Further analysis of the data from both 
studies show that this conclusion is not correct. In Table 4.1 the comparative 
data of prognostic factors and survival rates after curative gastric cancer 
surgery in Oulu University Hospital and Tartu Hospital of Oncology are. Re­
lative frequencies of prognostic factors differed significantly (p<0.05) in T 
stages, N stages and Borrmann types. Although higher incidence of cardial 
cancer was observed in Oulu, the overall difference in locational distribution 
between two groups was not significant. Histologic types were not comparable 
because different grading systems were used in two centres: WHO classi­
fication in Tartu and the Lauren classification in Oulu (Devessar, 1990; Lauren, 
1965; Oota, 1977).
Comparative analysis of the 5-year survival rates shows no differences in 
the survival rates for T1 and T2 cases in two groups, but it was highly different 
for T3 tumors. Moreover, patients in Tartu had higher incidence of T3 tumors 
and no patients with T4 tumors were operated on with curative intention in 
Oulu. The 34.0% 5-year survival rate of T4 patients in the Tartu study is 
unquestionably high and confirms the importance of combined resections of 
neighbouring organs in gastric cancer surgery.
In Oulu only patients with N0-N1 involvement were subjected to the 
curative surgery. In Tartu 124 (30.6% of all cases) patients with métastasés in 
N2 and N3 nodes were also curatively operated on with subsequent 5-year 
survival 25.3% and 12.0% respectively.
Borrmann type III—IV tumors were found only in 21.6% of curative cases in 
Oulu compared with the equal distribution of expansive and infiltrative types in 
Tartu and also in the overall material from Oulu (Table 4.1, Table 3.16). 
Despite of the fact that the distribution of Borrmann types within two Hospitals 
was different, the survival rate was significantly higher after extensive surgery 
only in infiltrative Borrmann types of gastric cancer. In general these results 
show that differences in survival rates are more noticeable in more advanced 
stages (T2-T3, N2-N3, Borrmann type III-IV). Within both series the sex of 
patients had little influence on the survival rate but younger patients had better 
survival curves. These differences can be explained by a more aggressive 
approach to combined organ resection and extensive lymph node dissection. 
Otherwise we may conclude that the patients in Oulu are more carefully 
selected for curative surgery than the patient in Tartu Hospital of Oncology.
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Frequencies of prognostic factors and survival rates 
after curative gastric cancer surgery
T a b l e  4.1





5-year survival rates 
Tartu studv Oulu study
All cases 4 0 6 (1 0 0 .0 ) 88 (100.0) 46.1 45.5
Sex
male 198 (48.8) 52 (59.1) 46.9 48.1
female 208 (51.2) 36 (40.9) 45.2 41.7
Age
< 7 0 281 (69.3) 56 (63.6) 50.9 50.0
> 6 9 125 (30.8) 32 (36.4) 35.2 37.5
T stage
T1 31 ( 7.6) 20 (22.7) 80.7 85.0
T2 63 (15.5) 31 (35.3) 54.0 48.4
T3 2 1 8 (5 3 .7 ) 37 (42.0) 44.0 21.6
T4 94 (23.2) 0 34.0 -
N stage
N 0 225 (55.4) 67 (76.1) 60.0 49.3
N1 5 7 (1 4 .0 ) 21 (23.9) 42.1 33.3
N2 99 (24.4) 0 25.3 -
N3 25 (6.2) 0 12.0
Location
Lower 200 (49.3) 49 (45.4) 51.5 55.0
Middle 140 (34.5) 22 (25.0) 47.9 50.0
Upper 4 2 (1 0 .3 ) 22 (25.0) 28.6 31.8
Total 24 (5.9) 4 (4.5) 20.8 0.0
Borrmann
I-II 193 (47.5) 69 (78.4) 59.1 53.6
III-IV 213 (52.5) 1 9 (21 .6 ) 34.3 15.8
Size
< 4 cm 5 7 (1 4 .0 ) 27 (30.7) 71.9 81.5
4 -7  cm 192 (47.3) 47 (53.4) 44.3 29.8
8 -1 2  cm 123 (30.3) 1 2 (13 .6 ) 43.1 33.3
> 12 cm 34 (8.4) 2 (2 .3 ) 23.5 0.0
Simple resectional procedures, that is the excision of the primary tumor, 
including perigastric nodes, guarantee the fair prognosis only in cases without 
serosal invasion and lymph node métastasés (Korenaga, 1991; Santoro, 1991). 
According to our data gastric cancer, if operated during the early phase, is 
curable without extensive lymph node dissection, resulting in Finland in a 5- 
year survival rate 85%. Nevertheless, the comparative analysis of survival rates 
after radical gastric cancer surgery in conditions of limited and extended
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lymphadenectomy confirm that in cases of nodal involvement the latter is 
instrumental in effecting the cure. As determining of the extent of excision may 
present a problem in the absence of palpable abnormalities in lymph nodes or 
without obvious invasion into adjacent structures, the standardisation of ope­
rative policy in gastric cancer surgery is essential (deAretxabala, 1987; 
Korenaga, 1991; Maruyama, 1987b). The extensive lymphadenectomy made in 
the absence of palpable abnormalities in lymph nodes may also be important in 
establishing N stages more accurately and may result in a higher prevalence of 
patients with (micro)metastases. A relationship between the number of nodes 
dissected and the proportion of patients with lymph node métastasés has been 
reported also by others (deAretxabala, 1987; Maruyama, 1989; Soga, 1988).
T a b l e  4. 2
Surgical complications and mortality after curative surgery









in Oulu: 88 14 (15.9) 9 (1 0 .2 ) 45.5
total 59 13 (22.0) 6 (1 0 .2 ) 39.0
subtotal 29 1 (3.4) 3 (10.3) 58.6
curative gastrectomy
in Tartu: 406 5 9 (1 4 .5 ) 24 ( 5.9) 46.1
total 170 37 (21.8) 18 (10.6) 32.3
subtotal 226 22 (9.7) 5 (2.2) 56.2
proximal 10 0 (0.0) 1 (10.0) 50.0
Not only in Japanese studies (deAretxabala, 1987; Jatzko, 1992a; Maruyama,
1989) a low rate of postoperative mortality (1.7-4.8% ) is observed after radical 
gastric cancer surgery and it is not affected by the extent of node dissection 
performed. In this comparative study the postoperative surgical complications 
rate was similar in two hospitals (Table 4.2). It had the same rate after total 
gastrectomy and was lightly higher after subtotal gastrectomy with R2-R3 
lymphadenectomy compared with conventional subtotal gastrectomy. Therefore 
we can conclude that the extensive surgery can safely be performed without 
adverse effect on postoperative complications and mortality.
Thus, we found that the same overall survival rate after curative gastric cancer 
surgery may be the result of different selection of patients. It is caused by the 
more or less aggressive approach to the dissection of cancer.
The conservative techniques in gastric cancer surgery in the United States 
and in Europe may, in part, explain the low number of curative cases and the 
disappointing survival rates after potentially curative resections (Candela, 
1990; Jaehne, 1992; McCulloch, 1994; Wanebo, 1993). As it was already
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pointed out, the reports from centres with a special interest show results that are 
clearly superior to those (Buyse, 1991; Diggory, 1985; Green, 1988; Irvin, 
1988; Jatzko, 1992a; paper I). The authors emphasised that the treatment of 
cancer patients by few surgeons specialising in oncological surgery improve the 
outcome (Allum, 1989; McCulloch, 1994; Wanebo, 1993). In Estonia there is 
the relatively well operating network of specialised oncological aid, where most 
of the gastric cancer patients are operated on by surgical oncologist with the 
similar concept of resection policy as has been described in this study. In Tartu 
most of the operations analysed in this study were performed by one 
experienced surgeon —  professor Karl Kull. Our results demonstrate high 5- 
year survival rates even in cases of more advanced tumors (T2N3, T3N2, 
T4N0). Therefore it is concluded that special education of surgeons in the 
requisites for adequate gastrectomy and the use of such resection techniques 
which have demonstrated more adequate control over the locoregional disease 
may increase the survival of patient with gastric cancer.
In conclusion it is extremely important to analyse the survival rates in 
different hospitals and its associations with prognostic factors. As we can see 
from the present study the same overall survival rate after curative gastric 
cancer surgery may be the result of different selection of patients or different 
treatment policy. However, caution must still be exercised in drawing con­
clusions from retrospective studies in which results from different hospitals are 
compared. A prospective randomised trial comparing the results of the gastric 
cancer surgery with different extension might be initiated in the future. Despite 
the suspicions, the results obtained from this study support the concept that 
extensive methods of surgery have a role in the treatment of gastric cancer.
*
The incidence rate of gastric cancer in Estonia is relatively high, the percentage 
of early gastric cancer is extremely low, and the great differences between 
survival rates of patients with early and advanced tumors exist. In addition, the 
high incidence of precancerous changes in Estonians already in their early 
decades of life (Rätsep, 1976; Villako, 1991), expressive clinical symptomato­
logy and the long duration of preoperative symptoms is characteristic for 
patients with gastric cancer in Estonia.
We look forward to the day when effective non-surgical therapies will make 
gastrectomy and lymphadenectomy obsolete surgical procedures (Jatzko, 
1992a). But for now, adequate surgical resection offers the best chance for 
long-term survival for a patient who has potentially curable gastric carcinoma. 
Even though only some prospective randomised trials have been performed to 
study the use of radical gastrectomy with wide lymphadenectomy, a prepon­
derance of cure results in Japan support its therapeutic merit. In the Western 
world the surgery of gastric cancer is covered with pessimism. The surgeons
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perform palliative procedures because they believe that gastric cancer is nearly 
incurable at presentation (McCulloch, 1994). Many Western surgeons incline to 
conservatism also because of the concern over the potential complications 
associated with more radical operations. In addition, extensive gastric lymph­
adenectomy does require extra time and effort in performing a gastrectomy.
Our study indicates that extensive surgery with systemic lymph node 
dissection and combined organ resections is a surgical procedure that allows a 
precise TNM staging, offers the possibility of improving the survival in certain 
patients (particularly in those with limited lymph node métastasés), and helps to 
define the risk groups for early tumor recurrences. It should form the basis for 
further studies to improve the prognosis of gastric carcinoma. We agree with 
Jatzko, 1992a that the extended radical surgery for gastric cancer should no 
longer be a controversial topic in Europe. At present a decrease in the mortality 
for the gastric cancer can be achieved only by these methods. We also believe 
that the cure results might be much better when the radical surgery will be 
combined with successful program of screening for early disease.
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CONCLUSIONS
1.1. Univariate analysis of prognostic factors for curative gastric cancer brought 
forth as favourable factors the age below 70, tumor location in the lower or 
middle part of the stomach, Borrmann I—II type, tumor size less than 4 cm, 
differentiated histological type, T 1-2 stage, limited (N0-N1) lymph node 
involvement, subtotal gastrectomy, R2 versus R3 lymphadenectomy and the 
extent of lymphadenectomy more than one N-group from the involved lymph 
nodes. The year of operation and the sex of patients did not have a significant 
influence on the survival.
1.2. By the multivariate analysis five prognostic variables for our patients 
were identified that independently influenced the risk of death. Among these, 
lymph node involvement was the most important independent prognostic factor, 
followed by the extent of gastrectomy, the depth of invasion, the histological 
type of cancer and the age of patients.
1.3. According to the results of 5-year survival analysis of the two more 
important independent predictors of death —  depth of gastric wall invasion and 
presence of lymph node métastasés —  all cases can be divided into three 
prognostic groups: 1) tumors with good prognosis (T1N 0-2 and T2N0-1); 
2) tumors with intermediate prognosis (T3N0-1 and T4N0); and 3) tumors with 
poor prognosis (T2N2-3, T3N 2-3 and T4N 1-3).
Because the survival rate of T l tumors with lymph node métastasés is 
significantly lower compared to the rate of early cancer without nodal 
involvement, only the T l cases without evidence of lymph node métastasés 
might be defined as early cancers.
1.4. As there was relatively fewer male patients capable of undergoing 
radical surgery, we conclude that men tend to care less for their health and need 
more attention in cases of gastrointestinal disorders. The age of the patients is 
not a contraindication to radical resection for gastric cancer. Aggressive surgery 
with extensive lymphadenectomy can safely be performed on young patients, 
on elderly patients with concomitant systemic disorders this approach must 
have a selective use. The long duration of expressive clinical symptoms is 
characteristic for gastric cancer.
2. The results of this study support the value of extensive surgery for gastric 
carcinoma. We are positive, that there must be three considerations in planning 
the extent of a resection for gastric adenocarcinoma: 1 ) the extent of stomach 
resection; 2) the scope of lymphadenectomy, and 3) the need for en bloc 
resection of adjacent organs.
2.1. All the tumor related factors must dictate the extent of gastrectomy in 
individual patients. Total gastrectomy is indicated when the proximal distance 
from the cardia is less than required (5 cm in circumscribed and 8 cm in 
infiltrative tumors), in Borrmann types 3 and 4, and in cases with non-
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differentiated histological pattern. The policy for applying total gastrectomy in 
case of any gastric cancer when it can be widely resected with a subtotal 
gastrectomy is not justified.
2.2. As the N2 nodes are frequently involved, even in T1 cases, group 1 and 
2 nodes should be removed in all cases. To achieve adequate lymph node 
dissection and to avoid the recurrence of the disease at least one uninvolved 
nodal level should be resected. In this connection it is extremely important in 
our opinion to interpret the hepatoduodenal, retropancreatic and mesenteric 
nodes, as well the nodes at the splenic hilus as regional (N3) and all cases with 
involvement of these nodes as curative.
2.3. Direct invasion to adjacent structures is not an indicator of incurability. 
These tumors had good cure results in our study, particularly in cases without 
nodal involvement. Therefore we think that combined resection of neigh­
bouring organs directly invaded by gastric cancer is a very effective method of 
therapy. Curative gastric resection should also be regularly combined with en 
bloc resection of neighbouring organs to achieve the better lymphatic tissue 
dissection.
2.4. We conclude that the splenectomy is the cause of higher postoperative 
mortality induced by the infectious complications, but it does not influence the 
5-year survival rates more strongly conditioned by the prognostic factors 
associated with primary tumor. Nevertheless, splenectomy is indicated to 
achieve better lymphadenectomy.
3. Similar overall survival rates after curative gastric cancer surgery in different 
hospitals may be the result of different selection of patients for radical surgery. 
The differences in the distribution of clinicopathological factors of gastric 
cancer between two hospitals observed in this study can be explained by the 
different extent of tumor resections. More aggressive approach to combined 
organ resection and extensive lymph node dissection in Tartu enlarged the 
relative amount of potentially curable patients.
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RADIKAALSELT OPEREERITUD MAOVÄHI- 
HAIGETE ELULEMUST MÕJUTAVAD TEGURID
Kokkuvõte
Haigestumusnäitajate üldisele langustendentsile vaatamata on maovähk üks 
juhtivaid pahaloomulistest kasvajatest tingitud surmapõhjusi kogu maailmas. 
Ka Eestis on maovähi esinemissagedus viimastel aastakümnetel pidevalt vähe­
nenud, jäädes aga kiiruselt märgatavalt alla meie läänepoolsete naaberriikide 
omadele (Cancer Society of Finland, 1990; Cancer Society of Finland, 1992; 
Craanen, 1992; Holleb, 1991; Lauren, 1993; Lindahl, 1988; Tekkel, 1992; 
Thomson, 1994). Euroopas ja  Põhja-Ameerikas on maovähk enamasti tuntud 
kui haigus, mis seostub suure hilisjuhtude osatähtsuse, ravis kasutatavate 
operatsioonimeetodite heterogeensuse, kõrge operatsioonijärgse suremuse ja 
ebarahuldavate ravitulemustega (Akoh, 1991; Allum, 1989; Guardagni, 1993; 
Inoue, 1993; Sano, 1992; Wanebo, 1993).
Maovähi ravi tunduvalt paremad tulemused Jaapanis on tingitud ühelt poolt 
edukalt tehtavatest sõeluuringutest, teiselt poolt aga ühtse metoodikaga laien­
datud ja  kombineeritud operatsioonide järjekindlast rakendamisest (deAretxa- 
bala, 1988; Maruyama, 1987b; Maruyama, 1989; Soga, 1988). Et suhteliselt 
madalate haigestumusnäitajate tõttu ei ole sõeluuringud Euroopas poolehoidu 
leidnud, on maovähi ravitulemusi siin võimalik parandada vaid õiget kirurgilist 
ravitaktikat kasutades. Samas lähevad arvamused nii kasvaja algkolde kui magu 
ümbritsevate lümfisõlmede eemaldamise ulatusest tublisti lahku (Allum, 1989; 
Bonenkamp, 1993; Jatzko, 1992a; McCulloch, 1994; Roukos, 1990; Sigal, 
1991; Wanebo, 1993).
Eespool öeldust tulenesid käesoleva töö eesmärgid:
1. Analüüsida maovähi radikaalse kirurgilise ravi tulemusi Tartu Ülikooli 
Kliinikumi Onkoloogiahaiglas ja  selle kaudu selgitada Eestis radikaalselt ravi­
tavate mao vähihaigete prognoosi mõjutavad tegurid.
2. M äärata elundite ja  lümfisõlmede eemaldamise näidustused ja  sobilik 
ulatus maovähi radikaalses kirurgilises ravis.
3. Võrrelda maovähi kirurgilise ravi taktikat ja  kaugtulemusi üldkirurgilises 
ja  spetsialiseeritud onkoloogilises raviasutuses.
Käesolev retrospektiivne uurimus on valminud 406 Tartu Ülikooli Kliinikumi 
Onkoloogiahaiglas (endises Tartu Linna Onkoloogiadispanseris) aastatel 1978— 
1987 radikaalselt opereeritud maovähihaige haigusloo analüüsi tulemusena. 
Kõikidel juhtudel rakendati raviks gastrektoomiat või subtotaalset maoresekt- 
siooni koos lümfisõlmede laiendatud eemaldamisega (R2- või R3-lümfadenek-
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toomia). Radikaalne ravi on sellistel põhimõtetel meie haiglas kasutusel 1970. 
aastate lõpust. Võrdlemaks maovähi kirurgilises ravis kasutatavaid operat- 
sioonitaktikaid, on hinnatud ka 203 üldkirurgilises raviasutuses —  Oulu Üli­
kooli Haigla kirurgiaosakonnas —  ravitud maovähihaige prognostilisi tegureid. 
Selles osakonnas kasutatakse maovähi radikaalse ravi meetodina konventsio­
naalset gastrektoomiat koos Rl-liimfadenektoomiaga.
Statistiliseks andmeanalüüsiks koguti haiguslugudest 38 erinevat haige, kas­
vaja ja  raviga seotud näitajat, mis võiksid olla prognostilise väärtusega. Kõiki 
haigeid jälgiti viie aasta vältel, elulemusnäitajad on kogutud vastavalt Eesti ja  
Soome Vähiregistritest.
Vaadeldud perioodil tehti Tartu Ülikooli Kliinikumi Onkoloogiahaiglas 170 
radikaalset gastrektoomiat ja  236 radikaalset subtotaalset maoresektsiooni, 260 
R2-lümfadenektoomiat ja  146 R3-lümfadenektoomiat. 30-päevane operatsiooni­
järgne suremus oli 5,9% ja üldine suhteline viie aasta elulemus 46,1%.
Haigete keskmine vanus oli 62,5 (ulatus 31-85) aastat. Leidsime, et kuigi 
alla 40 aasta vanuseid haigeid oli radikaalselt opereeritute hulgas vähe, olid 
nende ravitulemused head (viie aasta elulemus 71,4%). Vanemaealistel haigetel 
oli operatsioonijärgseid üldtüsistusi sagedamini, nende elulemusnäitajad olid 
keskmisest madalamad ja  seda osalt ulatuslikuma lümfogeense metastasee- 
rumise tõttu.
Kui kõikide maovähihaigete hulgas oli Eestis meeste ja  naiste suhe 1,35, 
siis radikaalselt opereeritute seas oli see näitaja 0,95 ja  varajase vähi juhtudel 
vaid 0,48. Selliseid erinevusi ei saa seletada ei erineva sümptomatoloogia ega 
kasvaja iseloomuga; põhjusi tuleb otsida meeshaigete suhtumisest neil esine­
vatesse haigusnähtudesse.
Haiguse anamneesi keskmine pikkus oli 11,1 kuud, varajase maovähiga 
haigetel oli see isegi mõnevõrra pikem. Nii varajase kui ka radikaalselt ravitava 
mittevarajase maovähiga haigetel olid sagedasemateks haigusnähtudeks epi- 
gastraalne valu (vastavalt 77,4% ja 70,2%), kaalulangus (45,2% ja  61,8%), 
düspeptilised vaevused (19,4% ja  39,2%) ja  üldine halb enesetunne (nõrkus, 
väsimus jms.; 25,8% ja 33,3%).
Kolmekümne ühel (7,6%) haigel oli tegemist T1-, kuuekümne kolmel 
(15,5%) T2-, kahesaja kaheksateistkümnel (53,7%) T 3 -ja  üheksakümne neljal 
(23,2%) T4-kasvajaga. Seega on varajase maovähi osatähtsus radikaalselt 
opereeritud haigete hulgas äärmiselt madal. Saja kaheksakümne ühel juhul 
(44,6%) leiti lümfisõlmede metastaatiline kahjustus, mille ulatus oli statistiliselt 
oluliselt määratud kasvaja algkolde invasioonisügavuse, makroskoopilise 
kasvuvormi ja  läbimõõduga. Prognoosi seisukohalt kahe kõige olulisema mao­
vähi patoloogilis-anatoomilise omaduse —  invasioonisügavuse ja  lümfisõlmede 
kahjustuse ulatuse alusel oli võimalik moodustada kolm prognostilist gruppi; 
hea ( T lN0-2, T2N0-1), rahuldav (T3N0-1, T4N0) ja  halb (T2N2-3, T3N2-3, 
T 4N 1-3). Selgus, et sageli on olulisem just lümfisõlmede seisund.
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Maovähi diferentseerumata histoloogilised vormid olid diagnoosimise het­
kel sügavama invasiooniga, infiltratiivsema kasvuvormi ja  suurema läbimõõ­
duga ning seetõttu prognostiliselt halvemad. Diferentseerunud vormide tagasi­
hoidlik ülekaal (1,06 korda) näitab muuhulgas, et kuulume kõrge maovähi- 
riskiga piirkondade hulka.
Töö tulemused näitasid, et haige ja  kasvajaga seotud prognostiliste tegurite 
kõrval on maovähihaigete prognoosile suur mõju kirurgilisel ravitaktikal. Sel­
gus, et mao antrumis või korpuses lokaliseeruvate piirdunud vähikollete ravis ei 
ole gastrektoomial eelist subtotaalse maoresektsiooni ees. Samas oli oluline 
mao naaberelundite resetseerimine, andes T4-kasvajate korral haigete hea viie 
aasta elulemuse (34,0%). Heade ravitulemuste saavutamiseks oli oluline ka 
lümfikoestiku eemaldamine piisavas kauguses vähist kahjustatud lümfisõlme- 
dest, mille eelduseks omakorda oli laiendatud lümfadenektoomia kasutamine.
Selgus ka, et viie aasta elulemus pärast radikaalseid operatsioone oli kahes 
võrreldud haiglas samane (vastavalt Oulus 45,5% ja  Tartus 46,1%). Samas 
opereeriti Oulu Ülikooli Kliinikus radikaalselt vaid 43,3% kõikidest maovähi- 
haigetest, Tartus oli radikaalsus 58,8%. Kahe võrreldud haigerühma prognosti­
liste tegurite suhtelised sagedused erinesid oluliselt (p<0,05) T- ja  N-astmete 
ning Borrmanni tüüpide osas. Tartus oli opereeritud tunduvalt rohkem T3- 
kasvajaid ja  T4-juhud olid Oulus arvatud radikaalselt mitteopereeritavateks. Ka 
N l-sõlm edest ulatuslikuma metastaseerumisega kasvajaid Oulus radikaalselt ei 
opereeritud, Tartus oli selliseid haigeid aga 30,6% kõikidest juhtudest. Piir­
dunud ja  infiltratiivsete kasvuvormide suhe oli Tartus 0,9 ja  Oulus 3,6. Seega 
võib järeldada, et samane viie aasta elulemus pärast maovähi radikaalset ravi 
erinevates haiglates oli haigete erisuguse valiku tulemus. Patoloogiliste 
näitajate jaotumuse lahknevus kahes vaadeldud haiglas on seletatav kasvajate 
eemaldamise erineva ulatusega. Ekstensiivse, naaberorganite resektsioonide ja 
laiendatud lümfadenektoomiaga kombineeritud maooperatsiooni tähtsus muutus 
oluliseks just lokaalselt või lümfogeenselt levinud kasvajate (T3-4, N2-3, 
Borrmanni III—IV tüüp) puhul. Et just need kasvajad moodustasid suurema osa 
haigusjuhtudest, võimaldas selline metoodika suurendada potentsiaalselt ravita­
vate haigete hulka Tartus.
Vastavalt üksiktunnusanalüüsi tulemustele olid radikaalselt ravitavate maovähi­
haigete seisukohalt soodsad järgmised prognostilised tegurid: vanus alla 70 
aasta (viie aasta elulemus 51,9% 35,2% vastu), T 1-T 2 staadium (viie aasta 
elulemus 67,8% 41,0% vastu), piirdunud (N0-N1) lümfisõlmede kahjustus 
(viie aasta elulemus 56,4% 22,6% vastu), diferentseerunud histoloogiline ehitus 
(viie aasta elulemus 55,0% 39,6% vastu), I—II tüüpi kasvuvorm Borrmanni 
klassifikatsiooni järgi (viie aasta elulemus 59,1% 34,3% vastu), kasvaja asetsus 
mao alumises või keskmises kolmandikus (viie aasta elulemus 50,0% 25,8% 
vastu), distaalne subtotaalne maoresektsioon (viie aasta elulemus 55,0% 32,4% 
vastu), R2-lümfadenektoomia (viie aasta elulemus 52,7% 34,3% vastu) ja  roh-
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kern kui ühe lümfogeense metastaseerumise taseme profülaktiline eemaldamine 
(viie aasta elulemus 58,1% 27,2% vastu).
Hulgitunnusanalüüs Coxi mudeli järgi, milles on arvestatud kõiki muutujate 
omavahelisi mõjusid, selgitas viis sõltumatut prognostilist tegurit radikaalselt 
ravitavate maovähihaigete jaoks. Toime tugevuse järjekorras loetletuna on need 
järgmised: lümfisõlmede kahjustuse ulatus, mao eemaldamise ulatus, kasvaja 
invasiooni sügavus, kasvaja histoloogiline ehitus ja  haige vanus. Seega oli 
lümfogeenne metastaseerumine maovähi taaspuhkemise kõige olulisem riski­
tegur. Kirurgilise raviga seotud näitajad olid tihti tugevasti mõjutatud kasvaja 
patoloogilis-anatoomilisest iseloomust. Nii oli näiteks gastrektoomia sageda­
mini tehtud infiltratiivse ja  lümfogeenselt ulatuslikult metastaseerunud kasvaja 
korral. Ka R3-tüüpi laiendatud lümfadenektoomia oli enamasti sooritatud koos 
gastrektoomiaga ja  seotud ulatuslikuma kasvaja või selle mitteantraalse lokali­
satsiooniga.
Töö tulemuste põhjal võib väita, et kirurgide seas vaidlusi põhjustanud kom­
bineeritud ja  laiendatud operatsioonide vajalikkus maovähi radikaalses kirur­
gilises ravis leidis kinnitust. Gastrektoomia või distaalne subtotaalne mao- 
resektsioon koos kasvajast haaratud naaberelundite resektsiooni ja  lümfi­
sõlmede laiendatud eemaldamisega peaks olema maovähi radikaalse kirurgilise 
ravi valikmeetodiks kõikidel kaugmetastaasideta haigusjuhtudel. Mao naaber­
elundite eemaldamine on õigustatud ka lümfadenektoomia parema teostamise 
eesmärgil. Laiendatud lümfadenektoomia peaks alati haarama vähemalt teist 
lümfogeense metastaseerumise taset, metastaaside esinemisel lümfisõlmedes 
tuleks lisaks eemaldada vähemalt ühe kahjustamata taseme sõlmestik.
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FACTORS INFLUENCING SURVIVAL OF PATIENTS AFTER RADICAL 
SURGERY  FOR GASTRIC CANCER 
A regional study o f  406 patients over a 10-year period
A n d r u s  A r a k  ami K a r i . K u l l
The present retrospective report presents a review of prognostic factors influencing the survival o f 406  
gastric cancer patients radically operated 011 in the Tartu O ncology H ospital, Estonia in 1 9 7 8 -1 9 8 7 . 
All patients underwent total (n =  170) or subtotal (11 =  236) gastrectom ies with extensive lymphadenec­
tomy (2 6 0  R2- and 146 R3-resections) according to the General Rules for the G astric Cancer Study  
in Surgery and Pathology established by the Japanese Research Society  for G astric Cancer, introduced 
in our hospital at the end o f the 1970s and now used as the unavoidable procedure for curative gastric 
cancer surgery. The 30-day postoperative m ortality was 5.9%  and the overall 5-year survival 46.1% . 
The m ale:fem ale ratio was 0.95 and the mean age 62.4 years. O nly 7.6%  o f all our patients operated 
on had early gastric cancer with a 5->ear survival o f 80.7%  whereas 76.8%  had T 3 -T 4  tumours with 
a 5-year survival o f 41.0% . Lymph node involvement was found in 44.6%  o f the patients. Independent 
favourable prognostic factors were (th e 5-year survivals are presented within parentheses): limited 
( N 0 - N 1 )  lymph node involvement (5 6 .4  vs. 22.6% ), pT 1 - 2  stage (62 .8  vs. 41.0% ), papillary, tubular 
or poorlv differentiated histological pattern (5 1 .9  vs. 33.1% ), subtotal gastrectom y (55 .9  vs. 32.4"/.) and 
age below 70 sears (5 1 .9  vs. 35.2% ). S ex  o f patients, Borrmann type, size and site o f tumour were not 
statistically associated with prognosis at multivariate analysis. Our results also suggested that besides 
predetermined prognostic factors, the surgical policy had a great im pact on the prognosis o f gastric 
cancer patients. W e conclude that gastrectom y with combined resections o f neighbouring organs 
directly invaded and with extensive lym phadenectom y at least up to the second node group might be the 
procedure o f choice for advanced gastric cancer.
M a r k e d  v a r ia b ili ty  o l’ th e  g a s t r ic  c a n e c r  in c id e n c e  is 
o b s e r v e d  a s  w ell a s  a g e n e ra l  t e n d e n c y  to  d e c re a s e . In  
l i s to n ia  th is  d e c lin e  h a s  b ee n  less e x p re s s e d  th a n  in  m o s t  ol 
th e  n e ig h b o u r in g  N o r '.h -F .u io p e a i i  c o u n t r ie s  ( 1 4). T h e  
m o rb id i ty  ra te  m  o u r  c o u n try  h a s  c h a n g e d  f ro m  53.1 in 
m a le s  a n d  f ro m  3 9 .4  in  fe m a le s  p e r  100 0 0 0  in  th e  19 7 .is to
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Accepted 3 A ugust 19l)4
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4 1 .9  in  m a le s  a n d  3 2 .0  in fe m a le s  in th e  I9NÜS (5 . M o s t 
c a s e s  o f  g a s t r ic  c a n c e r  w e re  d e te c te d  in  a d v a n c e d  s ta g e s , 
a n d  o n ly  v e ry  ra re  c a se s  w e re  o p e r a t e d  in  e a r ly  s ta g e s . It is 
th u s  e s s e n tia l  to  a n a ly s e  th e  r e s u lts  o f  g a s t r ic  c a n c e r  t r e a t ­
m e n t a n d  im p ro v e  th e  re s u lts  o f  th e ra p y .
T h e  h ig h  s u rv iv a l  r a te s  in J a p a n  a r e  a t t r ib u te d  to  a 
s u c c e s s fu l  s c r e e n in g  p r o g r a m m e  fo r  th e  d e te c t io n  o f  early  
g a s t r ic  c a n c e r ,  b e t te r  s ta g in g  a n d  m o re  a g g re s s iv e  su rg ic a l  
t r e a tm e n t  w ith  e x te n d e d  ly m p h a d e n e c to m y  (7 ) . F x te n d e d  
ly m p h  n o d e  d is s e c t io n  ( s o - c a l le d  R 2  a n d  К З  re se c tio n s )  
b e c a m e  s t a n d a r d  t r e a tm e n t  in J a p a n  fo r  a ll c a se s  o f  a d ­
v a n c e d  g a s t r ic  c a n c e r  in th e  m id d le  o f  th e  1970s a n d  m o st 
o f  th e  J a p a n e s e  a u th o r s  h a v e  p o in te d  o u t  th e  r e la t io n s h ip  
b e tw e e n  e x te n s iv e  ly m p h  n o d e  d is s e c t io n  a n d  b e t te r  c u re
S c a n d in a v ia n  U n iv e rs ity  P res*  Н У 4 IS S N  (O N 4-I80X 913
•114 Л ЛК Чк W O  к М  I !
re s u lts  I 8 I I ). In  th e  o p in io n  o f  m a n y  a u th o r s  a d ju v a n t  
c h e m o th e ra p y  h a s  o ffe re d  n o  s ig n if ic a n t b e n e fit  in  c u r a t iv e  
t r e a tm e n t  o f  g a s t r ic  c a n c e r  ( 1 2 -  14).
In  E u ro p e , e x te n s iv e  s c r e e n in g  p ro g r a m »  h a v e  n o t  b ee n  
e s ta b l is h e d  a n d  th e  t h e r a p e u t ic  re s u lts  c a n  b e  im p ro v e d  
o n ly  b> u s in g  e x te n s iv e  s u rg ic a l  te c h n iq u e s . T h a n k s  t o  th e  
g o o d  re s u lts  s h o w n  in  J a p a n e s e  s tu d ie s  th e  p ra c t ic e  o f  e x ­
te n d e d  ly m p h a d e n e c to m y  h a s  g a in e d  in c re a s e d  a c c e p ta n c e  
in m a n y  E u r o p e a n  h o s p i ta ls  in  re c e n t y e a r s  ( I .  16, 17).
In  o u r  h o s p i ta l  th e  p r in c ip le s  o f  e x te n d e d  ly m p h a d e n e c ­
to m y  w e re  in t ro d u c e d  a t  th e  e n d  o f  th e  1470s a n d  w e 
c o n s id e r  th is  p r o c e d u r e  n e c e s s a ry  in  c u r a t iv e  g a s t r ic  c a n c e r  
s u rg e ry . In th e  p re s e n t  r e tr o s p e c t iv e  r e p o r t  w e h a v e  
a n a ly se d  th e  in f lu e n c e  o f  d if fe re n t p r o g n o s t ic  f a c to r s  o n  
th e  surv  ival o f  g a s t r ic  c a n c e r  p a t ie n ts  w ith  re fe re n c e  to  th e  
e f fe c tiv e n e ss  o f  e x te n s iv e  .su rg ica l p ro c e d u re s .
M a te r ia l  an d  M e th o d s
A m o n g  64(1 p a t ie n ts  w ith  p r im a r y  g a s t r ic  c a n c e r  (w ith  
th e  e x c e p t io n  o f  s to m a c h  s tu m p  c a n c e r) ,  t r e a te d  s u rg ic a lly  
a t  th e  D e p a r tm e n t  o f  O n c o s u rg c r y .  T a r tu  H o s p i ta l  o f  
O n c o lo g y . E s to n ia  d u r in g  th e  1 0 -y e a r  p e r io d  f r o m  1478 to  
1487. 4 0 6  ( 5 8 .S' -I u n d e r w e n t  c u r a t iv e  r e s e c tio n  (1 8 )  w ith  
e x te n d e d  I R 2  o r  R 3 i ly m p h a d e n e c to m y . T h e  fo llo w in g  
c a se s  w ere  e x e lu d e d  f ro m  th e  p re s e n t s tu d y : p a t ie n ts  w h o  
u n d e r w e n t  b y p a s s  p ro c e d u re s  o r  p a l l ia t iv e  re s e c tio n s  d u e  
to  d i s ta n t  m é ta s ta s e s  o r  te c h n ic a l  in o p e ra b i l i ty :  th o s e  w h o  
u n d e r w e n t  g a s t re c to m ie s  w ith  o n ly  g r o u p  I ly m p h  n o d e  
d is s e c tio n  ( R I ly m p h a d e n e c to m y )  b e c a u s e  o f  h ig h  o p e r a ­
tive  r isk . i.e n o n -c u ra t iv e  p r o c e d u re s  in  o u r  c o n c e p t io n ;  
a n d  so m e  o f  th o s e  w h o  u n d e r w e n t  R 4  ly m p h a d e n e c to m y  
( i .e . d is s e c t io n  o f  N 4 . m a in ly  th e  p a r a - a o r t a l  ly m p h  n o d e s )  
w ith  v e ry  h ig h  p o s to p e ra t iv e  m o r ta l i ty  o r  e a r ly  r e c u r r e n c e  
o f  m a l ig n a n c y . A ll th e  c l in ie o -p a th o lo g ic a l  d a t a  w e re  c o l­
lec te d  f r o m  c a se  h is to r ie s  a n d  f ro m  th e  d a t a b a s e  o f  th e  
E s to n ia n  C a n c e r  R e g is try .
D e p th  o f  in v a s io n  w a s  c la ss ifie d  as  p T i  ( t u m o u r  
c o n f in e d  lo  m u c o s a  a n d  s u b m u c o s a l .  p T 2  ( in v a s io n  o f  
p ro p e r  m u sc le  la y e r  a n d  s u b s e r o s a ) .  р 'П  ( in v a s io n  in fo  
s e ro s a )  a n d  p T 4  ( in v a s io n  o f  c o n t ig u o u s  s t r u c tu r e s )  a c ­
c o r d in g  to  th e  I* IC C  ru le s  ( 14). A d v a n c e d  g a s t r ic  c a n c e r  
w a s  d e f in e d  a s  " in v a s io n  o r  d e e p e r  in v a s io n  o f  th e  tu m o u r  
in to  m u se u U tn s  p r o p r ia  by  h i s to p a th o lo g ic a l  e x a m in a t io n '
I I s  I. r u m o u r  lo c a tio n  w a s  d iv id e d  in to  u p p e r ,  m id d le  a n d  
i o w v  th i rd  o r  to ta l  in v o lv e m e n t o f  tile  s to m a c h . H is to lo g y  
w a s  c la ss ifie d  a .  p a p il la ry  a n d  w ell o r  m o d e ra te ly  d il le re n -  
f ia te d  tu b u la r  a d e n o c a r c in o m a .  in te r p r e te d  a s  flic  in ie s t i-  
n a l ty p e , a n d  p o o r ly  d if fe re n t ia te d  a d e n o c a r c in o m a  
s ig n e t- r in g  ce ll o r  m u c in o u s  tu m o u r s ,  i n te r p r e te d  a s  th e  
d iffu se  tv p e . a n d  u n d if fe re n t ia te d  c a r c in o m a s  l IS). T h e  
m a c ro s c o p ic a l  ty p e s  o f  tu m o u r  w e re  c la ss if ie d  a c c o r d in g  lo  
B o r r m a n n 's  c la s s if ic a tio n  a s  iv p e  1 - - p o ly p o id ,  ty p e  2 -  
u lc e ra te d .  ty p e  3 —  u lc e ra te d  w ith  p a r tia lly  d iffu se  in f i l tr a t ­
in g  b o rd e r ,  a n d  ty p e  4 — d iffu se ly  in v a d in g  tu m o u r
L y m p h  n o d e s  f r o m  d if fe re n t a n a to m ic a l  p o s i t io n s  ( ly m p h  
n o d e  s ta t io n s  1 - 1 6 )  w e re  d iv id e d  in to  4  N - g r o u p s  l \ i .  
N 2 . N 3  a n d  N 4 ) a c c o rd in g  lo  th e  l o c a tio n  o l th e  p r im a ry  
tu m o u r  (1 8 ) . In  e a c h  e a se  on ly  th e  m o s t  d i s ta n t  ly m p h  
n o d e  s ta t io n  a l le c te d  is m e n t io n e d
T h e  o p e r a t iv e  p r o c e d u re s  w e re  p e r fo rm e d  a c c o rd in g  to  
th e  r e c o m m e n d a t io n s  o f  J a p a n e s e  s u rg e o n s  (S . 4 . IS i. 
O p e r a t io n  w iih  c u r a t iv e  in te n t io n  w a» d e f in e d  a -  'r e m o v a l  
o f  a ll m a c ro s c o p ic  c a n c e r  i.e .. p r im a ry  tu m o u r  w ith  m a r ­
g in s  h is to lo g ic a l ly  free  o f  e a n c c r  a n d  a ll in v o lv e d  ly m p h  
n o d e s ' ( IK). T h e  re q u ir e d  c a n c e r - f r e e  d i s ta n c e  a t th e  p r o x ­
im a l m a rg in  w a s  m o re  th a n  5 c m  in c i r c u m s c r ib e d  tu m o u r s  
a n d  m o re  t h a n  S e in  in  in f i l tr a t iv e  t u m o u r s .  T o ta l g a s t re c ­
to m y  w a s  re g a rd e d  a s  in d ic a te d  w h e n  th e  p ro x im a l  d is ­
ta n c e  f r o m  th e  c a r d ia  w a s  less th a n  re q u ir e d  o r  in 
B o r rm a n n  ty p e s  ; a n il  4  (S i  i .x le u d c d  Iv in p h  n o d e  d is s e c ­
t io n  w a s  c a r r ie d  o u t a c c o id m g  lo  th e  r e c o m m e n d a t io n s  of 
th e  J a p a n e s e  R e s e a rc h  S ocie ly  fo r  C ja .stnc  C a n c e r  t IM . 
D is s e c tio n , c a lle d  R 2  ly m p h a d e n e c to m y . a lw a y s  in c lu d e d  
l lie  p e r ig a s t r ic  ii. hIc v  e x c lu d in g  th e  left c a rd ia l  n o d e s  in 
d is ta l  g a s t re c to m y  a n d  n o d e s  lo c a te d  a lo n g  th e  left g a s tr ic , 
c o m m o n  h e p a t ic ,  sp le n ic  a n d  c o e iia c  a r te r ie s .  In e a se s  o f  
n o n - a n tr a !  lo c a tio n  th e  n o d e s  in th e  s p le n ic  l iilu m  w ere  
a ls o  re m o v e d . T h e  n o d e s  o f  g r o u p  3 |R 3  Iv m p h a d c n c c -  
to in y )  fro m  flic  h e p a lo d u o d c n a l  l ig a m e n t, b e h in d  th e  p a n ­
c r e a tic  h e a d  a n d  th e  ro o f  o f  m e s e n te r iu in  w e re  d is s e c te d  in 
e a se s  o f  p a lp a b le  c h a n g e s  in  th e  p e r ig a s t r ic  ly m p h  n o d e s  If 
n e e d e d , f ro z e n  s e c tio n s  w e re  e x a m in e d  b e f o re  m a k in g  d e c i­
s io n s  a b o u t  th e  e x te n t o f  ly m p h a d e n e c to m y . In  c a s e s  o f  
ly m p h  n o d e  m c la s la s c s .  th e  a im  w a s  to  o b t a in  a m a rg in  o f  
a t le a st o n e  u m n v o lv e d  g ro u p  o f  ly m p h  n o d e s  d is ta l  to  th e  
m o s t p e r ip h e ra lly  in v o lv e d  g r o u p  f l ic  ly m p h  n o d e s  w ere 
a lw a y s  re m o v e d  en  b lo c  w ith  th e  s to m a c h  a n d  s u r r o u n d in g  
fa t ly  tissu e .
T h e  s ta t is t ic a l  d a ta  a n a ly s is  w a s  m a d e  in th e  SPS S  
sy s te m , u s in g  u n i-  a n d  m u l tiv a r ia te  ( C o x  re g re s s io n i 
a n a ly se s  o f  v a r ia n c e ,  th e  s ig n if ican c e 's  w e re  c a lc u la te d  by 
th e  / ' - m e t h o d  a n d  S tu d e n t 's  ( - te s ts
Results
T h e  3 0 -d a y  p o s to p e r a t iv e  m o r ta l i ty  fo r  all ra d ic a lly  o p ­
e r a te d  p a t ie n ts  w a s  5 4 (2 4  o f  4 0 Ы : n  w a s  h ig h e s t  fo r  R 3 
ly m p h a d e n e c to m y  i I 1.0",.). fo llo w e d  by i u a l  g a s tre c to m y  
( 10.6";,) a n d  p ro x im a l  s u b to ta l  g a s t rc e to n .v  < I 0 .P '- | .  a n d  
w a s  re la tiv e ly  low lo t  R 2  Iv m p h a d c iic c to m y  ( 3 1  i am ! 
f o r  d is ta l  s u b to ta l  g asiiccuH T iv  (2 .2  . > T a b le  I s h o w s  th e  
d i s t r i b u t io n  o f  (h e  p r o g n o s t i c 'f a c t o r s  a n d  th e  5 -y e a r  s u r ­
v iv al r a le s  fo r  th e  p a t ie n ts  w h o  u n d e r w e n t  c u r a t iv e  s tn g ery  
a n d  T a b le  2 p re s e n ts  th e  r e s u lts  o f  d ie  u n iv a r ia te  a n a ly s is  
o f  th e  in f lu e n c e  o f  th e se  fa c to r s  o n  s u rv iv a l  I n iv a n a tc  
a n a ly s is  s h o w e d  a s  f a v o u r a b le  ( a e lo i s  a g e  below  ~4 y e a rs  
tu m o u r  lo c a tio n  in th e  lo w e r  o r  m id d le  p a n  o f  d ie  s to m ­
a c h . B o r rm a n n  I II ty p e , tu m o u r  s i /e  less th a n  4  e in . 
in te s t in a l  h is to lo g ic a l  ty p e . p T  I 2 s ta g e ,  l im ite d  l N o  M l
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T a b le  I
5 - rear \iirvicul rules in relation lo different prognostic factors  
P rognostic  facto r P atien ts 5-year survival
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L oca tion  
A n trum  
C o rp u s 
C ard ia  
T o ta l 





T u m o u r d iam ete r (cm )




H isto logic type
Papillary adenocarc inom a 
T u b u la r adenocarcinom a 
well differentiated 
m odera tely  differ.
Poorly  d ilferen tialed  
adenoca  rcinom a 
M ucinous adenocarcinom a 
S ignet ring cell carcinom a 
U ndifferen tia ted  carcinom a 





pN  category  
pNO 
p \ l  
pN 2 
pN  3
G a strec to m y  
D istal sub to ta l 
P roxim al sub to ta l 
Total
Lym ph node rem oval
r :
КЗ
I'x len t o f  lym phadenectom y 
relative to  nodal stage 























































































У 16 Л Л К Л К  AND K. K U LL
T a b le  2
U n iva ria te  a n a ly s is  o f  p ro g n o s tic  fa c to r s  in fluencing the 5 -y e a r  su rv iva l o f  g a s tr ic  can cer p a tie n ts
Prognostic lac to r F av o u ra b le  (5 -year U nfavourab le ( 5-year p-value
survival) survival)
Sex N S '
Age < 7 0  (51.9% ) >  70 ( 35.2“/.,) <0.01
T~ 1 - 2  ( 67.8% ) 3 - 4  (41.0% ) <0.0001
N 0 - 1  (56.4% ) 2 - 3  (22.6% ) < 0.00001
H istologic t>pe in testina l ( 55,0%) diffuse (39.6% ) <0.01
B orrm ann t_\pe 1 11 (59.1% ) l l l - I V  (34.3% ) < l).00 tn
Size o f  tu m o u r <  4 cm (71.9% ) J: 4 cm  (41.8% ) <0.0001
Site o f tum our an tru m  and ca rd ia  and
co rp u s (50.0% ) to tal (25.8% ) <0.0001
G astrec tom y su b to ta l (55.0% ) to tal ( 32.4%) <0.00001
L ym phadenectom y R2 (52.7% ) R3 (34  3%) <0.00001
R m inus N : 2 - 3  (58.1% ) 0 - 1  (27.2% ) <0.00001
' N o t significant. ’ Extent o f  lym pliadenectoniy  relative lo  nodal stage
ly m p h  n o d e  in v o lv e m e n t ,  s u b to ta l  g a s l re c io m y , R 2  v e r su s  
R 3  ly m p h a d e n e c to m y  a n d  a n  e x te n t  o f  ly m p h a d e n e c to m y  
m o re  th a n  o n e  N - g r o u p  f r o m  th e  in v o lv e d  ly m p h  n o d e s . 
T h e  in flu e n c e  o f  a g e  o f  p a t ie n t  a t  o p e r a t io n ,  t u m o u r  s ite s , 
a n d  d if fe re n t  h is to lo g ic a l  ty p e s  w e re  s ta t is t ic a l ly  less 
m a rk e d  th a n  o th e r  fa c to rs .  T h e  y e a r  o f  o p e r a t io n  a n d  th e  
sex  o f  p a t ie n ts  d id  n o t  s ig n if ic a n tly  in f lu e n c e  s u rv iv a l .  T h e  
o v e ra ll  5 -y e a r  su rv iv a l  w a s  4 6 .1 %  in c lu d in g  th e  3 0 -d a y  
p o s to p e r a t iv e  m o r ta l i ty .  T h e  m a le : f e m a le  r a t i o  w a s  0 .9 5  
( 1 9 8 :2 0 8 )  a n d  th e  m e a n  a g e  w a s  6 2 .4  y e a r s  ( r a n g e  3 1 - 8 0  
y e a rs ) . W e o b s e r v e d  a d e c re a s e d  s u rv iv a l  w ith  in c re a s in g  
a g e  o f  th e  p a t ie n ts  a t  t im e  o f  th e  o p e r a t i o n .  O f  o u r  
p a t ie n ts  4 9 .3 %  h a d  c a n c e r  w ith  a n t r a l  lo c a tio n  a n d  o n ly  
1 0 .3%  w ith  c a r d ia l  lo c a tio n . D u r in g  th e  o b s e r v e d  1 0 -y c ar 
p e r io d  w e d id  n o t  n o tic e  s ig n if ic a n t c h a n g e s  in  th e  lo c a ­
t io n a l  d i s t r ib u t io n  o f  t u m o u r s .  T h e  s u rv iv a l  r a te s  w e re  
n e a r ly  tw o  t im e s  h ig h e r  in th e  c a se s  w ith  a n t r a l  o r  m id d le  
lo c a tio n  th a n  in th o s e  w ith  c a r d ia l  l o c a tio n  o r  to ta l  in ­
v o lv e m e n t o f  th e  s to m a c h . T h e  ra t io  o f  th e  c irc u m s c r ib e d  
a n d  th e  in f i l tr a t iv e  m a c ro s c o p ic  ty p e s  o f  t u m o u r s  a c c o r d ­
ing  to  th e  B o r r m a n n  c la s s i f ic a t io n  w a s  I : I a n d  th e  d if fe r ­
e n c e  o f  th e  5 -v e a r  s u rv iv a l  r a le s  b e tw e e n  th e s e  tw o  g r o u p s  
w a s  s ig n if ic a n t. T h e  5 -y e a r  s u rv iv a l  r a te s  d im in is h e d  w ith  
i n c re a s in g  t u m o u r  size. S ig n if ic a n tly  d i f fe re n t  s u rv iv a l  ra te s  
w e re  fo u n d  o n ly  b e tw e e n  tu m o u r s  s m a l le r  th a n  4  c m  a n d  
la rg e r  o n e s . T h e  m e a n  d ia m e te r  o f  th e  re m o v e d  tu m o u r s  
w a s  6 .2  c m  a n d  r a n g e d  f ro m  I t o  23 c m .
T h e  m o s t  c o m m o n  h is to lo g ic  ty p e s  w e re  m o d e ra te ly  
d i f fe re n t ia te d  t u b u la r  a d e n o c a r c in o m a  (2 7 .6 % ) a n d  p o o r ly  
d if fe re n t ia te d  a d e n o c a r c in o m a  (2 6 .6 % ). T h e  s u rv iv a l  ra te s  
w e re  n o t ic e a b ly  h ig h e r  in  c a se s  o f  p a p i l l a r y  a n d  w ell o r  
m o d e ra te ly  d if fe re n t ia te d  a d e n o c a r c in o m a .  T h e  5 -y e a r  s u r ­
v iv al r a te  w a s  a ls o  re la t iv e ly  h ig h  (47,2"/..) in  c a s e s  o f  
p o o r ly  d i f fe re n t ia te d  a d e n o c a r c in o m a  t h a t  o n e  m ig h t  s u s ­
p ec t to  h a v e  p o o r  p ro g n o s is  T h e  5 -y e a r  s u rv iv a l  r a te  w a s  
30 .4  -3 6 .7 "  и fo r  p a t ie n ts  w ith  th e  c a n c e r s  o f  m u c in o u s ,  
s ig n e t- r in g  ce ll ty p e  o r  u n d i f fe re n t ia te d  s t r u c tu r e .
O n ly  7 .6 %  o f  a ll o u r  p a t i e n t s  o p e r a te d  o n  h a d  e a r ly  ( T i t  
g a s t r ic  c a n c e r  w ith  a  5 -y e a r  s u rv iv a l  r a te  o f  8 0 .7 %  w h e re a s  
7 6 .8 %  h a d  T 3 - T 4  tu m o u r s  w ith  a  5 -y e a r  s u rv iv a l  o f  
4 1 .0 % . L y m p h  n o d e  in v o lv e m e n t w a s  fo u n d  in  4 4  (V .. o f  
th e  p a t ie n ts  a n d  in  31" . o f  th e  n o d e - p o s it iv e  c a se s  it 
e x te n d e d  lo  N1 -n o d e s , in 54.7" . to  \ 2 - i i o d e s  a n d  in  13.л' 
lo  N 3 - n o d c s .  T h e  5 -y e a r  s u rv iv a l  r a te s  d iffe re d  m u c h  d e ­
p e n d in g  o n  th e  p re s e n c e  o f  ly m p h  n o d e  m é ta s ta s e s  a n d  
w e re  s t ro n g ly  c o r r e la te d  w ith  th e  e x te n t  o f  ih e  n o d a l 
in v o lv e m e n t .
In  ih is  m a te r ia l  2 2 6  d is ta l  s u b to ta l .  170 to ta l  a n d  10 
p ro x im a l  s u b to ta l  g a s t r e c to m ie s  w e re  p e r fo rm e d . N e ig h ­
b o u r in g  o r g a n s  w e re  r e s e c te d  in  176 c a s e s  (42.9"/«), m o s t 
f r e q u e n t ly  th e  sp le e n  ( 141 c a se s )  a n d  th e  d is la l  p a r t  o f  (he 
p a n c r e a s  (2 8  ca se s ) . In  6 4 .0 %  o f  th e  c a se s  th e  p a t ie n ts  
u n d e r w e n t  d is s e c t io n  o f  N 1 a n d  N 2  n o d e s  ( R 2 -re s e c tio n )  
a n d  in  36.0'V;. s o -c a l le d  R 3 -re s e c t io n s .  T h e  5 -y e a r  su rv iv a l  
r a te  5 2 .7 %  f o r  R 2 - re s e c t io n s  a n d  34.3"/., fo r  R 3 -re s e c i io n s  
C o m p a r in g  th e  ly m p h a d c n e c lo m ie s  w ith  d if fe re n t e x te n ­
s io n  a s  to  th e  e x te n t  o f  ly m p h  n o d e  in v o lv e m e n t  ( R m in u s  
N ) , e x te n s iv e  ly m p h a d e n e c to m y  h a d  a f a v o u r a b le  effec t 
o n ly  w h e n  it e n c o m p a s s e d  m o re  t h a n  o n e  u n in v o lv e d  
g r o u p  o f  ly m p h  n o d e s  T h e  5 -y e a r  s u rv iv a l  w a s  27 .2  
w h e n  R  m in u s  N  w a s  e q u a l  to  0  o r  I a n d  5 8 .1 % . w h e n  it 
w a s  e q u a l  lo  2 o r  3.
In  th e  m u l t iv a r ia te  a n a ly s is  u s in g  C o x ’s re g re s s io n  
m o d e l ( T a b le  3 ). a ll f a c to r s  te s te d  b y  th e  u n iv a r ia te  a n a ly ­
s is  w e re  u se d . T h is  a n a ly s is  id e n tif ie d  5 p ro g n o s t ic  v a r i­
a b le s  t h a t  s ig n if ic a n tly  in f lu e n c e d  th e  risk  o f  d e a th  A m o n g  
th e s e , ly m p h  n o d e  in v o lv e m e n t w a s  th e  m o s t im p o r ta n t  
in d e p e n d e n t  p ro g n o s t ic  f a c to r ,  fo llo w e d  b y  e x te n t  o f  g a s ­
t r e c to m y ,  d e p th  o f  in v a s io n , h is to lo g ic a l  ty p e  o f  c a n c e r  
a n d  a g e  o f  p a t ie n ts .
T a b le  4  s h o w s  th e  r e la t io n s h ip  b e tw e e n  th e  5 -y e a r  s u r ­
v iv a l r a te  a n d  th e  p re s e n c e  o l ly m p h  n o d e  m é ta s ta s é s  a n d  
th e  level o f  i n t r a m u r a l  c a n c e r  in v a s io n . In  g e n e ra l ,  th e  
5 -y e a r  su rv iv a l  r a te  c o r r e la te d  w ell w ith  b o th  th e  e x te n t o f
T a b le  3
R esults о/ the Сол regression m uhivnriale analysis o f  prognostic fa c to rs  a fter curative surgery
V ariab le Relative risk o f  death  p-value to  rem ove
( 95'/ confidence interval)
PROGNOSTIC FACTORS IN GASTRIC CANCER
N odal involvem ent
Nil 1.0
N1 1.57 (1 .04-2 .37 .)
N2 2.48 ( I .  XI -3 .4 1 )
N ? 3 .9 8 (2 .4 5 -6 .4 8 )
Extent o f  gastrectom y 
S u b to ta l 1.0
T o ta l 1 .6 8 (1 .2 7 -2 .2 3 )
D epih  o f  invasion
TI 1.0
T 2 2.04 (0 .8 4 -4 .9 6 )
T 3  2.27 (0.99 5.23)
T4 3.24 (1 .38  -7.62)
H isto logic type
P apillary  o r tubu lar 1.0
Poorly  d ifferen tiated  1.01 (0 .7 0 -1 .4 3 )
O th ers ' 1.51 (1 .0 9 - 2 0 9 )
Age. years
< 7 0  1.0
> 6 9  1 .4 2 (1 .0 7 -1 .8 8 )
D id not significantly im prove m odel 
B orrm ann  type 
Location  
S i/e
E xtent o f  lym phadenectom y
К m inus N factor
Sex
M ucinous, signet-ring cell an d  undifferen tiated  carcinom as
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Nil :x 82 1 J7 М.Ч lOti 56.6 54 51.9 225 60.0
N1 0 ? 71.4 45 42.2 5 0.0 57 42.1
N2 3 66.7 10 30.0 57 28.1 29 13.8 49 25.3
N3 n ') 22.2 10 10.0 6 0.0 25 12.0
T otal 31 80.7 6? 54.0 218 44.0 94 34.0 4(16 46.1
ly m p h  n o d e  m é ta s ta s e s  a n d  llic  d e p th  o f  t u m o u r  p e n ­
e t r a t io n .  T h e r e  w a s  a s ig n if ic a n t d if fe re n c e  o f  th e  5 -y e a r  
s u rv iv a l  ra te s  b e tw e e n  th e  n o d e - p o s it iv e  a n d  th e  n o d e - 
n e g a tiv e  g r o u p s .  28.7"'.. a n d  6 0 .0 %  re s p e c tiv e ly , a n d  a lso  
b e tw e e n  th e  cu r ly  a n d  th e  a d v a n c e d  c a se s  o f  c a n c e r ,  N0.7" ,, 
a n d  4 3 .2 %  re s p e c tiv e ly  T h e  h ig h e s t  5 -v c a r  su rv iv a l  r a te  
w as fo u n d  in  p a t ie n ts  w ith  e a r ly  g a s t r ic  c a n c e r  w i th o u t  
ly m p h  n o d e  m é ta s ta s e s  (N2 !".•) a n d  th e  lo w csl r a te  in
p a t ie n ts  w ith  T 3 - T 4  tu m o u r s  w ith  N 3 -p o s it iv e  n o d e s  
(6 .3 % ). T h e  e x te n t o f  ly m p h  n o d e  in v o lv e m e n t sh o w e d  a 
c o r r e la t io n  w ith  th e  T  s tag e .
D iscu ssio n
A d e c lin e  in o p e r a t iv e  m o r ta l i ty  ra te s  a f te r  ra d ic a l  g a s ­
tr ic  c a n c e r  su rg e ry  o v e r  th e  p as t 30  y e a rs  h a s  b ee n  d e m o n ­
\  VK \K  \ М )  К Kl и
s t r a te d  th r o u g h o u t  th e  w o  г kl I 20 ). h m  U is siill r e g a rd e d  as  
u n a c c c p ta b ly  in g li by m a in  p ra c t i t io n e r s .  T h e  o v e ra ll  30- 
dav  p o s to p e r a t iv e  m o r ta l i ty  lo r  o u r  p a t i e n t s — 5 .9 7 m— is 
h ig h e r  th a n  th e  o n e  re p o r te d  a l l e r  c o m p a r a b le  s u rg e ry  in 
J a p a n ,  b in  и is e q u a l  ю  th e  ra te s  p u b l ish e d  in n o n -  
J a p a n e s e  se r ie s  (2 .  12. 15. 16. 21). T h e  p o s to p e r a t iv e  
m o r ta l i ty  w a s  h ig h  a l l e r  R 3  ly m p h a d e n e c io m y  a n d  to ta l  
.la s trc c to n iy  i l l . t r  a n d  H).f>".< re s p e c tiv e ly ) . A l th o u g h  w e 
a c h ie v e d  th e  h ig h e r  r a d ic a l l y  p a r t ly  a t th e  c o s t  o l a h ig h e r  
m o r ta l i ty ,  w e d o  n o t  c o n s id e r  th e se  m o r ta l i ty  ra te s  as  
re a s o n s  to  a v o id  e x te n s iv e  s u rg e ry ,  th e  m o re  so  a s  th e re  a rc  
n o  e ffec tiv e  a l te r n a t iv e  m e th o d s
D iffe re n c e s  in  th e  in c id e n c e  o f  e a r ly  g a s t r ic  c a n c e r ,  in  th e  
.■ \icnt o f  su rg ic a l  re s e c t io n s  a n d  in th e  e p id e m io lo g ic a l  
f a c to r s  a r e  c o n s id e r e d  re s p o n s ib le  fo r  th e  v a r ia t io n  in th e  
su rv iv a l  r a te s  o f  p a t ie n ts  w h o  h a v e  u n d e r g o n e  c u r a t iv e  
su rg ic a l  t r e a tm e n t  o f  g a s t r ic  c a r c in o m a  (4 .  20 . 2 2 ). In  o u r  
s tu d y , h o w e v e r ,  m u l tiv a r ia te  a n a ly s i s  in d ic a te d  th a t  e x te n t 
o f  ly m p h a d e n e c to m y  t K 2 o r  R 3 ) by  i ts e l f  o r  r e la t iv e  to  th e  
s ta g e  o f  n o d a l  in v o lv e m e n t ,  a s  w ell a s  lo c a tio n ,  s ize  a n d  
B o r rm a n n  ty p e  o f  t u m o u r  w e re  n o t  in d e p e n d e n t  p r o g n o s ­
tic  fa c to rs .  T h is  s tu d y  in c lu d e d  o n ly  p a t ie n ts  in w h o m  
e x te n s iv e  ( R 2 o r  R 3 ) ly m p h a d e n e c to m y  w a s  p e r fo rm e d  
a n d  th e re fo re  th is  f a c to r  c o u ld  n o t  in f lu e n c e  th e  s u rv iv a l  
ra te s  in th e  a n a ly s e d  ca ses . S ize a n d  B o r rm a n n  ty p e  o f  
tu m o u r  h a d  a s t r o n g  c o r r e la t io n  w ith  p r o g n o s is .  H o w e v e r , 
s in ce  th e s e  f a c to r s  a r c  close ly  r e la te d  to  d e p th  o f  in v a s io n  
.niii ly m p h  n o d e  m é ta s ta s e s ,  th e y  h a d  n o  in d e p e n d e n t  
p ro g n o s t ic  s ig n if ic a n c e  w h e n  th e  a n a ly s i s  w a s  a d ju s te d  fo r  
o th e r  v a r ia b le s .  M u ltiv a r ia te  a n a ly s is  id e n tif ie d  live p r o g ­
n o s tic  f a c to r s  a s  in d e p e n d e n t  a n d  im p o r t a n t  p r e d ic to r s  o f  
re c u r r e n c e  a n d  d e a th  o f  p a t ie n t .  T h r e e  o f  th e s e  im p o r ta n t  
f a c to r s  d e p th  o f  in v a s io n , n o d a l  in v o lv e m e n t  a n d  h i s to ­
lo g ica l p a t t e r n  a r e  in h e re n t  p a th o lo g ic  f e a tu re s  o f  th e  
tu m o u r  a t  th e  t im e  o f  o p e r a t io n .
A l te r  c u r a t iv e  g a s t r e c to m y  m  p a t ie n ts  w i th o u t  p e r i to n e a l  
d is s e m in a t io n  o r  l iv e r  m e ta s ta s is ,  g a s t r ic  w a ll in v a s io n  a n d  
ly m p h  n o d e  in v o lv e m e n t h a v e  p ro v e d  to  b e  th e  m o s t 
im p o r ta n t  p r e d ic to r s  o f  tu m o u r  p r o g r e s s io n  (V. IS ). 
L y m p h  n o d e  in v o lv e m e n t  is o f te n  s ta te d  to  b e  o n e  o f  th e  
m a in  p ro g n o s t ic  f a c to r s  t 16. 23. 2 4 ) a n d  o u r  d a t a  c o n f ir m  
th is  s ta te m e n t .  T h e  e x te n t  o f  ly m p h  n o d e  in v o lv e m e n t 
a m o n g  o u r  p a t ie n ts  sh o w e d  th e  d e p e n d e n c e  o n  th e  T  s ta g e . 
S ig n if ic a n t d ilfe re n c e s  e x is te d  in s u rv iv a l  ra te s  r e la t iv e  to  
th e  n o d a l  s ta tu s  D e s p ite  th e  e x te n s iv e  ly m p h a -d e n e c lo m y  
u sed  in a ll c a s e s , th e  c u r e  r e s u lts  in  N 3  p o s i tiv e  c a s e s  w e re  
q u i te  m o d e s t .  H o w e v e r , th e  f r e q u e n c y  o f  m é ta s ta s é s  in  N 2  
a n d  N 3  n o d e s  d e te rm in e d  th e  n e c e s s ity  o f  e x te n s iv e  n o d e  
d is s e c t io n . In  th e  p re s e n t s tu d y  th e  R 2 - ly m p h a d e n c c to m y  
h a d  a  s ig n if ic a n t! )  m o re  f a v o u r a b le  effec t o n  th e  p r o g n o s is  
th a n  R 3 - ly m p h a d e n e e to m y  b y  th e  u n iv a r ia te  b u t  n o t  by 
m u l tiv a r ia te  a n a ly s is . T h is  re su lt  c a n  b e  e x p la in e d  by  th e  
fa c t th a t  R 2 - ly m p h a d e n e c to m y  w a s  m o re  f r e q u e n t ly  
a s s o c ia te d  w ith  - u b to t a l  g a s t re c to m ie s  a n d  l im ite d  (N O  
N 1 ) ly m p h  n o d e  in v o lv e m e n t  (7X.5".., o f  th e  R 2 -c a s e s ) .
w h ile  m o s t l< 3 - ly m p h a d c n e c lo in ic s  w e re  p e r lo i i h e d  in  
c o m b in a t io n  w ith  to ta l  g a s t re c to m y  a n d  o n ly  >3 .4  o l 
th e s e  c a se s  w e re  a s s o c ia  te d  w ith  l im ite d  n o d a l  in v o lv e m e n t. 
T h e  c o n c e p t  th a t  ly m p h a d e n e c to m y  is b e n c - lic ia l  on ly  
w h e n  it w id e ly  e n c o m p a s s e s  th e  d is e a s e  is n o t  new t l 2 l  
T h e  p re s e n t  s tu d y  su g g e s te d  th a t  e x te n s iv e  ly m p h  n o d e  
d is s e c t io n  ( R 2  o r  К 3) o l lc re d  in o ie  b en e fit ю  p a t ie n ts  w ith  
n o  o r  lim ite d  ( N ! i  n o d a l  d is e a s e  a n d  th a t  th e  d is ta l  
d is ta n c e  o f  ly m p h a d c i ie c u u m  in  th e  m e ta s ta t ic  n o d e s  w a s  
im p o r ta n t .
W e h a v e  a t t e m p te d  to  d e te rm in e  th e  e x te n t  o f  n o d a l 
d is e a s e  b e f o re  g a s t r e c to m y  b y  I 'r o /e n - s c c t io n  e x a m in a t io n  
o f  m a c ro s c o p ic a lly  s u s p ic io u s  n o d e s  a r o u n d  th e  s to m a c h  
H o w e v e r , th e  p o s to p e r a t iv e  h is to lo g ic a l  e x a m in a t io n  of th e  
re m o v e d  ly m p h  n o d e s  s h o w e d  th a t  in c id e n ta l  b io p s ie s  
d u r in g  th e  o p e r a t i o n  c a n n o t  b e  re lie d  o n  b e c a u s e  o f  la rg e  
n u m b e r  o f  fa ls e -n e g a t iv e  a n d  fa ls e -p o s i t iv e  re s u lts . T h e  
h is to lo g ic a l  e x a m in a t io n  o f  ly m p h  n o d e s  d u r in g  th e  o b ­
se rv e d  p e r io d  im p lie d  o n ly  o n e - s te p  s e c tio n in g  o f  e n la rg e d  
n o d e s  a n d  th e r e f o r e  s o m e  m ic ro m e ta s ta s c s  m ig h t h a v e  
re m a in e d  u n d e te c te d .  A t p re s e n t a ll re m o v e d  n o d e s  u n ­
d e r g o  m ic ro s c o p ic a l  e x a m in a t io n  a n d  th e  th re c -s te p -  
s c c tio n in g  m e th o d  h a s  b e e n  in t r o d u c e d  to  m a k e  th e  d .n .i 
c o n c e rn in g  ly m p h o g e n ic  s p r e a d  m o re  p re c ise .
S e ro s a l  in v a s io n  is c o n s id e r e d  to  he a p r e d ic to r  o f  p o o r  
p ro g n o s is  l o r  g a s t r ic  c a n c e r  in v o lv e m e n t  t2 .  2 2 l l io n i  the 
r e s u lts  o f  th e  p re s e n t s tu d v  w e m ay  c o n c lu d e  th a t  a  p ro p e r  
m u s c u la r  la y e r  ( p T 2 )  is a s s o c ia te d  w ith  a  h ig h  in c id e n c e  ol 
ly m p h  n o d e  m é ta s ta s e s  a n d  th e  s u rv iv a l  ra te s  in th e se  ca ses  
c o m e  c lo s e r  to  th e  r a te s  fo r  13 th a n  fo r  I I c a se s . I hc rc - 
fo r e  w e a g re e  w ith  th e  J a p a n e s e  s u rg e o n s  a n d  c o n s id e r  the 
p T 2 - lu m o u r s  to  b e  ad v a n ce » ! I’.i t ie n ts  w ith  s e ro s a l  in v a ­
s io n  ( p T 3 )  h a d  a  re la tiv e ly  f a v o u r a b le  p ro g n o s is ,  e sp e cia lly  
w h e n  th e r e  w e re  n o  ly m p h  n o d e  m é ta s ta s é s  th e  5 -v c a r 
su rv iv a l  r a te  l o r  th o s e  p a t ie n ts  w a s  5 6 .(V’m . T u m o u r s  w ith  
in v a s io n  o f  c o n t ig u o u s  s t r u c tu r e s  f p T 4 )  h a d  a ls o  g o o d  
s u rv iv a l  (3 4 .0 ”/.. a l  5 -y e a rs )  p a r t ic u la r ly  c a s e s  w ith o u t 
n o d a l  in v o lv e m e n t  T h e r e fo r e  w e th in k  th a t  c o m b in e d  
re s e c tio n  o l n e ig h b o u r in g  o r g a n s  d ire c tly  in v a d e d  by g a s ­
tr ic  c a n c e r  is a n  e f fe c tiv e  m e th o d . W e d o  n o t  k n o w  exactly  
h o w  s p le n e c to m y  in flu e n c e s  th e  p o s to p e r a t iv e  c o u rs e  
M o s t s p le n e c to m ie s  w e re  a s s o c ia te d  w ith  to ta l  g a s t re c ­
to m ie s  a n d  R 3 - ly m p h a d e n c c lo m ie s  w ith  a  h ig h  p o s to p e r a ­
tiv e  m o r b id i ty  a n d  low  s u rv iv a l  ra te s  b e c a u s e  o f  th e  
a d v a n c e d  c a r c in o m a s
M u l t iv a r ia te  a n a ly s i s  sh o w e d  th a t  th e  h is to lo g ic a l  ty p e  
o f  c a n c e r  w a s  a n  in d e p e n d e n t  a n d  im p o r ta n t  p r o g n o s t ic  
f a c to r .  A h ig h  f r e q u e n c y  o f  th e  in te s t in a l  ty p e  is c o n n e c te d  
w ith  a  h ig h -r is k  p o p u la t i o n  a n d  a h ig h e r  s u rv iv a l  ra le  (2 3 i  
In  o u r  s e r ie s  th e  in te s t in a l  ty p e s  : d iffu se s  ty p e s  r a t io  w as
1.06  ( 1 7 1 :1 6 1 )  w h ic h  is c o m p a r a b le  lo  th a t  m  m o st ic- 
p o r t s  f ro m  h ig h -r is k  a r e a s  (4 . 'I. I s  |f>i I h e  ire q u e n c v  . ■! 
c a s e s  w ith  s ig n e t-c e ll  c a r c in o m a  w a s  re la t iv e ly  low in o u i 
s e r ie s  (7 .4 " '.)  c o m p a r e d  to  o th e r  s e r ie s  r e p o r te d  i s .  I(<. 2 ' i  
In  68,7"/.. o f  all c a s e s  th e  t u m o u r s  h a d  h is to lo g ic a l  p a l le t  n>
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I р л p ill.tr> . t u b u la r  o r  p o o r ly  d if fe re n t ia te d  a d e n o c a r ­
c in o m a )  w ith  h ig h e r  5 -y e a r  s u rv iv a l  r a le s  t h a n  th e  o v e ra ll  
ra te
С o u t r a n  to  iv,o s! r e p o r t s  (7 . N 22. 26 ) w e fo u n d  c a r ­
c in o m a s  in th e  u p p e r  th i r d  o t th e  s to m a c h  o n ly  in 10..’ " o f  
o u i c a se s  I 'r o x im a l  t u m o u r s  h a v e  p e n e t r a te d  in to  th e  
se ro sa  a n d  h a v e  l> m p h  n o d e  m é ta s ta s é s  m o re  o f te n  th a n  
tu m o u r«  in th e  d is ta l  s to m a c h  (2 2 . 26). F o r  e a r ly  d ia g n o s is  
ol c a n c e r  o l th e  u p p e r  th i r d  o f  th e  s to m a c h  th e re  is a  sp e c ia l 
n ee d  lo r  s c re e n in g  p r o g r a m s  a s  a s y m p to m a t ic  c o u r s e  o f  th e  
d ise a se  is c o m m o n .  T h e  t r a u m a ti c  t h o r a c o a b d o m in a l  a p ­
p ro a c h  w ith  c o m b in e d  g a s t re c to m y  in th e  t r e a tm e n t  o f  
c a rd ia l  l u m o u is  a ls o  c o n t r ib u te s  to  th e  h ig h  fre q u e n c y  o f  
in o p e ra b le  c a se s , p a r t i c u la r ly  in e ld e r ly  p a t ie n ts  w h o  f r e ­
q u e n t ly  s u t le r  I ro m  c o n c o m ita n t  d ise a se s . T h is  a ls o  a c ­
c o u n ts  fo r  th e  low n u m b e r  o f  o p e r a b le  c a rd ia l  c a n c e r . T h e  
o v e rw h e lm in g  m a jo r i ty  o l t u m o u r s  in o u r  s c r ie s  w e re  
lo c a te d  in th e  lo w e r  (4 4  3".„i a n d  m id d le  ( 3 4 .5 % ) p a r t  o f  th e  
s to m a c h , w h e re  it is e a s ie r  to  g u a r a n te e  r a d ie a l i ty  o f  
re se c tio n  T h e  su rv iv a l  r a te  in c a se s  o f  n o i l - c a rd ia l  c a r ­
c in o m a  w as m  o u r  s e r ie s  tw ice  a s  h ig h  c o m p a r e d  to  c a se s  
w ith  c a rd ia c  lo c a tio n  o r  to ta l  in v o lv e m e n t o f  th e  s to m a c h  
X lth o u g h  th e  tu m o u r  lo c a tio n  w a s  a  p ro g n o s t ic  i n d ic a to r  in 
th e  u n iv a r ia te  a n a ly s is . it w a s  n o t a  s ig n if ic a n t f a c to r  in  th e  
m u ltiv a r ia te  a n a lv s is  b e c a u s e  ««1 th e  c lo se  c o n n e c t io n  w ith  
o th e r  p a r a m e te r s ,  p e r h a p s  m ain ly  th e  e x te n t o f  g a s t r e c ­
to m y  W e still th in k  th a t  d i s t r ib u t io n  o l ' b o th  t u m o u r  
lo c a tio n s  a n d  h is to lo g ic a l  ty p e s  m a y  h e  c lo s ly  l in k e d  to  th e  
r e la tiv e ly  g o o d  su rv iv a l  r e s u lts  m  o u r  s tu d y . In  a d d i t io n  to  
th e  p r e d e te r m in e d  p ro u u o s i ic  f a c to r s  th e  su rg ic a l  s tra te g y  
p io b a b ly  a ls o  h a d  a n  im p a c t o il th e  p ro g n o s is .  O f  th e  th re e  
s u rg ic a l t r e a tm e n t  f a c to r s  fo u n d  to  b e  p ro g n o s l ic a lly  s ig n if i­
c a n t In  u n iv a r ia te  a n a lv s is .  o n ly  th e  ty p e  o f  g a s tre c to m y  
re m a in e d  a s  a n  im p o r ta n t  p r o g n o s t ic  i n d ic a to r  a t  th e  C o x  
a n a lv sis . T o ta l  g a s t re c to m y  w a s  a s s o c ia te d  w ith  a m u c h  
h ig h e r  risk, o f  d e a th  th a n  s u b to ta l  g a s t re c to m y  (5 - y e a r  
s u rv iv a l  34 4" vs. и 9" . i. I h is la rg e  d iffe re n c e  is p r o b a b ly  
m a in ly  e x p la in e d  bv v a r io u s  t u m o u r  p a r a m e te r s ,  a s  K o r­
u n a  n n  ty p e  o l g ro w th , a n d  s ize  a n d  in v a s io n  o f  th e  p r im a ry  
tu m o u r  W e p e r fo rm e d  to ta l  g a s t re c to m y  m a in ly  in c a se s  
w ith  in f i l tr a t iv e  tv p e s  a n d  d e e p  in v a s io n  w h ile  s u b to ta l  
g a s t re c to m y  w a s  p c f c r r c d  in l im ite d  tu m o u rs .  In  o u r  s tu d y  
th e  e x te n t o f  ly m p h  n o d e  in v o lv e m e n t a ls o  c o r re la te d  
s ig n if ic a n tly  w ith  th e  d e p th  o f  t u m o u r  in v a s io n . B o r rm a n n  
tv p e  a n d  tu m o u r  size . I lo w e v c r .  it d id  n o t  c o r r e la te  w ith  th e  
lllst o lo g ic  ty p e  o r  th e  lo c a tio n  o f  th e  c a n c e r .  T h e  sm a ll  
n u m b e r  o f  p ro x im a l  s u b to ta l  g a s t re c to m ie s  |() - ( 2 .5 %  o f  
th e  c a s e s )  c a n  b e  a c c o u n te d  fo r  by th e  fa c t th a t  th is  
o p e r a t io n  in p r in c ip le  w a s  p e r f o im e d  on ly  in  c a se s  w ith  
sm all c irc u m s c r ib e d  tu m o u r s  a n d  th e  in c id e n c e  o f  su c h  
tu m o u r s  in th e  c a rd ia l  re g io n  w a s  v e ry  lo w . p a r t ly  b e c a u se  
o f  d ia g n o s t ic  p ro b le m s
T h e  h ig h  5 -y e a r  s u rv iv a l  r a te  fo r  p a t ie n ts  in th e  34 39- 
v e a r  g r o u p  I n 1.4" .) a l t c i  e x te n s iv e  ra d ic a l  s u rg e ry  re q u ir e s  
a  sp ec ia l c o m m e n t .  B e c a u se  o f  th e  m o re  a g g re s s iv e  c o u r s e
o f  th e  d is e a s e  in y o u n g  p e o p le , th e  n u m b e r  o f  e u ra tiv e ly  
o p e r a te d  p a t ie n ts  in  th is  a g e  g r o u p  w a s  re la tiv e ly  low 
( 1 .7% ) a n d  th e  o v e ra ll  p ro g n o s is  w a s  w o rse  th a n  in o th e r  
a g e  g ro u p s .  O n  th e  o th e r  h a n d , th e  re s u lts  su g g e s t th a t  it 
is th e  v o u n g  p a t ie n ts  w h o  b en e fit m o s t f ro m  e x te n s iv e  
s u rg e ry :  3 0 .X"- o f  o u r  p a t ie n ts  w e re  o v e r  70 y e a rs  o ld . W e 
fo u n d  u r a th e r  lo w  5 -y e a r  su rv iv a l  r a te  in  th e  o ld  ( 35 .2 ' in 
p a t ie n ts  >  70  y e a rs )  a n d  th e  v e ry  o ld  ( 2U" in p a t ie n ts  SO 
y e a rs )  a g e  g ro u p s .  R e c u r re n t  g a s t r ic  c a n c e r  is p ro b a b ly  th e  
d o m in a t in g  o ff ic ia l c a u s e  o f  d e a th  a m o n g  e ld e rly  p a t ie n ts  
o p e r a te d  o n  f o r  g a s t r ic  c a n c e r . H o w e v e r ,  to o  few a u to p s ie s  
a r c  m a d e  in  th e s e  p a t ie n t  g r o u p s  a n d  th e  re a l c a u s e  o f  
d e a th  m a y  b e  o th e r  th a n  g a s tr ic  c a n c e r .  A g g re s s iv e  su rg e ry  
w ith  e x te n s iv e  ly m p h a d e n e c to m y  d o e s  n o t a lw a y s  see m  to  
c o n t r ib u t e  to  a  f a v o u r a b le  p ro g n o s is  in  e ld e rly  p a t ie n ts ,  
w h o  u s u a lly  h a v e  c o n c o m ita n t  s y s te m ic  c a r d io v a s c u la r  a n d  
r e s p ir a to r y  d is o rd e r s  a n d  w h o  a r e  th e r e f o r e  a t h ig h  risk  fo r  
p o s to p e r a t iv e  c o m p lic a tio n s  
T h e  m a le  fe m a le  r a te  o f  g a s t r ic  c a n c e r  p a t ie n ts  in  l-.sto- 
n ia  is 1 .35 . w h ile  in  m o s t r e p o r t s  it is sa id  to  be 1.5 o r  
m o re  (3 . 8 . 9 . 10. 16. 2 2 1. T h e  m a le  : fe m a le  r a t i o  in  th e  
ra d ic a lly  o p e r a te d  c a se s  w a s  0 .9 5  ( 19X : 20S|. T h a t  m e a n s  
t h a t  th e re  w e re  re la t iv e ly  fe w e r m a le  p a t ie n ts  s u i ta b le  fo r  
ra d ic a l  su rg e ry  as  m a le s  te n d  to  c o m e  less fo r  th e ir  h e a lth  
a n d  tu r n  la te r  t o  d o c to r s  th a n  fe m a le s
T o  c o n c lu d e , th e  p re s e n t s tu d y  sh o w e d  th a t  th e  p r o g n o ­
sis o f  g a s t r ic  c a n c e r  p a t ie n ts  d e p e n d e d  o n  th re e  p a th o lo g ie  
f e a tu re s  o f  t u m o u r :  ly m p h  n o d e  m e ta s ta s is ,  d e p th  o f  in v a ­
s io n  a n d  h is to lo g ie  ty p e . O u r  r e s u lts  d e m o n s t r a te  r a th e r  
h ig h  5 -y e a r  s u rv iv a l  ra te s , in  so m e  re la tiv e ly  a d v a n c e d  
tu m o u r  g r o u p s  (T 2 N 3 .  T 3 N 2 . T 4 N 0 I  O n e  p o s s ib le  e x p la ­
n a t io n  fo r  th is  o u tc o m e  m ay  b e  th e  re la tiv e ly  w ell f u n c ­
t io n in g  n e tw o r k  o f  sp e c ia liz e d  o n c o lo g ic a l  «.are in K s lo m a . 
w h e re  m o s t g a s t r ic  c a n c e r  p a t ie n ts  a r e  o p e r a te d  o n  by 
su rg ic a l  o n c o lo g is ts  w ith  s im ila r  c o n c e p t  o f  o p e r a t iv e  p o l ­
icy. W e th in k  th a t  c o m b in e d  e n  b lo c  re s e c tio n  o f  n e ig h ­
b o u r in g  o r g a n s  d ire c t ly  in v a d e d  bv g a s t r ic  c a n c e r  is an  
eU cc tiv e  t r e a tm e n t  m e th o d  W e w o u ld  like  to  e m p h a s iz e  
th a t  c u r a t iv e  g a s t  rie  re s e c tio n  s h o u ld  be re g u la rly  c o m ­
b in e d  w ith  e x te n s iv e  ly m p h a d e n e c to m y  u p  to  th e  s e c o n d  
ly m p h  n o d e  g ro u p  w h e n  n o  ly m p h  n o d e  in v o lv e m e n t is 
fo u n d . W h e n  th e re  a r e  c le a r  m a c ro s c o p ic  c h a n g e s  in  th e  
p e r ig a s t r ic  n o d e s . R 3 - ly m p h a d e n e c to m y  is in d ic a te d  
W h e n  m é ta s ta s e s  in  n o n -p e r ig a s t r ic  n o d e s  a re  fo u n d  o n  th e  
f ro z e n - s e c t io n s  e x a m in a t io n  b e f o re  g a s t re c to m y , th e  ly m p h  
n o d e  d is s e c t io n  s h o u ld  id ea lly  h a v e  a  m a rg in  o f  a t  lea st 
o n e  u n in v o lv e d  g r o u p  o f  ly m p h  n o d e s  d is ta l  to  th e  m o s t 
p e r ip h e ra l  in v o lv e d  g r o u p  o f  n o d e  s ta t io n s ,  a l th o u g h  i: 
d o e s  n o t a lw a y s  g a u r a n te e  a f a v o u ra b le  p ro g n o s is  In  
o u r  p a t ie n ts  th e  n u is c u la n s  p r o p r ia  la y e r  o r  d e e p e r  in ­
v a s io n  w a s  a s s o c ia te d  w ith  a h ig h  in c id e n c e  o f  ly m p h  
n o d e  m é ta s ta s e s  a n d  low su rv iv a l  ra te s  T h e r e fo r e  w e 
fa v o u r  e x te n s iv e  ly m p h  n o d e  d is s e c t io n  m  all ca ses  oi 
a d v a n c e d  c a n c e r s  o f  th e  s to m a c h . A g g re s s iv e  su rg e ry  w ith  
e x te n s iv e  ly m p h a d e n e c to m y  c a n  sa fe ly  be p e r fo rm e d  : r
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y o u n g  p a  п сп  I s. w h e re a s  in  e ld e r ly  p a t ie n ts  w ith  c o n c o m i­
ta n t  sy s te m ic  d is o rd e r s  th is  a p p r o a c h  m u s t b e  u se d  m o re  
se lec tiv e ly
T h e  re la t iv e ly  h ig h  5 -v e a r  s u rv iv a l  r a te s  p re s e n e te d  in  o u r  
s tu d y  m a y . a t  lea st p a r t ly ,  b e  d u e  to  th e  h ig h  f r e q u e n c y  o f  
in te s t in a l  h is to lo g ic a l  ty p e s  a n d  lo w e r  o r  m id d le  l o c a tio n  o f  
th e  tu m o u r s  in  th e  s to m a c h . T h e  in c id e n c e  o f  e a r ly  g a s t r ic  
c a n c e r  a m o n g  ra d ic a lly  o p e r a te d  p a t ie n ts  in  E s to n ia  is 
e x tre m e ly  lo w . W e a r e  o f  th e  o p in io n  th a t  a  s c re e n in g  
p ro g r a m  fo r  e a r ly  d e te c t io n  o f  g a s t r ic  c a n c e r  s h o u ld  b e  
s ta r te d .  A t p re s e n t  a  d e c re a s e  in  th e  m o r ta l i ty  o f  th e  g a s tr ic  
c a n c e r  c a n  b e  a c h ie v e d  o n ly  b y  e x te n s iv e  s u rg e ry .
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SUMMARY
This retrospective analysis of data about 361 patients with gastric 
cancer, who underwent curative surgery with extensive lymphadenectomy from 
1978 to 1986 at the Hospital of Oncology, Tartu, Estonia, was performed to 
define the prognostic factors for genesis of the lymph node métastasés. The nodal 
involvement was found in 46.3 % of cases. The overall 5-year survival rate was 
48.5 %. We observed the decreasing survival rates associated with increase o f  the 
extent o f  nodal involvement. According to univariate analysis the lymph node 
métastasés o f gastric cancer occured more frequently in elderly patients, in cases 
of infiltrative type o f  primary tumor, muscularis propria or deeper invasion and 
when tumor size was more than 4 cm. Multiple regression analysis revealed the 
Borrmann type, age o f patients and the extent o f lymph node dissection as 
statistically indipendent prognostic factors.
INTRODUCTION
The extent o f lymph node métastasés has previously been shown to 
be one o f  the most important prognostic factors in gastric cancer without distant 
métastasés and the presence o f lymph node métastasés adversely affects the cure 
rate (1,2,3,4). Unfortunately the pattern o f lymphatic spread is reported to be 
unpredictable in many cases and evaluation o f nodes by palpation is believed to be 
unreliable^) л , the other hand there are some expected prognostic factors for 
lymph node metastasis o f gastric cancer (larger tumor size, deeper tumor 
invasion, diffuse histologic pattern, young age o f patients) reported in the
C o p y rig h t 1 9 9 4  b y  M o n d u z z i E d ito re  S  p  A. - B o lo g n a  (Italy) 1 7 3 3
N ew  D elhi, Ind ia 





literature (5,6,7). This retrospective study was performed to evaluate the 
incidence o f lymph node métastasés in gastric cancer and to assess the influence 
o f other clinocopathological variables on nodal involvement.
PATIENTS AND METHODS
For this retrospective study, we used data on 361 
patients who underwent curative surgery for primary gastric cancer at the Tartu 
Hospital o f  Oncology, Tartu, Estonia from 1978 through 1986. AJ1 the data were 
collected from case histories and from the database o f  the Estonian Cancer 
Registry. Macroscopic and microscopic evaluations were made according to the 
Japanese General Rules for the Gastric Cancer Study (8). There were 174 men 
and 187 women in our study. The mean age was 62.3, ranged from 31 to 85.
134 (37.1%) total and 227 (62.9%) subtotal gastrectomies were performed. In all 
cases the extensive lymph node dissection was used: R2 lymphadenectomy in 239 
(66.2 %) and R3 lymphadenectomy in 122 (33.8 %) cases. When the palpable 
changes in lymph nodes occured, the aim o f the dissection was to have a margin 
o f one uninvolved group o f lymph nodes distal to the most peripheral involved 
group o f node station.
The univariate analysis o f variance and multiple regression analysis by the 
"Statgraphics" program was used to determine the prognostic variables.
RESULTS AND CONCLUSIONS
In the present study the nodal involvement was found 
in 167 (46.3 %) patients. Métastasés limited with perigastric (N1) nodes 
presented in 51 (14.1 %) patients, the involvement up to N2 nodes was found in 
89 (24.7 %) and up to N3 nodes in 27 (7.5 %) cases. Lymph node involvement 
was diagnosed in 65.4 % o f patients who survived less than one year, in 57.8 % 
o f patients who survived less than three years and in 26.9 % o f cases with five 
year survival time (p<0.00001). The overall 5-year survival rate was 48.5 %. 5- 
year survival rate was 65 5 % for patients without lymph node métastasés, 43.1 % 
for patients with métastasés in perigastric nodes, 24.7 % for patients with 
métastasés in N2 nodes and 11.1 % for patients with métastasés in N3 nodes. The 
survival rates for both node positive and node negative cases are comparable with 
those reported in literature (2,3,9,10).
Table 1 shows the incidence o f  node negative and node positive cases for other 
clinical and pathological variables according to the univariate analysis. Lymph 
node métastasés occured more frequently in cases o f  muscularis propria or deeper 
invasion, tumor size more than 4 cm and infiltrative macroscopic type. The 
metastasizing potential o f gastric cancer is reported to be more active in the 
young (7), but we found the node positive cases more frequently in elderly (over 
70 year o f age) people than in younger ones. Multiple regression analysis 
indicated that the age o f  patients, Borrmann type and the extent o f  lymph node 
dissection were statistically the indipendent prognostic factors (Table 2). 
Although the Borrmann type is closely related to the degree o f  gastric wall 
invasion and tumor size, it was the only independent pathologic prognostic factor 
associated with lymph node status. In our study the univariate analysis shows the 
significantly different distribution o f node negative and node positive cases only 
when the Tl and T>1 tumors were compared. So we may conclude that the 
muscularis propria or deeper invasion o f primary tumor is associated with higher 
frequency o f  nodal involvement and the extensive lymphadenectomy is advisable
Table 1. The distribution o f cases without lymph node métastasés and with lymph 
node metastasis for different clinicopathological variables












<50 50 58.0 42.0
<0.001
50-59 94 63.4 36.6
60-69 104 57.0 43.0
70-79 103 41.7 58.3
>79 10 40.0 60.0
Sex
Men 174 53.4 46.6
NS
Women 187 55.1 44.9
T stage 
T1 29 89.7 10.3
<0.001
T2 54 53.7 46.3
T3 190 47.4 52.6
T4 88 58.0 42.0
Borrmann type 
I-II 177 61.1 38.9
<0.005
III-IV 184 46.5 53.5
Location 
lower third 187 54.0 46.0
NS
middle third 116 60.3 39.7
upper third 15 40.5 59.5
total 10 47.6 52.4
Histologic type 
differentiated 152 57.9 42.1
NS
undifferentiated 209 51.7 48.3
Size 
< 4 cm 54 85.2 14.8
<0.005
> 4 cm 307 48.9 51.1
Gastrectomy
total 134 49.3 50.7
NS
subtotal 227 57.3 42.7
Lymphadenectomy
R2 239 61.9 38.1
<0.00001
R3 122 41.3 58.7
in all these cases to prevent local recurrence. The incidence o f lymph node 
métastasés in early gastric cancer is commonly reported as less than 15 % 
(11,12). In present study there was 10.3 % of early tumors with nodal 
involvement.
The distribution o f lymph node negative and positive cases differed significantly in 
two groups o f  lymphadenectomy but not in patients who undewent gastrectomy 
with different extension. There was 38.1 % o f node positive cases in the group o f  
R2-lymphadenectomy and 58.7 % in the group o f R3-lymphadenectomy. Survival 
analysis showed the better 5-year survival rate after R2-lymphadenectomy (59.6
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Table 2. Multiple regression analvsis of variables associated with lymph node
métastasés
Variable Regression Standard P-value
coefficient error
Age 0.01 0.01 0.0399
Borrmann type 0.11 0.06 0.0023
Lymphadenectomy 1.04 0.13 0.0000
%) than after R3-dissection (30.8 %). These results likely are reflective o f  the 
extent o f  disease: most o f  the R3-lymphadenectomies were performed in cases o f 
extended nodal disease and were associated with more advanced primary tumors. 
Conclusions. The extensive (R2 or R3) lymph node dissection offers more benefit 
to the patients with either no or limited (N1) nodal disease. When tumors are 
large, invasive, and have infiltrative type o f growth, extensive lymph node 
dissection is essential. In the absence o f palpable abnormalities in lymph nodes, 
the cure results o f  gastric cancer can be improved by a wide prophylactic node 
dissection, particularly in the patients with elevated risk to lymph node 
métastasés. In patients with all these risk factors close follow-up is necessary
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Summary
The experience of the Department of Surgery of Oulu University Hospital, 
Finland in the treatment of 203 consecutive patients (129 men and 74 women, 
mean age 64.9 years) with primary gastric cancer during the 5-year period from 
1983 to 1987 is reviewed.
196 (96.6 %)  patients underwent surgery: radical gastrectomy with limited 
lymphadenectomy in 88 (43.3 %)  cases, palliative gastric resections in 47 (23.2 
%) cases and symptomatic bypass-procedures in 27 (13.3 %)  cases. 
Postoperative complications occurred more frequently after total than after 
subtotal gastrectomy. Overall postoperative mortality was 9.2 %. The 5-year 
survival was 21.1 % for all patients and 45.5 % for curatively operated patients. 
Univariate analysis indicated that tumor size, location, gross appearance, 
degree of gastric wall invasion, presence of lymph node and/or distant 
métastasés, and operative procedures were the significant prognostic factors of 
survival. In a Cox multivariate analysis only the T stage and presence of distant 
métastasés independently affected survival.
Our results show that beside the early detection the standardization of surgical 
procedures (extent of gastrectomy and lymphadenectomy) as well as the 
substantial decrease of postoperative complications and mortality rates have 
importance in the improvement of the outcome of surgery for gastric cancer.
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Introduction
Also the incidence of gastric cancer has markedly decreased during recent 
decades in Finland as in most industrialised countries, it still represents one of 
the leading causes of death from malignant disease. The population-based 
incidence of gastric cancer in Finland in 1955 was 65.4 per 100 000 in the male 
population and 37.7 per 100 000 in the female population, and in 1985 it was
21.4 and 11.0 per 100 000 respectively (11).
The disappointingly low survival rates even after potentially curative in the 
Western world are attributed to the late diagnosis and less aggressive surgery 
compered with approach used in Japan (7, 13, 14, 21). Only half the patients 
present with resectable tumor, and less than half of these are suitable for 
curative resection (3). Besides, the treatment of gastric carcinoma by general 
surgeons have shown results considerably poorer than those reported by special 
referral centres and the proportion of the patients who underwent apparently 
curative resection have been low (15 %) (1, 15).
This analysis of our institutional experience was performed to evaluate the 
influence of clinicopathological factors and operative procedures on the 
prognosis of patients with gastric cancer in general surgical practice in Oulu, 
Finland.
Patients and Methods
The current study is based on all 203 consecutive patients with histologically 
proved primary gastric cancer treated at the Department of Surgery of Oulu 
University Hospital during the 5-year period from 1983 to 1987. All the 
clinicopathological data were collected from case histories. The data about 
survival come from the database of the Finnish Cancer Registry. There were 
129 men and 74 women in our study with the male.female ratio of 1.74. The 
mean age was 64.9 and the median age 68, the age range was from 27 to 88. 
The histopathologic TNM staging was determined according to the UICC 1987 
year classification (6). Tumor location scale included the upper, middle and 
lower third or total location, involving more than two thirds of the stomach. 
Histologically, tumors were either of intestinal or diffuse type according to 
Lauren's classification (10), or of mixed type, representing patterns of both 
types. All pathologic specimens were re-examined by the same pathologist 
(H.T.). Macroscopical Borrmann types were described as circumscribed 
(polypoid or ulcerated types) and infiltrative (ulcerated tumor with partially 
infiltrating border or diffusely infiltrating tumor).
Conventional resection performed for gastric cancer at Oulu University 
Hospital was either the total or subtotal removal of the stomach and perigastric 
lymph nodes - nodes along the lesser and greater curvature, paracardial and 
parapyloric nodes, and nodes along the left gastric artery, i.e. R l-
lymphadenectomy according to the Japanese General Rules for the Gastric 
( ancer Study (8). Roux-en-Y method was applied to reconstruct the alimentary 
tract. In this study the gastric resection was classified radical if the lymph node 
involvement was restricted to the perigastric (N1) nodes, no tumor was left 
following the surgery, and no microscopical invasion in the resection margins 
was tound on the postsurgical histological examination. The minimal distance 
ot the upper resection margin in radical cases was 5 cm, however in infiltrative 
cases total gastrectomy was always performed. Postoperative mortality was 
defined as the number of deaths within the 30 days after surgery.
All clinical, surgical and pathological data of the patients were stored in a 
personal computer and the statistical data analysis was performed with the 
SPSS program of univariate and multivariate Cox regression analysis, the 
significance level was calculated with the chi-square distrubution formula.
Results
No data about preoperative symptoms were available in seven case histories. 
The average duration of symptoms presence was 6.5 months. Abdominal pain, 
dyspepsia and weight loss were the most commonest presenting symptoms 
(Table 1). The initial diagnosis for one patient was gastric perforation. The 
laboratory analyses showed serum haemoglobin level lower than 120 g/1 in 76 
(37.4 %) and hypoproteinaemia (serum albumin level lower than 40 g/1) in 92 
(45.3 %) patients.
The clinicopathological data of all the cases discussed are presented in Table 2. 
The lower third of the stomach appeared to be the most common location, 
invaded in 44.3 % of the cases, followed by the upper third (22.7 %), the 
middle third (21.1 %)  and the total involvement (11.8 %).  The distribution of 
macroscopic types of tumors showed the prevalence of infiltrative cases. The 
pathological examination found Lauren's intestinal type in 50.2 %, diffuse type 
in 35.0 % and mixed type in 14.8 % % of the cases. The ratio of the intestinal 
type to the diffuse type was 1.43. T l was found in 9.9 %, T2 in 16.8 %, T3 in
32.5 % and T4 in 39.4 % of the cases. The lymph nodes were involved in 49.3 
% of the cases. In 12.3 % of the cases the extent of nodal involvement could not 
be retrospectively established. Distant métastasés were diagnosed in 23.7 % of 
the patients.
196 (96.6 %)  patients of 203 underwent surgery (Table 3). Radical gastrectomy 
was performed in 88 (43.3 %), palliative gastric resections in 47 (23.2 %) and 
bypass-procedures in 27 (13.3 %)  cases. Lymphadenectomy up to the nodes 
along the left gastric artery was performed in all radical cases. In addition to the 
91 splenectomies other neighbouring organs had to be resected in 16 cases (the 
distal part of pancreas in 6 cases, the abdominal part of oesophagus in 5 cases, 
mesocolon in 2 cases, liver in 2 cases and colon transversum in 1 case). Six 
patients with the postoperative histological examination showing microscopic
residual tumors at the resection margins made up the subgroup of the palliative 
surgery. Chemotherapy (5-FU alone or FAM-combination) was administered in 
6 cases and radiotherapy (up to 40 Gy) in 8 cases, but only when relapse 
occurred.
Thirty two patients (16.3 %) had postoperative complications. General 
complications were recorded in 6 cases and surgical complications in 27 cases, 
anastomotic insufficiency (n=10), wound infection (n=5), intra-abdominal 
infection (n=4) and postoperative acute pancreatitis (n=4) were frequent. The 
complications occurred more frequently after total than after subtotal 
gastrectomy (Table 3). Overall postoperative mortality was 9.2 % (n=18), with 
10.2 % (n=9) after the radical operations and 17.0 % (n=8) after the palliative 
operations (Table 3). Splenectomy, preoperative anaemia, hypoalbuminaemia 
or weight loss had no significant influence on the postoperative course of our 
patients.
Table 2 shows the clinical and pathological data of the 88 patients radically 
operated on and the 108 patients not radically operated on. Those two groups 
differed significantly in depth of invasion, nodal status, Borrmann type and 
tumor size. However, the groups did not differ significantly as to the age and 
sex of the patients.
The overall 5-year survival for all patients was 21.1 %. The mean survival time 
was 34.5 months after curative resections, 15.7 months after palliative 
resection, 5.0 months after bypass procedures, 5.8 months after explorative 
laparotomy and 3.0 months after conservative treatment. There were only four 
patients alive after a year from a non-resective operations. The total 
gastrectomy adversely influenced the 5-year survival rates of patients both in 
curative and in palliative cases (Table 3). The 5-year survival rates influenced 
by the clinicopathological variables are shown in Table 2. Univariate analysis 
indicated that tumor size, location, gross appearance, degree of gastric wall 
invasion, presence of lymph node and distant métastasés, and radicality of 
operative procedures were the significant prognostic factors of survival. No 
significant relationship was found between the survival rates and the age or sex 
of patients, Lauren histopathological type or splenectomy performed with 
gastrectomy. In a Cox multivariate analysis of the eleven clinicopathological 
and treatment variables analysed by univariate analysis only T stage and 
presence of distant métastasés independently affected survival (Table 4).
Discussion
The mean age of patients with new cases of gastric cancer registered in Finland 
in 1985 was 68.4 years for males and 72.2 years for females (11). In 
comparison our male patients were 4.0 and female patients 6.7 years younger. 
There was no significant differences in the 5-year survival rates relative to the
age and sex of patients. The elderly patients in our study tolerated operation 
well, as it has also been reported by other researchers (4, 19).
Although by univariate analysis all the pathologic features of gastric cancer 
excepted Lauren type did have significant influence on the survival rates, 
multivariate analysis using the Cox model identified only two variables - T 
stage and M stage - as independent predictors of survival. The study has again 
demonstrated that the depth of gastric wall invasion is the most important factor 
predicting survival.
Comparison of the curability and resectability rates in our study with those in 
other European hospitals revealed that our approach to gastric cancer therapy 
was justifiably aggressive (12, 15, 16, 22). Although only 3.4 % of the patient 
did not undergo surgery, in more than half of those who did, potentially 
curative resection was not feasible. Considering the 5-year survival rate in T1 
(85.0 %) and T2 cases (50.0 %)  our results seem to be satisfactory, however the 
results with T3 and T4 cases (5-year survival 12.1 % and 1.3 % respectively) 
leave much room for improvement. Moreover, the cases with a good prognosis 
represented a small proportion of all cases and therefore both the diagnosis and 
treatment of gastric cancer remains an important problem.
The prognosis for patients who had undergone total gastrectomy was worse 
compared with subtotally gastrectomized patients both in curative and in 
palliative cases (Table 3). However, it is not necessary caused by the type of 
operation but rather by the fact that the tumors were more advanced in these 
patients. On the other hand the surgical technique chosen significantly 
influences the complication and mortality rates. The high complication rates by 
palliative or curative total gastrectomy (28.6 % and 22.0 % respectively) and 
the high mortality rate after pallitive total gastrectomy (17.9 %)  are matters of 
serious concern. Too much anastomotic leakages and infectious complications 
were associated with these procedures. Nevertheless we consider that the 
overall postoperative mortality rate of 9.2 % is acceptable as it compares 
favourably with figures of 7 to 26.9 % in other Western countries (1, 22). 
Limited lymphadenectomy was routinely performed. Our results are easily 
comparable to those in contemporary Western hospitals where gastrectomy is 
performed without extended lymphadenectomy, but they are inferior to those in 
centres where extensive lymph node dissection is routinely practised (1, 2, 4, 5,
12, 15, 18, 20). In our study there were no lymph node métastasés in the T1 
cases, which correlates well with the high cure rate of those cases. The survival 
rates for limited node dissection in node positive cases, also low, are 
comparable with those reported in literature, but the 5-year survival in node 
negative cases (43.6 %)  might be higher. The results confirm that for both the 
cases with and without nodal involvement more extensive lymphadenectomy 
might be instrumental in effecting a cure. Besides, extensive lymphadenectomy 
made in the absence of palpable abnormality may by of importance in
3 2
establishing N stages accurately and may results in a higher prevalence of 
patients with lymph node micrometastases. However, it is difficult to analyse 
the importance of lymph node dissection in this retrospective study.
Although palliative resection for gastric cancer is mainly indicated to improve 
the quality of the patients remaining life by reducing the danger of 
complications (17), it also offers a possibility of longer survival for patients 
who cannot undergo radical surgery. In our study 6.4 % of the patients were 
alive five years after palliative resection. We agree with D.Korenaga, et al.,
1988 (9), who think that the resection palliative due to the presence of various 
incurable factors still seems preferable to laparotomy alone or 
gastrojejunostomy.
The effect of splenectomy on survival after resection for gastric cancer is not 
generally agreed upon (18). The results of our study indicate that splenectomy, 
performed with curative or palliative gastrectomy, did not significantly 
influence the postoperative complications, neither did not increase the survival 
rates as possible warrantor of more radical lymphadenectomy. The latter fact 
may be caused by the limited dissection in other nodal groups. So at present we 
have preferred to save the spleen by radical gastrectomies whenever possible.
Conclusions
For all patients with gastric cancer the T stage and presence of distant 
métastasés were the most important factors predicting. Our results indicate that 
to decrease the complications rate, subtotal resection should be preferred in 
cases of circumscribed tumors with location in the distal or middle third, total 
gastrectomy should be reserved for infiltrative tumors. To evaluate the 
importance of lymphadenectomy with different extention the prospective 
randomized study should be initiated. Palliative resection is to be preferred to 
gastrojejunostomy for incurable cases as it results in a longer mean survival.
Table 1. Symptoms and findings at admission
Symptom No. of cases %
Pain 123 62.8
Dyspepsia 107 54.6
Weight loss 80 40.8
Bleeding 49 25.0
Vomiting 46 23.5
General dyscomfort 40 20.4
Palpable tumor 28 14.3
Dysphagia 17 8.7
Anorexia 11 5.6
Gastric perforation 1 0.5













male 129 (63.5) 52(59.1) 71 (65.7) 20.2
female 74 (36.5) 36 (40.9) 37 (34.3) 23.0
Age NS NS
< 70 116(57.1) 56 (63.6) 57 (52.8) 25.0
>69 87 (42.9) 32 (36.4) 51 (47.2) 16.1
T stage <0.01 <0.01
T1 20 (9.9) 20 (22.7) 0 85.0
T2 34 (16.8) 31 (35.3) 3 ( .2.8) 50.0
T3 66 (32.5) 37 (42.0) 29 (26.9) 12.1
T4 80(39.4) 0 76 (70.3) 1.3
N stage <0.01 <0.01
N0 78 (38.4) 67 (76.1) 11 (12.4) 43.6
N1 32 (15.8) 21 (23.9) 11 (12.4) 21.9
N2 68 (33.5) 0 68 (75.2) 2.9
M stage <0.01 <0.01
MO 153 (75.4) 88 (100.0) 64 (59.3) 28.1
Ml 48 (23.7) 0 44 (40.7) 0.0
Location NS <0.05
Lower 90 (44.3) 40 (45.5) 49 (45.4) 25.6
Middle 43 (21.1) 22 (25.0) 20(18.5) 27.9
Upper 46 (22.7) 22 (25.0) 20(18.5) 17.4
Total 24(11.8) 4(4.5) 19 (17.6) 0.0
Borrmann <0.01 <0.01
I-II 92 (45.3) 69 (78.4) 22 (20.4) 43.5
III-IV 111 (54.7) 19(21.6) 86 (79.6) 2.7
Size <0.01 <0.01
<4 cm 27 (13.3) 27 (30.7) 0 81.5
4-7 cm 66 (32.5) 12(13.6) 20 (42.6) 15.6
>12 cm 10(4.9) 2 (2.3) 8 (17.0) 0.0
Lauren NS NS
Intestinal 102 (50.2) 52(59.1) 50 (43.5) 24.5
Diffuse 71 (35.0) 24 (27.3) 47 (40.9) 15.5














yes 91 (61 A f 63 (71.6) 28 (59.6) 29.4
no 44 (32.6)a 25 (28.4) 19 (40.4) 36.4
Resection — <0.01
curative 88 (43.3) 88 (100.0) — 45.5
palliative 47 (23.2) — 47 (43.5) 6.4
no 68 (33.5) — 61 (56.5) 0.0
t - significance for curability; t - significance for 5-year survival rates; * - not 
significant;a - % from all the resections
Table 3. 5-vear survival, postoperative complications and mortality after different types 
of surgery.





curative resection 88 14(15.9% ) 9(10 .2% ) 45.5
total gastrectomy 59 13 (22.0%) 6(10.2 %) 39.0
subtotal 29 1 ( 3.4 %) 3 (10.3 %) 58.6
gastrectomy
palliative 47 11 (23.4 %) 8(17.0% ) 6.4
resection
total gastrectomy 28 8 (28.6 %) 5 (17.9 %) 3.6
subtotal 19 3 (15.8 %) 3 (15.8 %) 10.5
gastrectomy
bypass procedures 27 1 (3.7 %) 1 (3.7 %) 0.0
exploratory 34 1 (2.9 %) 0 — 0.0
laparotomy
Table 4. Cox regression analysis o f factors affecting survival
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Andrus Arak Karl Kull
maovfihk, regionaalne m etastaseerum ine, 
laiendatud lüm fadenektoom ia
Mitme vähilokalisatsiooni puhul on 
edukas kemo- ja  immunoteraapia, hor- 
moon- ja  kiiritusravi vähendanud ulatus­
like kirurgiliste manipulatsioonide vaja­
dust. Radikaalses maovähi ravis on need 
ainult täiendmeetoditeks, kuid ainsaks 
edu tagavaks ravi viisiks on siiski jäänud 
kasvaja täielik eemaldamine. Epiteliaal- 
sete pahaloomuliste kasvajate puhul on 
onkoloogiliste operatsioonide põhinõu- 
d f . K S  haiguse algkolde laialdane ekstsi- 
sioon tervete kudede piires koos regio­
naalse lümfisoonte ja  -sõlmede võrgustiku 
eemaldamisega ühtse blokina. Ü ldtun­
nustatud seisukoha järgi tuleb maovähi 
algkolle eemaldada piisavas kauguses 
kasvaja makroskoopilisest piirist ja  kas- 
vajarakkudest vaba resektsioonijoon on 
üks olulisi haigete prognoosi mõjutavaid 
faktoreid. Nii peetakse maovähi infiltra- 
tiivsete vormide korral radikaalseks ope­
ratsiooniks ainult gastrektoomiat, kuna 
antrum i eksofüütsete kasvajate ravis on 
õigustatud ka mao distaalne subtotaalne 
resektsioon (12, 29). Ka magu üm britse­
vate lümfisõlmede eemaldamise vajadu­
ses ollakse enamasti veendunud, kuid sel-
A/idrus Arak, Karl Kull — Turlu Ülikooli Rudioloo- 
gia ja  Onkoloogia Kliinik
le ulatuse osas lähevad arvamused tublis­
ti lahku. Kuigi maovähki haigestumine 
kogu maailmas järjekindlalt väheneb, on 
ta kasvajatest tingitud surm a põhjustest 
esimeste seas enam ikus lääneriikides, 
kus seda haigust põdejate viie aasta elu­
lemus püsib 5... 10% piires (12). Radikaal­
selt opereeritute väljavaated on pisut pa­
remad: neist elab üle 5 aasta Euroopas
35...40% ja  Jaapanis 60...75%, varase 
maovähi opereerimisel on elulemus aga 
100% lähedane (2, 9, 29, 31, 34). Tabelis
1 on näitena esitatud 100 maovähihaige 
elulemust käsitleva artikli ülevaade (2).
Tabel 1. M aovähihaigete radikaalne kirurgili 




Uuringuseeriaid 15 85 100
Haigeid kokku 19048 80738 99786
neist opereeritud (%) 99,8 74,1 79,0
Radikaalseid
operatsioone (%) 58,6 17,8 25,6
viie aasta elulemus
pärast radikaalseid
operatsioone (%) 60,5 39,4 52,2
Jaapan on ainus riik, kus maovähisure- 
muse vähendamine on kiirem kui -haiges­
tumuse vähenemine (12). Võimalikke bio­
loogilisi erinevusi Jaapanis ja Läänes esi­
neva maovähi vahel on raske määratleda. 
Mõnel pool esitatud intestinaalse ja  di­
fuusse vormi esinemissageduse mõninga­
ne erinevus eri geograafilistes piirkonda­
des ei mõjuta ravitulemusi nii olulisel 
määral, kui need tegelikult erinevad (22, 
25). Samal ajal on aga täheldatud maovä- 
hipuhuse lümfisõlmede metastaatilise 
kahjustuse sarnasust Jaapanis ja Euroo­
pa riikides (28).
Maovähi ravi tunduvalt paremad tule­
mused Jaapanis on tingitud ühelt poolt 
edukalt tehtavatest sõeluuringutest, mis 
on seal viimase 15 aastaga tõstnud vara­
jase maovähi osatähtsuse 5%-lt peaaegu 
50%-ni (23, 34), teiselt poolt aga ühtse me­
toodikaga laiendatud lümfadenektoomia 
järjekindlast kasutam isest rohkem kui 20 
aasta  vältel (20, 29).
Jaapanlased toovad olulise eelisena esi­
le oma haigete suhteliselt noorema eluea
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ja  väiksema kehakaalu. Kõhnadel ja  «ma­
dala» kõhuõõnega haigetel on võimalik 
hea juurdepääs magu ümbritsevatele 
lümfiteedele; noorematel haigetel esineb 
harvem raskeid kaasnevaid elutähtsate 
elundite häireid. Kõik see võimaldab ju l­
gemini teha laiendatud operatsioone, mil­
le puhul ka operatsioonijärgne letaalsus 
on minimaalne, mitte üle 2...3%  (2, 29). 
Haigete suurema kehakaaluga kaasnev 
pikem operatsiooniaeg, keskmisest suu­
rem verekaotus ja  komplikatsioonide arv 
ning sagedam kaasnevate haiguste esine­
mine põhjustavad suurema suremuse pä­
rast operatsiooni ja  on põhjuseks, miks 
laiendatud lümfadenektoomia põhimõtted 
on läänemaailmas visad juurdum a (5, 8, 
10, 28). Suures operatsioonijärgses letaal- 
suses ei ole «süüdi» ainult haiged. On lei­
tud, et ravitulemuste erinevus sõltub ka 
sellest, kas laiendatud lümfadenektoomia 
metoodika on omandatud omal käel või 
kogenud (Jaapani) kirurgide juhendam i­
sel (8).
Ulatuslikul morfoloogilisel materjalil 
põhinev ja  kõikides Jaapani kirurgiakes- 
kustes ühesugustel põhimõtetel kasuta­
tav lümfadenektoomia metoodika maovä­
hi kirurgilises ravis on veenvalt tõestanud 
oma efektiivsust eemaldatud lümfisõlme­
de hulga suurenemise ja  ravitulem uste 
paranemise omavahelise sõltuvuse kaudu 
(vt. tabel 2) (3, 34).
Tabel 2. L üm fisõlm ede eem aldam ise ja  ravitu­
lem uste paranem ise seos
Lümfadenek- Ajavahemik
toomiat
iseloomustav 1961... 1971... 1976... 1981...
näitaja 1970 1975 1980 198Г)
Lümfisõlmede arv prepa­
raadis (keskmiselt) 29,7 31,1 33,8 37,9
M etastaasidega





aasta  elulemus (ü) 35,2 42,1 49,6 -
Lümfisõlmede süsteemikindla eemal­
damise aluseks on lümfivoolu iseärasuste 
tundm ine ning m etastaseerum ise põhja­
lik ja  ulatuslikul kliinilisel m aterjalil põ­
hinev analüüs (29). Magu üm britsevad 
lümfisõlmed on süsteemselt rühm itatud. 
Meie kliinilises praktikas kasutusel oleva 
TNM-süsteemi N-kategooria kõrval on 
teine enam kasutatav ja  tunduvalt täp­
sem jaotus esitatud Jaapani Maovähi 
Uuringute Ühingu (Japan Research So­
ciety of Gastric Cancer — JRSGC) poolt 
(18). Selle järgi jaotatakse magu üm brit­
sevad lümfisõlmed 16 gruppi (vt. tabel 3, 
joonis 1), millest suur osa langeb kokku 
magu toitvate arteritega. Need grupid 
koondatakse nelja N-rühma vastavalt 
nende kaugusele kasvaja algkoldest ja 
sõltuvalt viimase lokalisatsioonist on gru­
pi asukoht N-süsteemis erinev (vt. tabel 
3).
Tabel 3. M aoüm bruse lüm fisõlm ede rühm itus
Lümfisõlmede grupp Kasvaja algkolde asukoht maos
ant- kor- kar- to- 
rum pus dia taalne
N2 N1









N3 N 2 ___________ __
N3





takse kaugmetastaasidoKS N3-sõlmedesr 
kaugemal paiknevaid (N4) lümfogeenseid 
m etastaase, TNM-klassifikatsioonis aga 
on nendeks kõik intraabdominaalsed me- 
tastaasid, mis ei paikne perigastrilistes,
a. gastrica sinistra, a. hepatica commu- 
nis’e, a. lienalis'e või truncus coeliacus'e 
piirkonna lümfisõlmedes (13, 18). Seegi 
erinevus tundub olevat lümfadenektoo­
mia ulatusse erineva suhtum ise väljendu­
seks.
1 . . . 6 . grupi lümfisõlmi nim etatakse pe- 







Gastrica sin. p/k 
A  hepatica comm. p/k 
Truncus coeliacus’e p/k 
Põrnavärat 
A. lienalis’e p/k 
Hepatoduodenaalne 
Retropankreaatiline 
A. mesenterial sup. p/k 
A. colica med. p/k 
Paraaortaalne
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ses sõltuvuses kasvaja lokalisatsioonist 
maos. Nii on 1. ja  2. grupi lümfisõlmedes 
m etastaase vastavalt kuni 25%-l ja  10%-1 
haigetest, valdavalt kardiavähi korral, 
kuid ka kuni 10% mao antraalosa kasva­
ja test annab sinna metastaase. 3. grupi 
puhul olulist erinevust sõltuvalt lokalisat­
sioonist ei ole, siirdeid on kuni pooltel hai­
getest. 4. grupi kahjustust esineb 1/3-1 
haigetest, kardiavähi puhul üle kahe kor­
ra harvemini kui teiste lokalisatsioonide 
puhul. 5. ja  6. grupi lümfisõlmed on küll 
antrum ivähi m etastaseerum ise eelispai- 
gaks, vastavalt kuni 20%-l ja  50%-l juh tu ­
dest, kuid ka kuni 5% kardia-ja 15% kor- 
pusekasvajatest võivad sinna siirdeid 
anda.
7. grupi lümfisõlmede kahjustust esi­
neb kuni 35%-l haigetest; nende meta- 
staaside algkoldeks on peaaegu võrdväär­
selt kõik lokalisatsioonid; m etastaase esi­
neb seal 85%-1 haigetest, kellel on 
metastaase väikese maokõveriku lümfi­
sõlmedes, ja  7. grupi metastaasidega juh ­
tudest omakorda on 43%-l siirdeid ka 9. 
grupi lümfisõlmedes. 8. grupi kahjustusi 
täheldatakse umbes 25%-l juhtudest, alg­
koldeks on 50%-l antrum i-, 35%-l korpu­
se-ja  15%-1 kardiavähk. 9. grupi kahjus­
tust esineb 20%-l haigetest, metastaaside 
algkoldeks võivad võrdselt olla kõik loka­
lisatsioonid.
10. ja  11. grupi lümfisõlmedes esinevad 
metastaasid 10...12%-1 juhtudest, ena­
masti on need pärit võrdselt kas mao kar­
dia- või korpuseosast, kuid ka 4...6% ant- 
rumivähkidest annab siia siirdeid. Meta­
staaside esinemine neis gruppides on 
prognostiliselt halb näitaja. 12. grupi 
lümfisõlmede kahjustust tuleb ette alla 
10%-1 juhtudest, algkoldeks enam kui 
60%-l on antraalosa vähk; 8. grupi metas­
taaside korral on seal siirdeid 70%-l juh ­
tudest; see piirkond on sageli vaheetapiks 
3-ndast 13. gruppi. Prognostiliselt peetak­
se 12. gruppi parem aks kui 10... 11. grup­
pi ja  seetõttu on siit lümfisõlmede eemal­
damine väga oluline. 13... 15. grupis on 
m etastaase kuni 5%-l haigusjuhtudest, 
13. grupile on iseloomulik sage korrelee- 
rumine 6. grupiga. 16. grupp, s.o. paraaor-
taalsed lümfisõlmed, on viimane resetsee- 
ritav intraabdominaalne lümfisõlmede 
grupp, kuhu koonduvad maolt tulevad 
lümfiteed piki truncus coeliacus'e, a. me- 
senterica superior i ja  teiste arterite kul­
gu. Kahjustusi esineb seal kuni 8%-l radi­
kaalselt opereeritutest elulemusega kuni
2 aasta t (3, 6, 28, 30, 32).
Lümfogeenseid m etastaase perigastri- 
liste lümfisõlmede kahjustuseta leitakse 
vaid mõnel protsendil juhtudest, enam as­
ti a. gastrica sinistm , a. hepatica commu- 
ms’e ja a .  lienalis’e piirkonnas. N ähtavas­
ti ei ole sellistel juhtudel tegemist tõelis­
te nn. sßip*-metastaasidega, nagu seda on 
kirjeldatud mõne muu vähilokalisatsiooni 
puhul, vaid nende levik on toimunud aa. 
gastricae breves'eid või a. gastrica poste­
riori saatvate lümfiteede kaudu (28). See­
ga on maovähi lümfogeense m etastasee­
rumise puhul valdavalt tegemist kindlate 
seaduspärasustega, mida teadlikult ära 
kasutades on võimalik ravi tulemusi pa­
randada.
Edukalt kasutatakse lümfadenektoo- 
mia operatsioonieelset planeerimist per­
sonaalarvutil, kus patsiendi sugu ja  va­
nust, sam uti kasvajat iseloomustavaid 
näitajaid ning varasemate operatsiooni- 
leidude analüüsi arvestades koostatakse 
igal haigusjuhul oletatava m etastaseeru­
mise skeem ja  haiget opereeritakse selle­
le vastavalt (21). Sellise analüüsi kasu ta­
mine annab võimaluse makroskoopiliste 
metastaaside puudumise korral m itte pi­
dada rangelt kinni lümfadenektoomia 
tüüpoperatsioonide printsiipidest ja  
eemaldada vaid need lümfisõlmede gru­
pid, millesse metastaseerum ine on tõe­
näoline. Enamasti on niisugused katsetu­
sed siiski tiivustatud rohkem soovist püü­
da operatsiooni ulatuse vähendamisega 
vähendada kõrget operatsioonijärgset su ­
remust, kui parandada ravitulemusi.
M etastaaside olemasolu määram ist
* skip-m etastaas: skip (inglise k.) — ülehüpe, vahe­
lejätmine; s. o. siire, mis esineb kasvaja algkoldest 
kaugel lümfisõlmes samaaegse vahetult kasvajat 
üm britsevate (antud juhul perigastriliste) sõlmede 
kahjutuseta; on lümfisõlmede baijäärfunktsiooni a r ­
vestades raskesti seletatav.
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Joon is. Mao reg io n a a lse te  lüm fisõlm ede grupid.
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palpatsiooni teel ei peeta kuigi usaldus­
väärseks ja  soovitatavaks meetodiks nii 
valepositiivse kui valenegatiivse leiu suu­
re tõenäosuse tõttu (3). Lümfisõlmede 
kahjustuse täpsem aks määramiseks ka­
su tatakse laialdaselt operatsiooniaegset 
kiiruuringut. Seda ei pea mitmed autorid 
sam uti õigeks ühelt poolt kasvajarakkude 
leviku ohu tõttu (6, 33), teiselt poolt an ­
nab niisugune m etastaaside juhuslik otsi­
mine väga suure eksimise võimaluse mik- 
rom etastaaside esinemise tõttu makro­
skoopiliselt m uutum atutes lümfisõlmedes
— neid võib olla kuni 20%-l haigusjuhtu­
dest (15, 20). Oluline on meeles pidada, et 
samal ajal kui lümfisõlmede metastaase 
esineb keskmiselt 50...60%-l hematogeen- 
sete kaugm etastaasideta haigetest, piir­
dub kasvajarakkudega lümfisõlmede arv 
enamasti 2.,.8-ръ. (6, 27, 32, 34). Lihtne 
loogika ütleb, et mida rohkem lümfisõlmi 
eemaldada, seda rohkem varjatud metas­
taase on võimalik avastada. Tehes näili­
selt varajase (makroskoopiliselt vaikese 
algkoldega) maovähi puhul laiendatud 
lümfadenektoomia, võime avastada hoo­
piski II staadium i vähi (Tl N2 MO — 
UICC TNM-klassifikatsiooni järgi).
Laiendatud lümfadenektoomia all 
mõistetakse kõikide maost lähtuvate lüm- 
fiteede ja  -sõlmede eemaldamist koos 
kogu neid ümbritseva rasvkoega ühtse 
blokina kasvajast haaratud maoga (või 
selle osaga), arvestades magu ümbritse­
vate fastsiate ja  serooskelmete struktuuri 
(30). Lümfadenektoomia ulatusest ehk ra­
dikaalsusest (R) sõltuvalt jaotatakse mao­
vähi puhul tehtavad operatsioonid viide 
kategooriasse: RO on operatsioon, mille 
puhul eem aldatakse osaliselt Nl-lümfi- 
sõlmed, R1 tähistab N1-sõlmede, R2 — 
N l- ja  N2-sõlmede, R3 — N1-, N 2-ja N3- 
sõlmede ja  R4 — N1-, N2-, N3- ja  N4-sõl- 
mede täielikku eemaldamist.
Radikaalseks peetakse operatsioone lümf­
adenektoomia ulatusega R2-st kuni R4-ni 
ja need on Jaapanis maovähi ravis kasu­
tatavate operatsioonide obligatoorseks 
koostisosaks. RO- ja  Rl-resektsioonid on 
õigustatud ainult eakatel, suure riskiga 
haigetel ja  neid ei peeta radikaalseks (18 ).
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Laiendatud lümfadenektoomiat a lu sta­
takse lig. gastrocolic uni i eemaldamisega 
koos mesocolon transuersunii pindmise 
lestmega. Mao ülemist poolt toitva, lig. 
gastropancreaticum  is kulgeva a. gastrica  
sinistra  ligeerimine vahetult tema välju­
miskohas truncus coeliacus'est võimaldab 
eemaldada selle, m etastaseerumise seisu­
kohalt nii ohtliku sideme täielikult. Mao 
alumise osa verevarustus toimub peami­
selt a. hepatica communis'e kaudu. Selles 
piirkonnas on oluline eemaldada lig. he­
patogastric urrii ja  lig. hepatoduodenale 
kogu koestik, säilitades a. hepatica coni- 
m unis’e, v. portae ja  ühissapijuha. Duo- 
deenumi mobiliseerimine ja  foramen 
Winslow laiendamine annavad hea või­
maluse põhjalikuks lümfadenektoomiaks. 
Edasi eemaldatakse pankreast kattev p e­
ritoneum  (nn. omentobursektoomia). 
Järgmiseks sammuks on kõhunäärme 
distaalosa ja  põrna mobiliseerimine me- 
senteriaaltüve, a. linealis’e ja  põrnavära- 
ti piirkonna lümfisõlmede eemaldami­
seks. Paljud, eriti Jaapani autorid, soovi­
tavad põhjaliku lümfadenektoomia 
huvides eemaldada lisaks veel põrna ja 
kõhunäärme distaalosa. See on vajalik ka 
juurdepääsuks paraaortaalsetele lümfi- 
sõlmedele R4-resektsiooni korral. Põrna 
eemaldamine on tekitanud rohkeid vaid­
lusi, selle põhjuseks on mõnel pool leitud 
splenektoomiaga kaasnev madal elule­
mus. Siiski ei ole elulemust vähendavaks 
teguriks neil juhtudel mitte splenektoo- 
mia ise, vaid asjaolu, et see m anipulat­
sioon võetakse ette rohkem ulatuslike, 
põrnaväratisse m etastaseerunud kasvaja­
te korral. Lisaks nendele piirkondadele 
tuleb kindlasti eemaldada ka mõlema­
poolselt parakardiaalne kude, mis on teh ­
niliselt võimalik nii gastrektoomia kui ka 
distaalse subtotaalse maoresektsioom 
korral (14, 16, 26, 29, 30).
Oluline on seos maovähi algkolde inva- 
sioonisügavuse ja lümfogeense m etasta­
seerumise ning lümfadenektoomia vahel. 
Varajase maovähi puhul 011 tähele pan­
dud, et submukooskoe invasiooni korral 
on m etastaaside esinemissagedus suurem  
kui limaskestaga piirduva vähi korral, ol-
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les vastavalt 20% ja  alla 5% (31, 34). Sel­
lise erinevuse morfoloogiliseks aluseks 
peetakse m etastaseerumiseks piisava 
laiusega lümfiteede paiknemist maoseina 
submukooskoes ja sügavamal, kuna li­
m askesta pindmine ja keskmine kiht lüm- 
fikapillaare ei sisalda (24). Ravitaktika 
valik sel juhul aga eeldab kasvaja inva­
sioonisügavuse m ääram ist endosonograa- 
filiselt koos morfoloogilise materjali üli­
täpse võtmisega, mis isegi paljude arene­
nud riikide juhtivates ravikeskustes ei ole 
veel rutiiniks muutunud (11, 31, 35, 36). 
Selliste võimaluste olemasolul võiks ain­
saks erandiks olla limaskestaga piirduv 
nn. kergitatud int.estinaalset tüüpi vara­
jane maovähk, mille korral lümfogeenseid 
m etastaase tuleb ette üliharva ja  ravitu- 
lemused H i- ja  laiendatud resektsioonide 
korral oluliselt ei erine (17, 23). Muudel 
juhtudel on ka varajase maovähi korral 
kasvaja taas tekke j>eamise põhjusena he- 
matogeensete maksametastaaside kõrval 
täheldatud ebapiisavast lümfadenektoo- 
miast säilinud lümfogeensete mikrome- 
tastaaside arengut (6). Seetõttu peetakse 
ka sel juhul vajalikuks vähemalt R2-re- 
sektsiooni (6, lõ, 19, 35).
Vaidlusaluseks küsimuseks on laienda­
tud lümfadenektoomia otstarbekus kas­
vaja invasiooni korral mao serooskihisse. 
Juhtudel, kui operatsiooni eel või ajal on 
tekkinud serooskihi kahjustuse kahtlus, 
soovitatakse peritoneaaivedelikku tsüto- 
loogiliselt. uurida. Selleks pestakse kõ- 
huõõnt kohe pärast avamist 100...200 ml 
füsioloogilise lahusega temperatuuril 
37°C. tagasi aspireeritakse 50 ml loputus- 
vedelikku, mis kohe tsentrifüugitakse ja  
sademest valmistatakse äigepreparaadid 
kiiruuringuks. Selline meetod näitab int- 
raperitoneaalsete vabade vähirakkude 
olemasolu umbes 20%-l haigetest, kellel 
makroskoopiliselt mao serooskihi kahjus­
tust ei täheklata (7). Lümfogeensete me- 
tastaaside esinemissagedus suureneb 
koos serooskihi kahjustuse ulatusega. 
Niisugune seos kehtib kõikides 16 lümfi­
sõlmede gruppides ja ka kõikides N-etap­
pides (4. 28). Nii on mao serooskihi alga-
"{)
va invasiooni korral m etastaase lümfisõl- 
medes leitud 53...65%-\ juhtudest, m ärga­
tava invasiooni korral umbes 80%-l ja 
naaberelunditesse sissekasvu korral üle 
90%-' haigetest (7, 32, 34). Serooskihi 
kahjustuse korral peetakse haiguse ope­
ratsioonijärgse varajase taastekke peami­
seks põhjuseks peritoneaalseid implan- 
tatsioonimetastaase, mis jäävad väljapoo­
le kirurgilist ravimeetodit ja  sel juhul 
kaheldakse lümfadenektoomia otstarbe­
kuses. Siiski näitavad ravitulemused sel­
le meetodi efektiivsust juhtudel, kui mao 
serooskihi invasioon kasvajast on algjär­
gus ja  lümfisõlme kahjustus piirdub N1- 
rühmaga (20,34). Ulatuslikumal maosei­
na väliskihi haaratusel (iile 3 cm) (1,7) 
aga lümfadenektoomia enam ravitulemu- 
si ei paranda. Sellise maovähi ravis pan­
nakse suuri lootusi operatsiooniaegsele ja 
varajasele operatsioonijärgsele intraperi- 
toneaalsele kemoteraapiale (37)
Andmed muude maovähki iseloomusta­
vate näitajate (makroskoopiline kasvu- 
vorm, histoloogiline ehitus, kasvaja suu­
rus) mõju kohta lümfogeensele metasta- 
seerumisele on vastukäivad (21, 23, 27, 
28, 29, 30, 31, 34' ja  liimfadenektomia 
ulatuse planeerimine nendest lähtuvalt ei 
ole õigustatud.
Järeldused.
1. Et kem oteraapiaja muud m ittekirur- 
gilised ravimeetodid ei oie maovähihaige- 
te elulemust oluliselt parandanud, jääb  
selle haiguse ravi valikmeetodiks kasvaja 
radikaalne eemaldamine.
2. Et. lümfogeense m etastaseerum ise 
hindamine ravi eel ja  ajal on raske, kuid 
samal ajal on haiguse retsidiveorumi.se 
peapõhjuseks regionaalsed metastaasid, 
tuleb laiendatud lümfadenektoomiat pi­
dada maovähi kirurgilist* ravi lahutam a­
tuks osaks ja  ravi tulem uste peamiseks 
parandajaks.
3. Magu ümbritseva lümfivõrgustiku 
rikkaliku anastomoseerumise ja meta- 
staaside põhjustatud takistustest tingitud 
retrograadse lümfivoolu tõttu peab laien­
datud lümfadenektoomia haaram a kõiki 
lümfogeense? m etastaseerum ise piirkondi.
sõltum ata kasvaja algkolde asukohast 
maos.
4. Enam ikus Euroopa riikides ja  ilmselt 
ka Eestis on laiendatud lümfadenektoo- 
miast hoidutud kõrge operatsioonijärgse 
letaalsuse tõttu. Seda on võimalik vähen­
dada haigete operatsioonieelse etteval­
mistamise parandam isega ühelt poolt, tei­
salt selle operatsiooni sooritamisega 
ainult kõrge professionaalsusega, operat- 
sioonitehnikat hästi valdavate kirurgide 
poolt.
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Summary
Extended lym phadenectom y in gastric  
cancer surgery. In this review of publications the 
therapeutic value of extended regional lym phaden­
ectomy for gastric cancer has been analysed. Japan 
is the only country where the decline of mortality 
due to gastric cancer is faster than  the decline of in­
cidence. Japanese surgeons consider their success to 
be in early detection and extended lyniphadenec- 
tomv.
The Japanese classification (JRSGC) of gastric re­
gional lymph node stations, the frequency of their 
m etastatic involvement and the systemic lymph 
node dissection technique have been shortly De­
scribed.
Most of the studies indicate th at the extensive 
lymphadenectomy improves the results of gastric 
cancer treatm ent and can be safely performed in all 
cases by propely trained surgeons without increas­
ing surgical mortality.
Kommentaar
Ülevaateartiklis käsitlem ist leidev 
probleem on ülimalt aktuaalne, kuna 
maovähi kirurgiline ravi on otsustavaks 
ravi või maiuseks. Operatsiooni metoodika 
ja  radikaalsus määravad haige elulemu- 
se. Autorid on analüüsivalt esitanud nüü­
disaja kirjanduse seisukohad selles küsi­
muses. eriti hinnatav on jaapani koolkon­
na ülevaatlik esitamine, mis on 
nimetatud probleemi alal juhtiv  m aail­
mas.
Väino Rätsep — Eksperim entaalse /a 
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Sum m ary
E esti A rst, 1994, 6, 476—483
A daption w ith rem ovable dentures: the c lin i­
cal study. An investigation of removable dentures 
(RD) wearers with protheses covering of hard palate 
after one year using period were examined clinically, 
including biomechanical param eters and adaptional 
difficulties. Only correlation between above m en­
tioned sign groups, the negative relation of general 
stability of denture to shewing ability was found. 
Correlation between occlusal stability and retention 
would be interpreted as the necessity to the construct 
of bilaterally balanced occlusion for dentures with 
free-end saddles, for preservation of retention ability. 
The relation of patients with signs of erythema in 
some type of edentulism/denture is caused ra ther by 
denture design with worse hygien contition then con­
struction difference.
Teade
«Eesti Arsti» 1994. a as ta  4. num bris ilm us 
T artu  Ülikooli Füüsilise Antropoloogia K esku­
se teade jaoskonnaarstidele  (perearstidele), e t 
TÜ A rstide ja  Proviisorite T äienduskeskuse 
kaudu  hakkab  Füüsilise Antropoloogia K eskus 
korra ldam a tä ienduskursusi «M editsiinilise ja  
an tropom eetrilise andm estiku  töötlus arvutil».
N üüd on koostatud TÜ A rstide j a  Proviiso­
rite  T äienduskeskuse tööplaan jä rg m isek s a a s ­
taks. Need kursused  toim uvad 6 ... 10. m ärtsin i 
1995 (I tsükkel) ja  6...10. novem brini 1995 (II 
tsükkel) T artus . Sellel kursusel saadakse  ko­
gem usi igapäevase arstitöõ  andm ete  töötlem i­
seks, an tropom eetrilisteks m õõtm isteks ja  a r ­
vuti kasu tam iseks.
ÜLEVAATED
Mao kartsinogenees
Andrus Arak Karl Kull
in testin aa ln e  ja  d ifuu sn e  m aovähk, etio loogili- 
sed tegurid , lim askesta  vähieelsed  m uutused, 
preventsioon
1980-ndate aastateni oli maovähk üks 
sagedamini esinevaid pahaloomulisi kas­
vajaid maailmas, andes igal aastal ligi­
kaudu 700 000 uut juh tu  (3). Viimastel 
aastaküm netel on selle kasvaja esinemis­
sagedus kõikjal pidevalt vähenenud, kuigi 
selle languse kiirus on piirkonniti olnud 
väga erinev. Jaapani kui erandi kõrval on 
maovähi esinemissagedus jäänud suhteli­
selt suureks m adala sotsiaalm ajandusli­
ku standardiga riikides, selle kiire vähe­
nemine on aga olnud üldise heaolu jä rk jä r­
gulise paranemise peegelduseks (3, 13).
Ka Eestis on maovähi esinemissagedus 
viimastel aastaküm netel pidevalt vähene­
nud, jäädes aga kiiruselt m ärgatavalt alla 
meie läänepoolsetele naaberriikidele (9, 
13, 34). Samal ajal on mitme rikka ühis­
konna statistika näidanud, et maovähi 
esinemissageduse vähenemine ei ole piira­
matu. Nii on maovähijuhtude absoluutarv 
Ameerika Ühendriikides viimastel aasta ­
tel pidevalt suurenenud ja  seni ei ole lõp­
likult selgunud, kas selle peamiseks põh­
juseks on elanikkonna vananemine, kõrge 
maovähiriskiga piirkondadest pärit im­
migrantide arvu suurenem ine või kardia- 
vähi sagenemine (3).
In te s tin a a ln e  j a  d ifu u sn e  m aovähk. 
Epidemioloogilistes uuringutes on mao-
Andrus Arak, Karl Kull — Tartu Ülikooli Radioloo­
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Askorbiinhape
Joonis. In testinaal- 
set tüüpi m aovõhi 
tekkes osalevad  
keskkonnategurid  
ning lim askesta  
m uutused. K oosta­
tud P. Correa (3, 4,
6), M. E. Craaneni 
(7), L.-E. H anssoni 
(11), P. S ipponeni 
(31) ja  G. M. Sobala  
(36) jfirgi.
vähk jaotatud kaheks peamiseks histoloo- 
giliseks tüübiks — intestinaalseks ja  di­
fuusseks— enam asti Laureni klassifikat­
siooni järgi (11). Lisaks monoloogilistele 
omadustele on selline jaotus õigustatud 
ka kliinilise ja  epidemioloogilise laadi tõt­
tu, mis viitavad nende kahe tüübi pato- ja  
histogeneesi võimalikule erinevusele (12). 
Kõikjal, kus on täheldatud maovähihai- 
gestumuse kiiret vähenemist, on see toi­
munud peamiselt intestinaalse tüübi a r ­
vel. Difuusne tüüp on jäänud nendest 
m uutustest peaaegu puutum ata ja  tema
suhtosa on seetõttu pidevalt suurenenud 
(5, 13).
In te s tin a a lse t  tü ü p i m ao v äh k i on
nim etatud ka epideemiliseks (2) tem a ti­
heda seose tõttu eksogeensete kantsero­
geensete teguritega ja  m ärgatavate esine­
missageduse m uutuste tõttu. Oma 
sarnasuse tõttu jämesoolevähi morfo­
loogilise ehitusega on seda ka dife- 
rentseerunuks nim etatud (19). Kliiniliselt 
esineb intestinaalset maovähki rohkem 
vanematel meestel, ta  on sagedam ini ek-
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sofüütse kasvuga ja  ravijärgne elulemus 
tema puhul on tavaliselt parem (12, 19).
D ifu u sse t tü ü p i m ao v äh k i nim eta­
takse endeemiliseks (2, 12, 19) tem a s ta ­
biilsema esinemissageduse ja  arvatava 
tugevama pärilike teguritega seostatuse 
tõttu. Morfoloogiliselt on difuusse maovä­
hi puhul näärm eline struk tuur vaid aim a­
tav, kuigi funktsionaalselt (näiteks lima- 
produktsioon) võib ta  olla küllalt hästi di­
ferentseerunud (4, 12, 19). Kliiniliselt on 
talle iseloomulikum infiltratiivne kasvu- 
vorm ja  halvem prognoos kui intestinaal- 
se tüübi puhul (19). Tugevamale seosele 
geneetiliste teguritega viitavad ju st selle 
maovähi-tüübi sagedam esinemine pere­
konniti (15, 33), esinemine noortel (9, 18) 
ja naistel (13), A-veregrupiga inimestel (2, 
18) ja  ühem unarakukaksikutel (17), sa­
muti stabiilsus ka nendes piirkondades, 
kus eksogeensete teguritega seostatud in- 
testinaalset tüüpi maovähi juhud on kii­
resti vähenenud (9, 13). Pärilikkusele vii­
tab ka selle maovähivormi sagedam esine­
mine koos mõne päriliku haigusega, nagu 
autosoomdominantse Lynch II sündroo­
mi, päriliku hüpogammaglobulineemiaga 
(7, 8).
Difuusset tüüpi maovähi puhul ei ole 
suudetud leida selgelt eristatavaid ega 
üksteisele järgnevaid vähieelseid m uutu­
si ja  see vorm näib tekkivat kas täiesti 
normaalse limaskesta või äärmisel juhul 
pindmise gastriidi foonil (12, 25, 26). Mao­
vähi erinevate histoloogi liste tüüpide 
morfogeneesi eristum ine võibki toimuda 
pindmise või aktiivse kroonilise gastriidi 
vältel — difuusne maovähk saab alguse 
atroofiliste m uutusteta limaskestast, 
kuna intestinaalne vorm peab läbi tegema 
mitmed eelastmed (26).
Kindlasti ei saa ka difuusse maovähi 
korral välistada eksogeensete kantsero­
geensete faktorite ja  intestinaalse maovä­
hi korral geneetiliste tegurite soodustavat 
osa. Siiski, kui on näiteks püütud maovä­
hi sagedam at perekondlikku esinemist 
seostada sarnaste eksogeensete tegurite­
ga, ei ole enamasti tehtud vahet selle 
kahe histoloogilise tüübi vahel; pärilike 
teguritega seotud autoimmuunsele atroo- 
filisele gastriidile järgnev maovähk on
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küll enamasti intestinaalset tüüpi, kuid 
pärilik seos on siin pigem prekantseroos- 
setel muutustel kui vähil endal (14, 15,
23, 33).
E tioloogilised  faktorid. Mao limas­
kesta vähieelseid m uutusi on ikka ja  jälle 
seostatud väliskeskkonna tegurite mõju­
ga. Magu on elund, mis esimesena, sageli 
ja  pikka aega järjest puutub kokku toidus 
sisalduvate ainetega nende m uutum atul 
kujul ja  järkjärguliste progresseeruvate 
m uutuste aastaküm neid kestev jada näib 
sobivat nende tegurite pideva toimega 
(29). Samuti on ju st muutused toitumista- 
vades kõige tugevamini mõjutanud intes­
tinaalse maovähi esinemissagedust (3). 
Mao kartsinogeneesi uurimise eksperi- 
mentaalmudelites on efektiivsemaks osu­
tunud otsese toimega kantserogeenid, 
kuna metaboolset aktivatsiooni vajavad 
prekantserogeenid on sarnase efektiivsu­
sega ka teiste, näiteks jämesoolevähi tek­
kes (19).
Teadmata aine toimemehhanismi, ei 
saa selle vähi teket soodustavas toimes 
siiski veel kindel olla. Toidu termilisel 
töötlemisel tekib tuhandeid pürolüüsipro- 
dukte, mille koguhulk arvatakse olevat 
umbes 2000 mg inimese kohta päevas ja  
tass kohvi sisaldab vähemalt 10 mg selli­
seid aineid, mis eksperimendis on osutu­
nud närilistele kantserogeenseks (1). 
Meie igapäevases taim ses toidus oleva­
test, enamasti kantserogeenseteks peetud 
pestitsiididest on kaaluliselt 99% loodus­
likud (s.o. toodetud taimede poolt enese­
kaitseks) ja olnud inimese toidu koostis­
osadeks aastatuhandeid (1). Võib oletada, 
et looduslikus olelusvõitluses looma- ja 
taimeriigi vahel on muu hulgas ka inime­
se mao limaskest omandanud mingisugu­
seid kaitsemehhanisme selliste ainete 
vastu .
Keedusool (NaCl) on üks olulisemaid 
maovähi tekkes osalevaid eksogeenseid 
tegureid, mille ülem äärane tarvitamine 
põhjustab limaskesta kahjustust ja  esial­
gu pindmise põletiku teket. Pikaajaline 
soola liigtarvitamine aga viib juba krooni­
lise gastriidini koos hilisemate atroofilis­
te m uutuste lisandumisega (5). Põletiku­
ga kaasnev hoogne rakustiku uuenemine
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kergendab ka teiste kantserogeensete 
ainete toimimist ja  suurendab sellega mu­
tatsioonide tekke võimalust (1, 5). NaCl-i 
läm m astikuühendite mutageense toime 
potentseerimine on tähtis mao kartsino- 
geneesiahela hilisemates etappides — 
düsplaasia ja  ka invasiivse kartsinoomi 
tekkes (5). Intestinaalse maovähi esine­
missageduse kiiret vähenemist oma sot­
siaalset seisundit parandanud riikides on 
suuresti seostatud ju st soolatud toitudest 
loobumise ja  toiduainete teiste säilitamis- 
võimaluste (külmikud) kättesaadava­
maks muutumisega (13).
Ka nitraadid on meie toidu lahutam a­
tud koostisosad, mida saam e koos juurvil­
ja, säilitamiseks töödeldud lihasaaduste 
ja  joogiveega. Kuigi andmed lämmasti­
kuühendite osast mao kartsinogeneesis 
on kohati vasturääkivad, on siiski mitmed 
epidemioloogilised vaatlused näidanud 
nende ainete rohkemat kasutam ist kõrge 
maovähiriskiga piirkondades, näiteks 
Kostariikas, Hiinas, Kolumbias (3, 5). 
Nende toime viib esialgu intestinaalse 
metaplaasia ja  hiljem vähi tekkeni. Nit- 
roühendite kantsero-ja mutageensust po- 
tentseerivad lisaks NaCl-ile ka sapphape- 
te lisandumine ja  askorbiinhappe defit­
siit; nende teke on soodustatud ala- 
happelises maos, mis on heaks keskkon­
naks reduktaase tootvatele anaeroobsete­
le mikroobidele (3, 5).
Limaskesta atroofia ja  maosisese pH 
tõusuni viivat kroonilist põletikku tekitab 
peale Helicobacter pylori tegevuse, 
autoimmuunse reaktsiooni ja  keemiliste 
põletikutekitajate ka toimunud vagotoo- 
mia või maoresektsioon (31). 15...20 aas­
ta t pärast neid manipulatsioone, eriti 
Billroth Il-tüüpi resektsiooni, suureneb 
vähirisk 7...8 korda: duodenogastriline 
refluks võib põhjustada limaskesta ero­
sioonideni ulatuva kahjustuse ja  sellega 
kaasnev proliferatsiooni protsess võib 
m uutunud tingimustes lõppeda intesti­
naalse m etaplaasia tekkega (19, 30, 31). 
Kartsinogeensete nitrosoühendite moo­
dustam isest vahetult limaskestal võtavad 
osa ka põletikulise infiltraadi rakulised 
elemendid, nagu aktiveeritud makrofaa- 
gid, polümorftuumsed leukotsiiüdid (5).
Geenitoksiliste ainete toime ei piirdu 
tavaliselt ühe kindla elundi kasvaja tek­
kega. Maovähi põhjustajatena geneetilis­
te häirete kaudu võiksid arvesse tulla nit- 
roühendid, loomsete valkude pürolüüsil 
tekkivad heterotsüklilised amiinid, vä­
hem mükotoksiinid või taimsed alkaloidid 
(5, 32).
Helicobacter pylon  infektsiooni on tä­
heldatud kõikjal üle kogu maailma mõne­
suguste variatsioonidega geograafilises 
esinemissageduses ja  nakatum ise eas 
(29). Arenenud tööstusriikides on ta  lap­
seeas harva esinev, kuid sageneb koos va­
nusega ja  vanuses üle 60 aasta  on naka­
tunud üle 50% inimestest. Arengumaades 
seevastu on nakatunud pooled lastest ja 
täiskasvanutel võib Helicobacter pylori 
esinemissagedus olla väga suur — üle 
90% (16). Sarnaseid erinevusi on ilmne­
nud ka ühe piirkonna erinevate sotsiaal­
sete klasside vahel. Epidemioloogilised 
uuringud on näidanud selle mikroobi ja 
maovähi esinemissageduse kokkulange­
vust (26). E t Helicobacter pylon  on pea­
aegu ilma kahtluseta umbes 80%-l ju h tu ­
dest seotud vähemalt pindmise ja  aktiiv­
se kroonilise gastriidi tekkega, need aga 
limaskesta järgnevate m uutuste kaudu 
intestinaalse maovähiga, siis ongi Helico­
bacter py lon  t püütud paigutada maovähi 
etioloogiliste faktorite hulka (25).
Kirjeldatud on maovähi mõnevõrra sa­
gedamat esinemist varem Helicobacter 
pylori ga nakatunud inimestel võrreldes 
nendega, kellel seda infektsiooni ei ole esi­
nenud (21, 22). Siiski on need uuringud 
tehtud piirkondades, kus Helicobacter 
pylori nakkus on väga sage ka neil ini­
mestel, kes maovähki kunagi ei haigestu. 
Leitud on ka Helicobacter pylori infekt­
siooni võrdselt nii intestinaalse kui ka di­
fuusse maovähi üm brusest (21, 22), kuigi 
viimase teket eelnevate limaskesta m uu­
tustega ei seostata. Kõige sagedamini on 
seda mikroobi leitud koos (antrumi) pind­
mise gastriidiga, vähem aktiivse kroonili­
se gastriidiga, atroofiliste m uutuste lisan­
dumisel tem a esinemissagedus järsu lt vä­
heneb ja  intestinaalse metaplaasiaga 
epiteelis puudub ta  enam asti täielikult (6, 
28, 38). Arvatakse, et lim askesta muutus-
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togu kaasnev mao sisekeskkonna m uutus 
(peamiselt pH tõus) võib olla Helicobacter 
pylori elutegevuseks ebasoodne, kuigi H2- 
blokaatorite tekitatud hüpoklorhüüdria 
suhtes on ta  resistentne (28).
Sjxm taanset Helicobacter py lon  infekt­
siooni paranem ist ei ole kirjeldatud ja 
saanud alguse lapseeas, on ta  üks pikema 
ekspositsiooniajaga etioloogilisi tegureid 
(22). Arvestades Helicobacter pylori tea­
daolevaid toimemehhanisme, võib ta  aas­
takümneid maos püsides tõesti vähi tek­
keni viia. Mao kartsinogeneesiga seotud 
Helicobacter pylori võimalike toimemeh­
hanismidena on kirjeldatud: 1) tsütotoksi- 
liste või põletikumediaatorite ultsero- 
geenset kaskaadi käivitava toimega aine­
te (atseetaldehüüd, fosfolipaas-A2 jt.) 
produktsiooni; 2) kõrget ureaasi aktiiv­
sust, mis uu reaga reageerides annab tu ­
geva mukolüutilise toimega ammoniaagi 
kontsentratsiooni tõusu maos; 3) hüper- 
proliferatsiooni indutseerim ist põletiku- 
koldes, mis soosib epiteeli metaplastilist 
progressiooni ja  võimalik, et ka maliign- 
sete rakuliinide teket; 4) üldise ja  lokaal­
se immuunreaktsiooni stimuleerim ist, 
mille tagajärjeks võib muu hulgas olla ka 
ristreaktsioon mao limaskesta vastu; 5) 
epidermaalse kasvufaktori stim uleeri­
mist; 6) askorbiinhappe kontsentratsiooni 
vähendamist maoõõnes (9, 20, 26, 36). Ot­
seste kantserogeensete ainete tootmist 
Helicobacter pylon, poolt ei ole leitud. Li­
saks sellele on põletikuline limaskest ise 
tundlik kantserogeensete ainete toime 
suhtes, näiteks vabade radikaalide põh­
justatud oksüdatiivse stressi suhtes, allu­
des kergemini m utatsioonideleja maliign- 
sele transformatsioonile (22). Peab aga ü t­
lema, et suur osa eespool nim etatud 
m ehhanismidest on kindlaks tehtud in 
vitro ja  seostub ka haavandi tekkega. 
Mainitud mikroobi osa maovähi tekkes 
saab tõestada vaid siis, kui on näidatud, 
et selle infektsiooni raviga on võimalik 
vähki haigestum ist vältida (4, 25).
Väliskeskkonna tegurid toimivad ena­
masti kindlal vähitekke etapil, vastavat 
limaskesta m uutust kas soodustades, ta ­
kistades või regressioonile viies. Arvatak­
se, et kantserogeenide ekspositsioon iaeg
peab olema pikk — kogu kartsinogenee- 
siprotsess saab alguse juba inimese elu 
esimesel veerandil ja  kestab aastaküm ­
neid (9).
Prekantseroosne protsess maos. In-
iestinaalse vähiga lõppev protsess mao li­
m askestas arvatakse üldjoontes kulgevat 
järgmise skeemi järgi: pindmine gastriit
— aktiivne krooniline gastriit — kroonili­
ne atroofiline gastriit — intestinaalne me- 
taplaasia — (III tüüpi intestinaalne me- 
taplaasia) — düsplaasia — (võimalik 
vähk) — vähk — invasioon (vt. joonis) (2,
3, 5, 6, 27). Sellise skeemi paikapidavust 
kinnitavad vaatluse tulemused, kus on 
leitud gastriidi raskusastm ete korreleeru- 
mine intestinaalse metaplaasia sageduse­
ga ja viimase erinevate raskusastm ete 
korreleerumine düsplastiliste m uutuste 
esinemissagedusega (2). Eestis kui küllalt 
suure maovähihaigestumusega riigis on 
vaatlused näidanud progresseeruvate 
muutustega gastriidi väga sagedat esine­
mist ja  seda ka noortel (37).
T eistest m aohaigustest on kõrget vä­
hiriski seostatud adenomatoosse polüübi­
ga, mao limaskesta limarakulise hüper- 
plaasia — M enetrier’ tõvega. Kroonilise 
maohaavandi korral ei ole vähi esinem is­
sagedus oluliselt suurem  kui kahjustam a­
ta maos; eksperimendis on kroonilise h aa­
vandida mao limaskest küll vastuvõtli­
kum kantserogeensete ainete toimele, 
mõned haavandi tekkes olulised faktorid 
(näiteks maohape) aga kaitsevad magu 
pahaloomulise kasvaja tekke eest (19, 22, 
24).
Pikaajalist ja  progresseeruvat gastriiti 
peetakse intestinaalse maovähi tekke eel­
duseks (3). Varajasemad arvukad gastrii­
di klassifikatsioonid on ühendatud nn. 
Sydney süsteemi, kus eristatakse ägedat 
ja  kroonilist põletikku, kusjuures viimane 
jaotatakse omakorda aktiivseks ja  atroo- 
filiseks (27). Selline jaotus sobib hästi ka 
maovähi prekantseroositeooriaga. Topo­
graafiliselt võib gastriit Sydney klassifi­
katsiooni järgi esineda antraalse, korpuse 
või pangastriidina (27). P. Correa on neid 
gastriite nimetanud hüpersekretoorse- 
teks, autoim muunseteks ja  keskkonnate­
guritest tingitud vormideks (3). Neist esi-
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mesele on iseloomulik krooniline (pindmi­
ne) põletik enamasti mao antraalosas (ka 
nn. difuusne antraalne gastriit), maohap- 
pe ja  pepsiini suurenenud sekretsioon 
ning ta  on seotud peamiselt duodeenumi 
või pülooruse piirkonna peptilise haavan- 
di tekkega, kuna tema vähirisk on väike 
(27). Hüpersekretoorne gastriit on
80...90%-l juhtudest seotud Helicobacter 
pylori infektsiooniga (3).
Mõnevõrra suurema maovähiriskiga 
autoimmuunne gastriit on seotud parie- 
taal rakkude vas taste antikehade ja  per- 
nitsioosse aneemia sündroomiga. See 
gastriit lokaliseerub tavaliselt mao korpu- 
seosas, temaga kaasnev näärmekoeatroo- 
fia on difuusne ja  põhjustab aklorhüüdria 
teket (23, 27). Peamiselt keskkonna toksi- 
listest teguritest põhjustatud mitmekol- 
deline metaplastiline gastriit algab pind­
mise põletikuna maokorpuse ja  -antrumi 
piiril ja  levib hiljem mõlemas suunas (27). 
Põletikule lisanduvad esialgu koldelised 
ja  hiljem omavahel laatuvad atroofilised 
muutused. Näärmekoeatroofia ei ole siin 
täielik, kuid tekkivast hüpoklorhüüdriast 
piisab nitraate redutseerivate bakterite 
elutegevuseks (14). Just see gastriidivorm 
arvatakse olevat peamine maovähi eelkäi­
ja  (3, 29).
Kroonilistele atroofilistele m uutustele 
lisanduva in testinaalse m etaplaasia
korral asendub mao limaskest vastavat 
tüüpi soole omaga, saades kaasa ka selle 
omadused (19). Peensoole tüüpi intesti­
naalset m etaplaasiat nim etatakse ka täie­
likuks ja  I tüüpi intestinaalseks meta- 
plaasiaks, millele on iseloomulik peensoo­
le tüüpi rakustiku ja  sialomutsiinide 
produktsioon, lisanduda võib ka peensoo­
le limaskestale iseloomulik alkaalse fosfa- 
taasi ja  mõne seedeensüümi (disahhari- 
daas, peptidaas) produktsioon (3, 19). J ä ­
mesoole tüüpi m etaplaasiat aga nime­
tatakse m ittetäielikuks ja  ka III tüüpi me- 
taplaasiaks, millele on omane vastav ehi­
tus ja  sulfomutsiinide produktsioon (19). 
Nende kahe tüübi kõrvale jääb veel üks —
II tüüpi ehk ka karikrakuline, olles ehitu­
selt lähedane jämesooleepiteelile, kuid 
produtseerides peaasjalikult sialomutsii- 
ne (29).
Neid mao limaskesta m uutuste vorme 
peetakse üksteisele järgnevateks lülideks 
intestinaalse maovähi tekke ahelas. Sa­
mas on aga leitud (peamiselt I ja  II tüüpi) 
intestinaalset m etaplaasiat ka suuremal 
osal mao kroonilise haavandiga haigetel 
ja  vaid III tüüp seostub maovähiga kind­
lam alt kui teiste maohaigustega (6). Nii 
ongi avaldatud arvam ust, et III tüüpi in­
testinaalne m etaplaasia võib olla hoopis­
ki paraneoplastiline m uutus ja  peensoole 
tüüpi m etaplaasia on vanemas eas niivõrd 
sage muutus, et kliiniliselt on tema pre- 
kantseroosne potentsiaal võrdne kroonili­
se atroofilise gastriidi omaga (19).
Kõikide eespool nim etatud mao limas­
kesta patoloogiliste m uutuste puhul võib 
nende vähieelsuses kahelda nende suure 
esinemissageduse ja  väikese vähiriski tõt­
tu. Düsplaasia on juba niisugune muutus, 
millel on maovähiga kindel seos. Raske 
astm e düsplaasiat on enamasti leitud 
koos kasvajaga või küllalt lühikest aega 
(aasta) enne varajase vähi avastamist.
Kui düsplaasia laiemas mõttes tähen­
dab abnormset kasvu üldse, siis vähi tek­
ke protsessis on ta  premaliignsuse süno­
nüüm iks ja  teda on defineeritud kui koe 
niisugust patoloogilist seisundit, mille pu­
hul rakulised ja  struktuursed muutused 
näitavad ilmekalt kalduvust pahaloomu- 
lisusele (19). Düsplastiliste rakkude DNA 
polü- ja  aneuploidsus, rakutsükli pikene­
mine ja  rakkude eluea lühenemine, kart- 
sinoembrüonaalse antigeeni ja  teiste on- 
kogeneesiproduktide esinemine viitavad 
kindlale seosele maliignsete rakkudega. 
Tihti ongi piiri tõmbamine düsplaasia ja  
vähi vahele võimatu, mille tõttu on ka ka­
sutusel mõiste «võimalik vähk» (19). Taas- 
pöördumine arvatakse olevat võimalik 
kuni kergetest düsplastilistest m uutus­
test (3, 19, 21).
P reventsioon. Prim aarse maovähi 
preventsioon sisaldab kontrolli selle tek­
kes oluliste faktorite üle. Suitsetamisest, 
kangetest alkohoolsetest jookidest ja  
kantserogeeniderikastest toitudest loobu­
mine ning rohke toores taimne toit seos­
tuvad intestinaalse maovähi esinemissa­
geduse kiire vähenemisega (13). Maovähi 
prim aarse preventsiooniga seostub ka
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jsuur hulk keskkonnakaitseprobleeme, 
kuigi näiteks pestitsiidide osas on vaiel­
dud selle üle, kas mitte neist saadav kasu 
taim se toidu rohkusena ei kaalu üles a r ­
vatavat vähiriski (1).
Arvestades aklorhüüdria ja  hüpoklor- 
hüüdria olulisust mao kartsinogeneesis, 
peaks üks maovähi vältimise võimalusi 
olema normaalse happesuse säilitamine 
atroofilise gastriidi tekkepõhjuste kont­
ro llija  haavandtõve adekvaatse ravi kau­
du (24). Helicobacter pylori infektsiooni 
puhul on oluline silmas pidada üldist hü- 
gieenitaset ja  kindlaks m äärata selle ravi 
näidustused ja  otstarbekus (5, 16).
Vähivastasteks aineteks peetakse värs­
kes taimetoidus sisalduvat askorbiinha- 
pet, ß-karotiini, a-tokoferooli, samuti mik­
roelemente (seleen), mis kui tugevad an- 
tioksüdandid pärsivad hapniku vabade 
radikaalide (siin peamiselt nitrosoühendi- 
te) mao limaskesta kahjustavat toimet, 
seejuures üksteist potentseerides (3, 35). 
Lisaks sellele osaleb askorbiinhape 
stresshormoonide tootmises, aitab im­
muunsüsteemi stimuleerimisega tõsta or­
ganismi resistentsust mikroobide (ka HP) 
ja  kasvajate suhtes, takistab nitritite 
amiinimist maos, aitab kõrvaldada mitme 
(näiteks tubakasuitsus sisalduvate) kan t­
serogeense aine toimet (9). Tubakasuits 
sisaldab lisaks paljudele muudele kantse­
rogeensetele ainetele ka hulgaliselt vabu 
radikaale, mis võivad olla oksüdatiivse 
stressi indutseerijateks suitsetajatel, ja  
nii on suitsetajatel täheldatud tunduvalt 
suuremat vitamiinivajadust m ittesuitse­
tajatega võrreldes (35). С-vitamiin on va­
jalik ka sidekoevalgu kollageeni sünteesi 
juures, osaledes nii juba tekkinud vähi 
mikrokollete piiramises ja  progresseeru- 
mise pidurdamises (3, 35).
Sekundaarne maovähi preventsioon 
peaks seisnema kõikide kartsinogeneesi- 
protsessist hõlmatud haigete praktiliselt 
ebareaalses väljaselgitamises, jälgimises 
ja ravimises. Varajase maovähi avastam i­
se suur sagedus Jaapanis näitab sõel- 
uuringute efektiivsust suure riskiga piir­
kondades küll vähi puhul (3), kuid pre- 
kantseroossete m uutuste suure esinemis­
sageduse tõttu tuleb siin, erinevate tegu-
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rite koosmõju arvestades, uuritavaid se­
lekteerida. M ääratavad on mao limaskes­
ta  muutustele viitavad bioloogilised m ar­
kerid: pepsinogeenid, intestinaalse me- 
taplaasiaga kaasnevad limaproduktsiooni 
muutused ja  soolestiku ensüümide esine­
mine maos, anomaalse Lewis-A-antigeeni 
ilmumine mao limaskestas jt. (2, 5, 10, 
29). Düsplastiliste m uutuste korral leita­
vad ja  malignisatsioonile viitavad m arke­
rid (CEA jt.) ei ole enam maovähispetsii- 
filised (19).
Kokkuvõte. Esitatud ülevaates on tä ­
helepanu pööratud viimastel aastatel esi­
tatud täiendustele maovähi tekke etioloo- 
giliste ja  patomorfoloogiliste aspektide 
osas. Intestinaalset tüüpi maovähi esine­
missageduse kiire vähenemine kõrge sot­
siaalm ajandusliku standardiga riikides 
on arengumaadega võrreldes andnud või­
maluse selgitada nende m uutuste põhju­
si. Üldine hügieenitase ja  toitum isharju­
mused seostuvad kindlalt suurem a osa 
teadaolevate etioloogiliste teguritega, mil­
lest praegu peetakse olulisemaks Helico­
bacter pylori infektsiooni, ülem äärast soo­
la tarbim ist ja  mao kartsinogeneesi pidur­
davate antioksüdantse toimega A-, C- ja 
E-vitamiini defitsiiti.
Nagu sellise multifaktorilise põhjuslik­
kuse puhul ikka, arvatakse siingi väliste­
le soodustajatele lisanduvat geenitoksi- 
liste kantserogeensete ainete toime ja 
pärilik eelsoodumus. Viimase osa ekso- 
geensete tegurite nõrgema toime kõrval 
peetakse oluliseks difuusse maovähi pu­
hul, mille geneesi selgitamisele hakatak­
se lähitulevikus ilmselt tunduvalt suure­
m at täh tsust omistama. Seal aga, kus 
maovähi esinemissagedus on veel küllalt 
suur ju st intestinaalse vähitüübi arvel, on 
võimalik teiste kogemustest omandatud 
teadmisi haigestumise vähendamise ees­
märgil ära  kasutada. Intestinaalse mao­
vähi tekkeks peavad väliskeskkonna te­
gurite pideval toimel arenem a mao limas­
kesta järjestikused progresseeruvad 
m uutused pindmise ja  aktiivse kroonilise 
pangastriidi ning atroofiliste, metaplasti- 
liste ja  düsplastiliste m uutustena, kuna 
difuusse vähi tekkeks atroofia eelnemise 
olulisust ei ole leitud.
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Summary
G astric C arcinogenesis. In this article a review 
of publications of recent years about the morphologi­
cal and aetiological aspects of gastric cancer is 
presented. The incidence of the gastric cancer has 
been declining, more rapidly in affluent societies 
than in developing countries. The decline has been 
observed mainly for the so-called intestinal type, 
when the incidence of the other, diffuse type has 
been changed less notoriously. The latter type seems 
to have a more obvious relationship to the hereditary 
aetiology and a little is known about the precancer- 
ous process of it. The intestinal type is considered to 
be the end result of a prolonged precancerous pro­
cess in which superficial gastritis, atrophy, intesti­
nal metaplasia and dysplasia appear in sequential 
steps. This changes are chiefly caused by the envi­
ronmental factors (Helicobacter pylori, different car­
cinogenic and genotonic chemical agents) in combi­
nation with hereditary and aquared genetic alter­
ations. So the cause of this disease is almost 
certainly multifactorial and the multidisciplinary 
approach is needful to resolve the problem of castric 
cancer. Screening of the gastric precancerous 
changes in high risk areas, anti-Helicobacter and 
adequate anti-ulcer therapy, use of micronutrient 
antioxydants with low salt intake are possible 
measures of prevention of this malignance.
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MAOVÄHI RADIKAALNE KIRURGILINE RAVI
Andrus Arak, Karl Kull —  Tartu Ülikooli arstiteaduskonna Radioloogia ja
Onkoloogia Kliinik 
Juhani Lehtola, Jyrki Mäkelä, Hannu Tuominen —  Oulu Ülikooli Kliinik
Autorid tänavad Soome ja Eesti Vähiregistreid koostöö eest ja Pentti Niemineni Oulu 
Ülikoolist abi eest andmete statistilisel töötlemisel.
Võtmesõnad: maovähk, kirurgiline ravi, operatsiooni radikaalsus
Kasvaja algkolde invasioonisügavus ja  lümfogeense metastaseerumise ulatus on 
kaks kõige olulisemat maovähihaigete prognoosi mõjutavat tegurit (9). Seetõttu 
on nende tegurite arvestamine oluline ka radikaalse kirurgilise ravi 
planeerimisel (9,12). Olemas on kaks erinevat arusaama maovähipuhuse 
operatsiooni radikaalsusest. Ühe järgi peetakse piisavaks nn. konventsionaalset 
ehk sarnaselt nii mao hea- kui halvaloomuliste haiguste ravis kasutatavat, kuna 
teine eeldab mao eemaldamise kombineerimist naaberorganite resektsioonide ja  
laiendatud lümfadenektoomiaga (2,3,9,12).
Käesoleva töö eesmärgiks oli võrrelda nende kahe erineva 
operatsioonimetoodika mõju maovähihaigete ravitulemustele prognostiliste 
tegurite ja  elulemusnäitajate alusel.
Uurimismaterjal ja -metoodid. Töös on vaadeldud 88 aastatel 1983 - 1987 
Oulu Ülikooli Kliiniku kirurgiaosakonnas ja  406 aastatel 1978 - 1987 Tartu 
Ülikooli Kliinikumi Onkoloogiahaiglas radikaalselt opereeritud maovähihaiget. 
Võrreldavate haiglate valikus osutus määravaks erinevus kirurgilise ravi 
taktikas ning samasus nii haigestumuses kui kasvajate patoloogilistes näitajates 
Põhja-Soomes ja  Eestis ( 1,4,13).
Soomes puuduvad spetsialiseeritud haiglad onkoloogiliste haiguste kirurgiliseks 
raviks. Oulu Ülikooli Kliinikus opereeritakse maovähihaigeid gastrektoomia 
või subtotaalse maoresektsiooni teel koos perigastriliste lümfisõlmede 
eemaldamisega. Radikaalseid operatsioone ei peeta võimalikuks kasvaja 
invasioonil mao naaberkudedesse (T4) ja  N1 sõlmedest ulatuslikuma 
lümfogeense leviku korral. Oluline on kasvajavaba resektsiooni-joone 
olemasolu, selle minimaalseks kauguseks on 5 cm kasvaja makroskoopilisest 
piirist. Infiltratiivsete kasvajate korral eelistatakse gastrektoomiat.
Eesti onkoloogiahaiglates on maovähi radikaalses ravis oluliseks peetud 
kombineeritud naaberorganite resektsioone ja  laiendatud lümfadenektoomiat. 
Seda metoodikat on varem lähemalt kirjeldatud (1). Need on ka peamised
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erinevused radikaalsuse mõistes epiteliaalsete pahaloomuliste kasvajate 
kirurgias Soomes ja  Eestis.
Retrospektiivseks analüüsiks on kogutud andmed mõlema kliiniku 
haiguslugudest. Kasvajad on klassifitseeritud TNM klassifikatsiooni 1987. 
aasta väljaande alusel, N-kategooria Jaapani Maovähi Uuringute Ühingu 
klassifikatsiooni alusel (5,7). Makroskoopilised kasvuvormid Borrmanni järgi 
on koondatud eksofüütseteks (polüpoidne, haavanduv) ja  infilitratiivseks 
(infiltratiiv-haavanduv, infiltratiivne). Histoloogilised tüübid jaotatakse Soomes 
P. Laureni järgi, Eestis aga ÜTO klassifikatsiooni alusel, ja  ei ole seetõttu antud 
uuringus võrreldavad (8,11). Elulemusnäitajad on arvutatud Soome ja  Eesti 
Vähiregistrist saadud andmete põhjal.
Statistiliseks andmetöötluseks SPSS programmis on kasutatud 
üksiktunnusanalüüsi ja  Cox’i hulgitunnuselist regresioonimudelit, statistikud on 
leitud x 2-testiga.
Uurimistulemused ja arutelu. Haigete keskmine vanus oli Oulus 63,0 (27 
kuni 81) ja  Tartus 62,4 (31 kuni 85) aastat. Suhteliselt rohkem oli meeshaigeid 
Oulu rühmas (59,1% Tartu 48,8% vastu) kuigi haigestumuse järgi sellist 
erinevust ei esine. Ühise joonena võib välja tuua haigete soo ja  vanuse mõju 
puudumise 5-aasta elulemusele.
Kõikide haigete 5-aasta suhteline elulemus oli Oulus 45,5%. See näitaja on 
väga lähedane 46,1%-sele elulemusnäitajale Tartus ja  jätab esmapilgul mulje, 
et laiendatud operatsioonidel ei ole eelist konventsionaalse metoodika ees. 
Kahe haigeteriihma lähem võrdlus näitab siiski sellise järelduse ennatlikkust. 
Tabelis 1 on toodud tähtsamate prognostiliste tegurite ja  nendega seotud 
suhteliste 5-aasta elumuste võrdlevad andmed. Selgus, et Oulu ja  Tartu Ülikooli 
kliinikutes opereeritud haigete prognoosi mõjutavate tegurite sagedused 
erinesid oluliselt (p<0,05) T  ja  N kriteeriumi ning makroskoopilise tüübi 
jaotumuse osas.
Konservatiivsema ravitaktika tõttu on Oulus haiged valitud radikaalseteks 
operatsioonideks tunduvalt hoolikamalt ja  mitmed potentsiaalselt ravitavad 
haiged (so. T1-3N2-3, T4N0-3) on sellest rühmast välja jäänud. Tartus 
moodustasid sellised haiged märkimise osa - 45,1% (n=183). Sel põhjusel 
oligi radikaalsus kahes kliinikus erinev - Oulus 43,3%, Tartus 58,8%.
Tartus opereeriti suhteliselt sagedamini ulatuslikumate (T3-T4) kasvajatega 
haigeid (76,9% Oulu 42,0% vastu), sest naaberkudede invasioon välistas Oulus 
radikaalse operatsiooni. T1-T2 kasvajate kirurgilise ravi tulemused ei sõltunud 
oluliselt erineva operatsioonimetoodika kasutamisest. Samas võis märgata 
erinevust T3 kasvajate puhul ja  T4 kasvajate radikaalne opereerimine andis 
Tartus maovähi jaoks märkimisväärse elulemuse (34,0%).
Kui Oulus rakendati radikaalset ravi vaid N0-N1 kahjustuse korral, siis Tartus 
moodustasid N2 ja  ulatuslikuma levikuga tuumorid 30,6% kõikidest juhtudest. 
Sõltumata kasvaja algkolde invasiooni sügavusest oli haigete 5-aasta suhteline
elulemus N2 kahjustusel 25,3% ja  N3 kahjustusel 12,0%. Et, kasvaja invsiooni 
sugavus korreleerub enamasti makroskoopilise ehitusega, siis oli ka 
infiltratiivsete vähitüüpidega haigeid Oulus radikaalselt opereeritute hulgas 
vaid 21,6%. Kõikidest maovähkidest moodustavad need enamasti ikka 
ligikaudu poole ja  nii on see olnud ka Tartus ravitute ning kogu Oulu kliiniku 
teeninduspiirkonna haigete puhul (2,3,9,12). Eksofüütsete vähi vormide 
ravitulemused osutusid samasteks, erinesid aga oluliselt infiltratiivsete 
kasvajate korral - Oulus 15,8%, Tartus 34,3%.
Olles tagasihoidlikud kombineeritud operatsioonides ja  lümfadenektoomias, 
eelistatakse Oulu haiglas gastrektoomiat maoresektsioonile sagedamini kui 
Tartus (tabel 2). Kuigi meie materjal ja  ka kirjanduse andmed näitavad, et 
piisava resektsiooni-kauguse korral on maokönt kasvaja taaspuhkemise kohaks 
harva (väide gastrektoomia parema radikaalsuse vastu), on mao täielik 
eemaldamine mitmel põhjusel õigustatud (2,3). Esiteks on operatsiooni eelselt 
kasvaja tegelikku levikut adekvaatselt raske hinnata ja  see võib olla ebaõige 
kuni 2/3-1 juhtudest (10). Nii on haiguskolde ulatuslikul eemaldamisel on ka 
diagnostiline eesmärk - võimalike mikrometastaaside või naaberorganitesse 
sissekasvu avastamine. Teiseks tagab gastrektoomia parema juurdepääsu 
eemaldamist vajavatele lümfisõlmedele (näiteks parakardiaalsed, a. lienalis’e 
ümbruse jt.). Eriti oluline on see mitte-varajaste, infiltratiivsete või madala 
diferentseerumisastmega kasvajate korral, kus lisaks suurele erinevusele 
vähikolde mikro- ja  makroskoopilise piiri vahel tuleb arvestada ka 
metastaseerumisega kõikidesse võimalikesse lümfikollektoritesse (6,9).
Meie andmetel ei ole põhjendatud arvamus laiendatud ja  kombineeritud 
maovähi-operatsioonide seosest suurema operatsiooni-järgsete tüsistuste ja  
letaalsuse sagedusega. Kirurgiliste tüsistuste arv ja  letaalsus olid kahes 
vaadeldud haiglas üsna samased, laiendatud subtotaalsed maoresektsioonid 
andsid aga isegi madalama suremuse (tabel 2). Seega võime kinnitada, et 
tüsistuste oht ei ole selliste operatsioonide sooritamise takistuseks (6). 
Järeldused.
1. Samased elulemusnäitajad võivad olla haigete erineva selektsiooni tulemus. 
Patoloogiliste näitajate jaotumuste erinevused kahes vaatluse all olnud kliinikus 
opereeritud maovähijuhtudel on seletatavad vaid erineva agressiivsusega 
kasvaja algkolde ja  metastaatiliste lümfisõlmede suhtes.
2. Ekstensiivse, naaberorganite resektsioonide ja  laiendatud lümfadenektoo- 
miaga kombineeritud mao-operatsiooni tähtsus muutub oluliseks just lokaalselt 
või lümfogeenselt levinud kasvajate (T2-T3(T4), N2(N3), Borrmanni III-IV 
tüüp) puhul. Et just need kasvajad moodustavad suurema osa haigusjuhtudest, 
võimaldab selline metoodika rahuldavate tulemustega radikaalselt ravida 
tunduvalt rohkem maovähihaigeid.
Tabel 1. Tähtsamate prognostiliste tegurite esinemissageduste ja 5-aasta suhteliste 
elulemuste võrdlus
Näitaja Haigete arv ja % 5-aasta suhteline elulemus
Tartu grupp Oulu grupp Tartu grupp Oulu grupp
Kõik juhud 406(100,0) 88 (100,0) 46,1 45,5
l.Sugu
mehed 198 (48,8) 52 (59,1) 46,9 48,1
naised 208 (51,2) 36 (40,9) 45,2 41,7
2.Vanus
< 7 0  aasta 281 (69,3) 56 (63,6) 50,9 50,0
> 69 aasta 125 (30,8) 32 (36,4) 35,2 37,5
3.T aste
T l 31 ( 7,6) 20 (22,7) 80,7 85,0
T2 63 (15,5) 31 (35,3) 54,0 48,4
T3 218(53,7) 37 (42,0) 44,0 21,6
T4 94 (23,2) 0 34,0 -
4.N aste
N0 225 (55,4) 67 (76,1) 60,0 49,3
N1 57 (14,0) 21 (23,9) 42,1 33,3
N2 99 (24,4) 0 25,3 -
N3 25 ( 6,2) 0 12,0
6.Lokalisats.
alumine 200 (49,3) 49 (45,4) 51,5 55,0
keskmine 140 (34,5) 22 (25,0) 47,9 50,0
ülemine 42(10,3) 22 (25,0) 28,6 31,8
totaalne 24 ( 5,9) 4 (4 ,5 ) 20,8 0,0
7.Borrmann
I-II 193 (47,5) 69 (78,4) 59,1 53,6
III-IV 213(52,5) 19(21,6) 34,3 15,8
8.Suurus
< 4 cm 57(14,0) 27 (30,7) 71,9 81,5
4-7 cm 192 (47,3) 47 (53,4) 44,3 29,8
8-12 cm 123 (30,3) 12(13,6) 43,1 33,3
> 12 cm 34 ( 8,4) 2 ( 2,3) 23,5 0,0
Tabel 2. Kirurgilised tüsistused ia letaalsus radikaalsete operatsioonide järgselt






Oulu Ülikooli Kliinik 88 14(15,9) 9(10,2) 45,5
gastrektoomia 59 (67,1) 13 (22,0) 6(10,2) 39,0
subtot. resektsioon 29 (32,9) 1 ( 3,4) 3 (10,3) 58,6
Tartu
Onkoloogiahaigla 406 59(14,5) 24 ( 5,9) 46,1
gastrektoomia 170 (41,9) 37 (21,8) 18 (10,6) 32,3
subtot. resektsioon 236 (58,1) 22 ( 9,3) 6 (  2,5) 55,9
KIRJANDUS
1. Arak A., Kull K. Factors influencing survival of patients after radical operations for 
gastric cancer. A regional study of 406 patients over a 10-year period. Acta Oncologica
1994;33:913-920.
2. Bollschweiler E., Boettcher K., Hoelscher A.H., Sasako M., Kinoshita T., Maruyama 
K., Siewert J.R. Is the prognosis of Japanese and German patients with gastric cancer 
really different? Cancer 1993;71:2918-2925.
3. Bonenkamp J.J., van de Velde C.J.H., Kampschöer G.H.M., Hermans J., Hermanek 
P., Bemelmans M., Gouma D.J., Sasako M., Maruyama K. Comparison of factors 
influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. 
World J Surg 1993;17:410-415.
4. Cancer Society of Finland Publication No. 51. Cancer incidence in Finland 1989 and 
1990. Cancer Statistics of the National Agency for Welfare and Health. Helsinki 1992.
5.Hermanek P., Sobin L.H. UICC International Union Against Cancer. TNM 
Classification of Malignant Tumours. Fourth, Fully Revised Edition. Springer-Verlag 
Berlin 1987.
6. Jatzko G., Lisborg P.H., Klimpfinger M., Denk H. Extended radical surgery against 
gastric cancer: low complication and high survival rates. Jpn J Clin Oncol 1992;22:102- 
106.
7. Kajitani T. Japanese Research Society for Gastric Cancer. The general rules for 
gastric cancer study in surgery and pathology. Part I and Part II. Jpn J Surg 
1981;11:127-145.
8. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called 
intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
9. Maruyama K. The most important prognostic factors for gastric cancer patients. A 
study using univariate and multivariate analyses. Scand J Gastroenterol 1987;22 
(Suppl.l33):63-68.
10. Noguchi Y., Imada T., Matsumoto A., Coit D.G., Brennan M.F. Radical surgery for 
gastric cancer. A review of the Japanese experience. Cancer 1989;64:2053-2062.
11. Oota K., Sobin L.H. Histological typing of gastric and oesophageal tumors. 
International Histological Classification of Tumors no. 18. Geneva, World Health 
Organization, 1977.
12. Pacelli F., Doglietto G.B., Bellantone R., Alfieri S., Sgadari A., Crucitti F. Extensive 
versus limited lymph node dissection for gastric cancer - a comparative study of 320 
patients. Br J Surg 1993;80:1153-1156.
13. Tekkel M. Pahaloomuliste seedetraktikasvajate haigestumus Eestis aastail 1968 ... 
1987. Eesti Arst 1992;4:248-253.
4 0
S um m ary
Radical su rgery  fo r gastric  cancer
Although close in the incidence and pathological features of gastric cancer 
Finland and Estonia have different policy of surgical treatment of this 
malignance. We performed a retrospective comparative study to analyse the 
causes of similar survival rates in different hospitals (Oulu University Hospital 
and Tartu Hospital of Oncology) and its associations with prognostic factors.
We found that the same overall survival rate after curative gastric cancer 
surgery may be the result of different selection of patients. Frequences of 
prognostic factors vary significantly (p<0.05) in T stages, N stages and 
Borrmann types. These differences can be explained by a more or less 
aggressive approach to combined organ resections and lymph node dissection. 
Thus, the results obtained from this study indicate that the extensive surgery 
with systemic lymphadenectomy is a safe surgical procedure that gives good 
cure result and offers the possibility of increasing the number of potentially 
curable patients.
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